

INFORME FINAL DE TESIS DOCTORAL

**Caracterización de factores genotípicos y fenotípicos de *Staphylococcus aureus*
asociados a la formación de biopelículas en mastitis bovina**

Giovanny Alexander Torres Lindarte

Directora

Dra. Martha Olivera Angel

Co-directora

Dra. Miryan Margoth Sánchez

Comité tutorial

Dr. Julián Reyes Vélez

Doctorado en Ciencias Animales

Facultad de Ciencias Agrarias

Universidad de Antioquia

2020

30

Agradecimientos

31 A Dios, a mi esposa Elizabeth y a mi hijo Juan David por ser la fuerza inspiradora y
32 apoyo moral para culminar este proceso formativo y de importancia en mi carrera
33 profesional.

34 A la Doctora Martha Olivera por toda su confianza, acompañamiento incondicional y
35 grandes enseñanzas, sin las cuales no habría sido posible crecer y finalizar esta
36 investigación.

37 A la Doctora Miryan Sánchez y el Doctor Julián Reyes por su apoyo y orientación
38 incondicional durante todo el proceso.

39 A la universidad de Antioquia, especialmente al Grupo de Investigación Biogénesis y la
40 Facultad de Ciencias Agrarias, por abrirme sus puertas y apoyarme durante la
41 investigación.

42 Al Instituto Colombiano de Medicina Tropical y la Universidad CES por su gran apoyo, el
43 tiempo y la confianza depositada para crecer profesionalmente.

44

45

46

47

48

49

50

51

52

53

54

Dedicatoria

55 A mi esposa Elizabeth y mi hijo Juan David por todo su amor, apoyo incondicional y
56 comprensión durante esta etapa.

57 A mis Padres que, aunque ya no me acompañan físicamente, entregaron todo para
58 educarme y ahora son mi apoyo moral, mi ejemplo y fuerza.

59 A mis hermanos que siempre me brindaron una voz de aliento.

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81	Tabla de contenido	
82	Lista de tablas	7
83	Lista de figuras	9
84	Lista de abreviaturas	11
85	Resumen general	13
86	General abstract	15
87	Introducción general	17
88	Objetivos	21
89	Objetivo general	21
90	Objetivos específicos	21
91	Marco teórico	22
92	Mastitis bovina.....	22
93	Infecciones intramamarias bovinas causadas por <i>S. aureus</i>	23
94	Respuesta inmune contra <i>S. aureus</i>	28
95	Inmunidad innata	28
96	Inmunidad adaptativa	30
97	Detección de <i>S. aureus</i> en leche de bovinos con infecciones intramamarias	31
98	Tratamiento antibiótico contra <i>S. aureus</i>	33

99	Resistencia de <i>S. aureus</i> a los beta-lactámicos.....	33
100	La meticilino resistencia y el fenotipo de biopelícula.....	35
101	Factores de virulencia de <i>S. aureus</i> asociados con la evasión de la respuesta inmune	35
102	Formación de biopelícula en glándula mamaria por <i>S. aureus</i>	40
103	Estudios sobre caracterización de cepas de <i>S. aureus</i> formadoras de biopelículas	43
104	Resultados por objetivo	46
105	Resultados del objetivo 1	46
106	Artículo 1.....	49
107	Genotypic and phenotypic characterization of biofilm production by <i>Staphylococcus aureus</i>	
108	strains isolated from bovine intramammary infections in Colombian dairy farms	49
109	Artículo 2.....	50
110	Molecular epidemiology of bovine mastitis caused by <i>Staphylococcus aureus</i> in Colombia	
111	reveals high genetic diversity and presence of clones associated with human infections.....	50
112	Artículo 3.....	71
113	Phenotypic characterization and whole genome analysis of a strong biofilm-forming	
114	<i>Staphylococcus aureus</i> strain associated with subclinical bovine mastitis in Colombia.....	71
115	Resultados del objetivo 2	72
116	Artículo 4.....	73
117	Proteomic analysis of the interaction between biofilm-forming <i>Staphylococcus aureus</i> strains and	
118	bovine mammary epithelial cells.....	73
119	Resultados del objetivo 3	97
120	Artículo 5.....	98

121	Utility of an indirect ELISA test based in recombinants proteins IsdA, ClfA and SdrD of	
122	<i>Staphylococcus aureus</i> to detect bovine intramammary infections	98
123	Conclusiones generales	125
124	Anexos	128
125	Referencias	129
126		
127		
128		
129		
130		
131		
132		
133		
134		
135		
136		
137		
138		
139		
140		
141		
142		
143		
144		

145

Lista de tablas

146 **Artículo 1**

- 147 • **Table 1.** *S. aureus* strains isolated from cattle from each region.
- 148 • **Table 2.** Genotypes identified in *S. aureus* isolates.
- 149 • **Table 3.** Distribution of the biofilm-forming and non-biofilm-forming *S. aureus* strains
150 by genotype.
- 151 • **Table 4.** Distribution of the genotypes by clusters obtained using hierarchical
152 analysis.

153 **Artículo 2**

- 154 • **Table 1.** Number of *S. aureus* strains isolated in each region.
- 155 • **Table 2.** Distribution and characteristics of the strains under study.
- 156 • **Table 3.** Spa type and clonal complexes by municipality.
- 157 • **Table 4.** Most frequent clonal complexes and spa type.

158 **Artículo 3**

- 159 • **Table 1.** General genome characteristics of *S. aureus* Sa1FB strain.
- 160 • **Table 2.** Percentage of cell invasion by strain.

161 **Artículo 4**

- 162 • **Table 1.** Characteristic genotypic and phenotypic of the selected strains.
- 163 • **Table 2.** Proteins number identified from biofilm-forming strains during contact with
164 MEC.
- 165 • **Table 3.** Proteins only identified from biofilm-forming strains by time evaluated.
- 166 • **Table 4.** Main characteristics of the identified proteins involved in the biofilm
167 formation process.

168 **Artículo 5**

- 169 • **Table 1.** Cows included in the study infected with a pathogen different to *S. aureus*.
170 • **Table 2.** Genotypes identified in *S. aureus* isolates.
171 • **Table 3.** IgG levels against the proteins evaluated by sample type and cows status.
172 • **Table 4.** Results obtained in the ROC curves analysis for each protein and sample
173 type.

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

Lista de figuras

189 **Artículo 1**

190 • **Figure 1.** Hierarchical clustering.

191 • **Figure 2.** Box plot

192 • **Figure 3.** Box plot

193 **Artículo 2**

194 • **Figure 1.** Number of strains (frequency) per clonal complex (CC) and number of
195 antibiotics to which they were resistant.

196 • **Figure 2.** Distribution of the resistance to at least one antibiotic by municipality.

197 **Artículo 3**

198 • **Figure 1.** Circular representation of *S. aureus* Sa1FB draft genome.

199 • **Figure 2.** An overview of the subsystem categories.

200 • **Figure 3.** Unique and shared orthologs.

201 • **Figure 4.** Whole genome alignment among *S. aureus* strains.

202 • **Figure 5.** Scanning electron microscopy images of the biofilms formed.

203 **Artículo 4**

204 • **Figure. 1.** Venn diagram.

205 **Artículo 5**

206 • **Figure 1.** Total IgG response against the proteins identified in blood serum from
207 infected and uninfected cows.

208 • **Figure 2.** Total IgG response against the proteins evaluated.

- 209 • **Figure 3.** Total IgG response against the proteins identified in milk serum from
210 infected and uninfected cows.
- 211 • **Figure 4.** Total IgG titers in blood serum versus genotype isolated.
- 212 • **Figure 5.** ROC curve.

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

Lista de abreviaturas

- 230 • AA: amino acids
- 231 • ALT: ácido lipoteicoico
- 232 • ATCC: American type culture collection
- 233 • Bap: Biofilm-associated protein
- 234 • CC: Clonal complex
- 235 • CDS: coding sequences
- 236 • CID: collision-induced dissociation
- 237 • Clf: Clumping factors
- 238 • CWA: Cell Wall Anchored
- 239 • DMEM: Dulbecco`s modified eagle`s medium
- 240 • EDTA: ácido etilendiaminotetraacético
- 241 • ELISA: Enzyme-linked immunosorbent assay
- 242 • FnBPs: Fibronectin-Binding Proteins
- 243 • IgG: immunoglobulin G
- 244 • Isd: Iron-regulated Surface determinants
- 245 • LC–MS/MS: liquid chromatography-tandem mass spectrometry
- 246 • LPS: lipopolisacarido
- 247 • M: molar
- 248 • MAMP: Microorganisms-Associated Molecular Pattern
- 249 • MEC: mammary epithelial cells
- 250 • MLST: Multilocus sequence typing
- 251 • mL: mililitro
- 252 • MOI: multiplicity of infection
- 253 • MRSA: methicillin-resistant *S. aureus*
- 254 • MSCRAMM: Microbial Surface Components Recognizing Adhesive Matrix Molecule
- 255 • NET: neutrophil extracellular trap

- 256 • ng: nano gramo
- 257 • nm: nanometros
- 258 • OD: optical densities
- 259 • PIA: Polysaccharide Intercellular Adhesion
- 260 • PBS: phosphate-buffered saline
- 261 • PCR: Polymerase Chain Reaction
- 262 • PFGE: Pulsed-field gel electrophoresis
- 263 • PRR: Pattern Recognition Receptors
- 264 • RP: recombinant proteins
- 265 • SpA: Staphylococcal protein A
- 266 • Sdr: Serine-aspartate repeat family proteins
- 267 • SEM: scanning electron microscopy
- 268 • SCC: somatic cell count
- 269 • SCCmec: Staphylococcal Cassette Chromosome
- 270 • SCV: Small Colony Variants
- 271 • t: spa tipo
- 272 • TBS-T: tris-buffered saline and tween
- 273 • TLR: Toll-Like Receptors
- 274 • TSA: Trypticase soy agar
- 275 • TSB: Trypticase soy broth
- 276 • μ M: micro molar
- 277 • μ L: micro litro
- 278 • WGS: whole genome sequence

- 279

- 280

- 281

Resumen general

282

283

284 *Staphylococcus aureus* es una de las principales bacterias causantes de infecciones
285 intramamarias en bovinos, las cuales se caracterizan por su limitada respuesta a los
286 antibióticos y persistencia en glándula mamaria. Uno de los factores de virulencia que
287 más se ha asociado con estas características es la formación de biopelícula, debido a
288 que le confiere al patógeno capacidad para evadir la respuesta inmune y la acción de
289 los antibióticos. En Colombia, donde *S. aureus* todavía es uno de los patógenos más
290 prevalentes, se desconocía sobre las características genotípicas y fenotípicas
291 relacionadas con la capacidad de formación de biopelícula de las cepas circulantes. Por
292 lo tanto, el objetivo fue caracterizar factores genotípicos y fenotípicos de *S. aureus*
293 asociados a la formación de biopelícula en mastitis bovina.

294 En total, 277 cepas de *S. aureus* fueron caracterizadas genotípicamente y fenotípicamente en
295 términos de formación de biopelículas y linajes mediante técnicas microbiológicas y
296 genómicas. Además, se identificaron y evaluaron potenciales marcadores (proteínas) de
297 infección empleando un análisis proteómico y un inmunoensayo.

298 Los resultados mostraron tres diferentes genotipos en cuanto a formación de
299 biopelícula. El genotipo 1 (*ica* positivo y *bap* negativo) fue el más prevalente (78,2%),
300 seguido del genotipo 2 (*ica* y *bap* positivos) (12,7%) y el genotipo 0 (*ica* y *bap*
301 negativos) (9,2%). El 81,3% de las cepas evaluadas fueron formadoras de biopelícula,
302 observándose que el 100% de las cepas del genotipo 2 fueron formadoras y
303 presentaron las densidades ópticas más altas (>2,4), demostrando su alta capacidad
304 para generar biopelícula. En cuanto a los linajes, se identificaron 38 spa tipos
305 diferentes, los cuales fueron agrupados en 16 complejos clonales. Los spa tipos más
306 frecuentes fueron el t267 y el t521, ambos pertenecientes al complejo clonal CC97.
307 Además, 51 cepas tipificadas se clasificaron como genotipos nuevos (no reportadas

308 previamente). El 68% de los genotipos identificados también han sido encontrados
309 causando infecciones en humanos.

310 Por otra parte, el determinante de superficie regulador del hierro A (IsdA), el factor de
311 agregación A (ClfA) y la proteína con repeticiones de aspartato-serina D (SdrD) fueron
312 las proteínas identificadas por métodos proteómicos, que mostraron potencial para ser
313 usadas como marcadores de infección, pues fueron expresadas en la fase inicial de la
314 infección, se han asociado con formación de biopelícula y tienen la capacidad de
315 desencadenar una respuesta inmune.

316 El inmunoensayo realizado mostró diferencias significativas en la respuesta de IgG
317 contra las proteínas evaluadas, resaltando el potencial antigénico de IsdA. Sin
318 embargo, fue la mezcla de las proteínas la que presentó la mayor capacidad para
319 diferenciar entre animales infectados y controles empleando muestras de sangre.
320 Aunque, es importante resaltar que cuando esta mezcla fue evaluada con muestras de
321 leche, se evidenció una alta especificidad (94%).

322 En conclusión, la mayoría (81,26%) de las cepas de *S. aureus* circulantes en Antioquia
323 son formadoras de biopelículas, resaltando la alta capacidad de las cepas *bap* positivas.
324 Igualmente, se encontró que estas cepas fueron ampliamente diversas en cuanto a los
325 genotipos, evidenciándose un alto porcentaje (68%) de genotipos causantes también de
326 infecciones en humanos. Además, se identificaron proteínas implicadas en la formación
327 de biopelículas que podrían ser usadas en inmunoensayos como marcadores de
328 infección.

329

330

331

332

General abstract

333 *Staphylococcus aureus* is one of the most common pathogens causing bovine
334 intramammary infections, which are characterized by the presence of persistent
335 microorganisms along with a poor response to antibiotic therapy. The ability of *S. aureus*
336 to persist in the mammary gland has been associated with multiple virulence factors.
337 Among these, biofilm formation is one of the most important because biofilms confer
338 protection against antibiotics and the host immune response. In Colombia however,
339 where this pathogen is one of the major causes of IMI in dairy cows, biofilm formation
340 ability remains unknown. Therefore, the aim of this study was to characterizer genotypic
341 and phenotypic factors from *S. aureus* associated with biofilm formation in bovine
342 mastitis.

343 In total, 277 *S. aureus* strains were characterized in terms of biofilm formation and
344 genetic lineages using microbiological and genomics techniques. In addition, potential
345 serologic markers were identified and evaluated by proteomic analysis and an
346 immunoassay.

347 Three different genotypes grouped into three separate clusters were identified from *in*
348 *vitro* assays. Genotype 1 (*ica* positive and *bap* negative) was the most prevalent
349 (78.17%), followed by genotype 2 (*ica* and *bap* positive) (12.66%) and genotype 0 (*ica*
350 and *bap* negative) (9.17%). Biofilm formation was observed in 81.26% of the strains
351 from which 100% of genotype 2 isolates showed biofilm formation. The biofilms formed
352 by genotype 2 isolates were also found to have the highest optical density (>2.4).
353 Regarding the lineages found, 38 different *spa* types were identified, which were
354 grouped into 16 clonal complexes. The most frequent *spa* types were t267 and t521.
355 Furthermore, it was determined that 51 of the genotypes described had been unreported
356 so far (new) and 68% had also been previously reported in humans.

357 On the other hands, IsdA, ClfA and SdrD were the identified proteins that could be used
358 as markers of infection, since are involved in the early stage of the infection, in the
359 biofilm formation and have the ability of elicit an immune response.

360 The result showed significant differences in the IgG response against markers
361 evaluated, highlighting the antigenic potential of IsdA. According to ROC curves
362 analysis, the protein mixture was the one that showed the greatest capacity to
363 differentiate between infected and uninfected cows when the blood samples were used.
364 In addition, this mixture also showed the highest specificity (94%) using milk samples,
365 suggesting its possible use as a diagnostic complement to somatic cell count, which is
366 highly sensitive but not so specific.

367 In conclusion, most (81,26%) *S. aureus* strains evaluated were biofilm former,
368 highlighting the high ability of the *bap* positive strains to produce biofilm. We also
369 identified that the *S. aureus* strains included were very diverse in terms of lineages,
370 evidencing a high percentage (68%) of genotypes that can also cause infections in
371 humans. Furthermore, three proteins involved in the biofilm formation process were
372 identified, which could be used as potential markers of infection.

373

374

375

376

377

378

379

380

Introducción general

381 *Staphylococcus aureus* es uno de los patógenos más aislado de infecciones
382 intramamarias (IIM) bovinas tanto en Colombia como en diferentes partes del mundo
383 (Keefe, 2012; Vidal et al., 2016). Estas infecciones se caracterizan por la persistencia
384 de la bacteria en glándula mamaria y limitada respuesta a los antibióticos (Veh et al.,
385 2015a). Los animales con infecciones crónicas se convierten en importantes reservorios
386 del patógeno y mantienen su ocurrencia dentro del hato, lo cual desencadena pérdidas
387 económicas importantes en las granjas lecheras (Halasa et al., 2007; Hernández-
388 Castellano et al., 2017a; Schukken et al., 2011; Veh et al., 2015a).

389 La capacidad de persistencia de *S. aureus* en la glándula mamaria bovina se ha
390 asociado con múltiples factores de virulencia, entre estos, la formación de biopelícula,
391 dado que esta conformación le confiere al patógeno protección frente a antibióticos y la
392 respuesta inmune del huésped, ambos elementos claves para la eliminación de la
393 infección (Gomes et al., 2016). Estudios previos han demostrado que el proceso de
394 formación de biopelículas por *S. aureus* es diverso y redundante (Zapotoczna et al.,
395 2016). Este patógeno puede formar biopelículas, principalmente, mediante dos
396 mecanismos. El más común y estudiado a la fecha es la biopelícula mediada por el
397 polisacárido de adhesión intercelular (PIA por sus siglas en inglés), el cual es codificado
398 por el operón *ica* y conocido como dependiente de PIA (Cucarella et al., 2004;
399 McCarthy et al., 2015). Se ha evidenciado que la mayoría de los aislados que causan
400 infecciones tanto en humanos como animales son portadoras del operón *ica* (Cucarella
401 et al., 2004). El otro mecanismo descrito es denominado independiente de PIA y se ha
402 relacionado con la proteína asociada a biopelícula (Bap por sus siglas en inglés) y la
403 meticilino resistencia (McCarthy et al., 2015). La proteína Bap es codificada por el gen
404 *bap* y se ha localizado en un transposón contenido en la isla de patogenicidad
405 SaPIbov2, uno de los elementos genéticos móviles de *S. aureus* (Cucarella et al.,
406 2004). Algunos reportes han indicado que las cepas portadoras del gen *bap* son

407 generalmente fuertes formadoras de biopelículas, incluso, en ausencia del locus *ica*, y
408 pueden generar infecciones más persistentes que las cepas *bap* negativas (Cucarella
409 et al., 2004; Torres et al., 2019). Sin embargo, algunos estudios también han descrito
410 otros elementos que parecen jugar un papel importante en el proceso, como es el ADN
411 extracelular (eADN), la aglomeración dependiente de fibrina y los agregados de
412 amiloide (Zapotoczna et al., 2016).

413 La fase inicial en el proceso de formación de biopelícula es la adhesión de la bacteria a
414 la superficie biótica o abiótica (Moormeier & Bayles, 2017). No se formará una
415 biopelícula madura sin una unión adecuada y fuerte de *S. aureus* a la superficie, debido
416 a que las bacterias no ancladas serán removidas del huésped (Gong et al., 2010). *S.*
417 *aureus* puede unirse a las superficies mediante diferentes proteínas pertenecientes al
418 grupo conocido como componentes de la superficie microbiana que reconocen
419 moléculas adhesivas de la matriz (MSCRAMMs por sus siglas en inglés), las cuales
420 hacen parte de las proteínas de anclaje a la pared (CWA por sus siglas en inglés)
421 (Foster et al., 2014). Algunas de las proteínas de este grupo que han sido implicadas en
422 la adherencia inicial y posterior formación de biopelícula son las proteínas de unión a la
423 fibronectina (FnBPA y FnBPB), los factores de agregación (ClfA y ClfB), proteínas con
424 repeticiones de aspartato-serina (SdrC, SdrD y SdrE), determinantes de superficie
425 reguladores del hierro (IsdA, IsdB, IsdC y IsdH) y Bap (Moormeier & Bayles, 2017).

426 Diferentes enfoques proteómicos y herramientas bioinformáticas se han usado para
427 estudiar la compleja interacción entre *S. aureus* y el huésped (Huang et al., 2014). La
428 mayoría de estudios proteómicos acerca de biopelículas han usado cultivos bacterianos
429 sobre superficies abióticas, los cuales probablemente no reflejan la total realidad *in vivo*
430 (Lei et al., 2017). Estas discrepancias han sido demostradas en algunos trabajos, en los
431 cuales se han observado diferencias importantes entre lo encontrado usando
432 superficies inertes y modelos vivos (Brady et al., 2006; den Reijer et al., 2016). Lo

433 anterior, demuestra la importancia de emplear modelos (celulares o animales) que
434 permitan acercar la bacteria a las condiciones más reales.

435 La detección temprana y precisa de *S. aureus* es una de las herramientas esenciales en
436 el adecuado control de las IIM causadas por este patógeno, pues permite optimizar los
437 tratamientos antibióticos y separar oportunamente los animales infectados, por
438 consiguiente, interrumpir la cadena de transmisión (Hernández-Castellano et al.,
439 2017b). Usualmente, el diagnóstico de IIM se realiza mediante el recuento de células
440 somáticas (RCS) y el cultivo bacteriológico (Rainard et al., 2018). Sin embargo, un
441 estudio reciente encontró que el RCS tenía una sensibilidad y especificidad (con un
442 umbral de detección de 200.000 células/mL) para detectar infecciones causadas por *S.*
443 *aureus* de 84,2% y 52,8%, respectivamente (Petzer et al., 2017). Estos hallazgos no
444 resultan totalmente convenientes para el control de este patógeno, pues al no ser tan
445 específico conlleva a que se apliquen tratamientos que probablemente no serán
446 efectivos. Al final, se hará un uso inadecuado de antibióticos, los animales seguirán
447 infectados con *S. aureus* y propagarán la bacteria dentro del hato, lo cual perpetuará el
448 ciclo. En el caso del cultivo bacteriológico, este resulta complejo de realizar en campo,
449 consume tiempo y su sensibilidad frente al patógeno es variable (Rainard et al., 2018).
450 De ahí, la importancia de encontrar alternativas diagnósticas eficientes que permitan
451 mejorar la detección de *S. aureus* o complementar las técnicas convencionales.

452 Existe evidencia que ha demostrado el potencial inmunogénico de algunas proteínas
453 expresadas por *S. aureus* durante la fase inicial de la formación de biopelícula, las
454 cuales podrían ser usadas a nivel diagnóstico, pues estudios han demostrado que
455 individuos infectados con la bacteria generaron títulos de anticuerpos más altos que los
456 controles sanos (den Reijer et al., 2017; Joost et al., 2011). Por lo tanto, estos
457 resultados conllevan a seguir buscando y evaluando marcadores que permitan
458 discriminar eficientemente los animales con IIM de los sanos, lo cual permitirá

459 implementar medidas de manejo que impacten oportunamente la prevalencia de este
460 patógeno dentro del hato.

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

Objetivos

477

478 **Objetivo general**

479 Caracterizar factores genotípicos y fenotípicos de *Staphylococcus aureus* asociados a
480 la formación de biopelícula en mastitis bovina.

481

482 **Objetivos específicos**

- 483 • Caracterizar genotípica y fenotípicamente cepas de *S. aureus* y evaluar diferencias
484 en susceptibilidad a meticilina y capacidad formadora de biopelículas.
- 485 • Caracterizar y comparar los proteomas generados *In vitro* durante la formación de
486 biopelícula por cepas de *S. aureus* aisladas de mastitis.
- 487 • Determinar anticuerpos en muestras de leche y sangre frente a las proteínas
488 recombinantes de interés.

489

490

491

492

493

494

495

496

Marco teórico

497 Mastitis bovina

498 La mastitis se define como la inflamación de la glándula mamaria de la vaca, la cual
499 puede ser causada por factores como traumatismos o lesiones, irritaciones químicas e
500 infecciones; aunque, son estas últimas las más comunes. Las infecciones
501 intramamarias (IIM) pueden ser causadas por diferentes microorganismos. Sin
502 embargo, son las bacterias las principales causantes de esta patología en bovinos
503 (Philpot & Nickerson, 2000).

504 La IIM se presenta luego de que los microorganismos penetran por el canal del pezón,
505 se establecen en el tejido, evaden la respuesta inmune, se multiplican y producen el
506 daño. La interacción entre el tejido mamario y el microorganismo en condiciones
507 normales desencadena una respuesta inflamatoria en la glándula (Philpot & Nickerson,
508 2000). La reacción inflamatoria es un mecanismo de protección que busca eliminar los
509 microorganismos, neutralizar sus toxinas y ayuda a reparar los tejidos comprometidos.
510 Esta respuesta está mediada principalmente por leucocitos (células somáticas),
511 especialmente neutrófilos, los cuales migran desde la sangre hacia el tejido afectado
512 con el objetivo de eliminar la infección (Wellnitz & Bruckmaier, 2012).

513 Dependiendo de los signos y síntomas que se presenten en la glándula mamaria y la
514 leche, la mastitis se puede clasificar en subclínica o clínica. La mastitis subclínica no
515 presenta síntomas ni signos evidentes y la apariencia de la leche es normal. No
516 obstante, su calidad y cantidad se ve afectada. Su diagnóstico solo se puede realizar
517 mediante pruebas de laboratorio que permiten detectar el microorganismo responsable
518 de la infección o el aumento del recuento de células somáticas (RCS). Este tipo de
519 mastitis es la más prevalente e importante, pues generalmente pasa desapercibida para
520 el productor durante mucho tiempo y le genera pérdidas económicas significativas. Un
521 estudio realizado en Antioquia por Ramírez et al. (2014) encontró una prevalencia de

522 mastitis subclínica alrededor del 37%. Por el contrario, la mastitis clínica se caracteriza
523 por las anomalías visibles en la ubre o en la leche, lo que facilita su diagnóstico, y
524 la severidad puede variar durante el curso de la enfermedad (Philpot & Nickerson,
525 2000).

526 La mastitis es considerada la enfermedad que más pérdidas económicas le genera a
527 los productores de leche debido a la reducción en la calidad y cantidad de leche
528 producida, el descarte temprano de animales y de leche, así como, por el aumento de
529 costos veterinarios (Shim et al., 2004). La industria láctea también se ve impactada por
530 esta enfermedad, pues se requiere más litros de leche para obtener un kilo de producto
531 final (por ejemplo, de queso o leche en polvo) y por acortarse la vida útil del producto en
532 el mercado (Keefe, 2010). Se estima que las pérdidas económicas anualmente en
533 Estados Unidos por mastitis pueden alcanzar los dos billones de dólares y en el Reino
534 Unido £300 millones (Viguiet et al., 2009). En Canadá, los costos por un caso de
535 mastitis están alrededor de US\$290 y en Holanda promedia los €150 por vaca al año
536 (Keefe, 2010; Viguiet et al., 2009). En Colombia, la cifra puede acercarse al millón de
537 pesos por animal (Bedoya & Ponce de León, 2008).

538 **Infecciones intramamarias bovinas causadas por *S. aureus***

539 Se han descrito alrededor de 150 microorganismos causantes de IIM, pero son las
540 bacterias, especialmente los cocos Gram positivos de los géneros *Staphylococcus* y
541 *Streptococcus*, los responsables de la mayoría de casos (Fu et al., 2013). *S. aureus* es
542 uno de los patógenos más aislado de las IIM a nivel mundial y es reconocido por
543 generar infecciones crónicas difíciles de eliminar. Diferentes artículos han evidenciado
544 que la patogenicidad de *S. aureus* es un proceso complejo, en el cual se involucran
545 diferentes factores de virulencia y condiciones del huésped. A la fecha, se han descrito
546 diferentes factores de virulencia del patógeno involucrados con la adhesión, invasión
547 celular, daño a tejido, formación de biopelícula y evasión de la respuesta inmune. Estos
548 elementos en conjunto le confieren a la bacteria un amplio repertorio de mecanismos

549 para infectar y persistir dentro de la glándula, con pocas probabilidades de eliminación
550 por el sistema inmune y los antibióticos (Zecconi & Scali, 2013).

551 *S. aureus* puede llegar a la piel del pezón a través de las manos del ordeñador,
552 pezoneras, leche o cualquier elemento contaminado con el que tenga contacto. Para
553 ingresar al pezón, la bacteria primero debe sobrepasar las barreras naturales
554 generadas por el esfínter y el tapón de queratina, mediante sus propios mecanismos de
555 adhesión y multiplicación o a través de elementos físicos que la pueden arrastrar hacia
556 el interior como las cánulas de aplicación de antibióticos y las diferencias de presión
557 ocasionadas por las fluctuaciones de vacío durante el ordeño mecánico. Una vez la
558 bacteria alcanza el interior del pezón, también debe superar la acción expulsiva del
559 ordeño frecuente, por lo que en este punto, su capacidad de adherencia al tejido influirá
560 sobre la permanencia dentro del cuarto infectado, evento decisivo en la fase temprana
561 de la patogénesis (Philpot & Nickerson, 2000).

562 La capacidad de adherencia de *S. aureus*, uno de los factores de virulencia más
563 relevantes, se le atribuye a una familia de proteínas conocidas como componentes de la
564 superficie microbiana que reconocen moléculas adhesivas de la matriz (*Microbial*
565 *Surface Components Recognizing Adhesive Matrix Molecule* - MSCRAMM), las cuales
566 hacen parte del grupo de proteínas de anclaje a la pared celular (*Cell Wall Anchored* -
567 CWA) (Foster et al., 2014). En *S. aureus* se han identificado alrededor de 28 diferentes
568 CWA y su expresión puede variar entre cepas, dependiendo del genotipo, condiciones
569 ambientales o necesidades bacterianas. Las MSCRAMM son proteínas de superficie
570 que median el ataque a componentes extracelulares tales como fibrinógeno,
571 fibronectina, laminina y colágeno, entre otras; incluso, algunas presentan funciones
572 adicionales a la adhesión (Foster et al., 2014).

573 Algunas de las MSCRAMM más estudiadas en *S. aureus* aislado de bovinos, debido a
574 su alta capacidad de adhesión y posterior participación en formación de biopelículas,
575 son las proteínas de unión a fibronectina A y B (*Fibronectin-Binding Proteins A and B* –

576 FnBPA and FnBPB), los factores de agregación A y B (*Clumping factors A and B* – ClfA
577 and ClfB), los determinantes de superficie reguladores de hierro (*Iron-regulated Surface*
578 *determinants* – IsdA, IsdB, IsdC, IsdH), proteínas con repeticiones de aspartato-serina
579 (*Serine-aspartate repeat family proteins* – SdrC, SdrD, SdrE) y la proteína asociada a la
580 biopelícula (*Biofilm-associated protein* – Bap). La mayoría de estas proteínas comparten
581 el mismo motivo (LPXTG); sin embargo, estas tienen diferentes blancos de unión sobre
582 la matriz extracelular del huésped (Moormeier & Bayles, 2017).

583 Las FnBPs, además de mediar la unión a fibronectina, también están involucradas en el
584 proceso de invasión celular, otro de los factores de virulencia importantes de la bacteria
585 (Brouillette et al., 2003; Budd et al., 2016). La fibronectina es una glicoproteína presente
586 en la matriz extracelular, compuesta por tres módulos estructurales (Tipo 1, Tipo 2 y
587 Tipo 3), donde las FnBPs de *S. aureus* presentan alta afinidad por el módulo tipo 1,
588 mientras que, el módulo tipo 3 es reconocido por la integrina $\alpha 5\beta 1$, un receptor
589 expresado en la superficie de las células epiteliales mamarias (CEM) (Foster et al.,
590 2014; Schwarz-Linek et al., 2003). En este caso, la fibronectina actúa como un puente
591 entre la bacteria y la célula (Fowler et al., 2000). Un estudio demostró que la expresión
592 de las FnBPs es cepa dependiente y su ausencia en la cepa evaluada redujo la
593 adhesión a las CEM hasta en un 40% y la invasión en un 95%, comparado con la cepa
594 control (Budd et al., 2016).

595 La proteína IsdA juega un papel importante en el proceso de adhesión y en la formación
596 de biopelícula bajo condiciones limitadas de hierro. El hierro es un elemento esencial
597 para el crecimiento de la bacteria y la formación de biopelícula, pero su disponibilidad
598 en el huésped generalmente es restringido, pues más del 90% del hierro disponible está
599 localizado dentro de las células (Hammer & Skaar, 2011). Uno de los mecanismos que
600 tiene *S. aureus* para captar hierro del ambiente es mediante IsdA. Algunos estudios han
601 demostrado que hay un aumento en la expresión de la proteína cuando la disponibilidad
602 de hierro se ha limitado (Clarke et al., 2004; Lin et al., 2012). No obstante, IsdA también

603 ha sido implicada en el proceso de adhesión a la fibronectina y al fibrinógeno durante la
604 etapa inicial de la colonización (Clarke et al., 2004). Estudios que han bloqueado esta
605 proteína han observado una reducción en la capacidad de colonizar el tejido del
606 huésped (Bennett et al., 2019; Cheung et al., 2009; Hammer & Skaar, 2011).
607 Adicionalmente, la capacidad antigénica de IsdA también ha sido demostrada por
608 Stranger-Jones et al. (2006), quienes lograron una inmunidad protectora en murinos
609 previamente sensibilizados con una vacuna compuesta de cuatro antígenos, entre estos
610 IsdA y SdrD, y retados con cepas patógenas aisladas de humanos.

611 ClfA es una importante adhesina, usualmente anclada covalentemente a la pared
612 bacteriana (Gong et al., 2010). Aunque, ClfA generalmente ha sido relacionada con la
613 unión al fibrinógeno plasmático, un estudio mostró que esta molécula también tiene un
614 mecanismo directo de anclaje a la célula en ausencia de fibrinógeno. Esta proteína
615 puede interactuar con la AnnexinaA2, una molécula encontrada en la superficie de las
616 CEM (Ashraf et al., 2017). En cuanto al papel de ClfA en la formación de biopelícula,
617 Zapotoczna et al. (2015) informó sobre un fenotipo de biopelícula mediado por esta
618 proteína, dado que tiene la capacidad de unirse a la fibrina formada por la enzima
619 coagulasa o al fibrinógeno disponible, conllevando a una agregación bacteriana.
620 Diferentes estudios han propuesto que ClfA es un buen candidato para vacuna, porque
621 es un importante factor de virulencia, la mayoría de las cepas son portadoras del gen
622 *clfA* y es antigénica (Camussone et al., 2014; Nour El-Din et al., 2006).

623 Sdr es otra de las proteínas importantes en el proceso de colonización y formación de
624 biopelícula por *S. aureus*, aunque, no todas las cepas son portadoras de los genes que
625 conforman este grupo (Josefsson et al., 1998). Ma et al. (2012) y Vaishampayan et al.
626 (2018) observaron en sus trabajos una reducción en la expresión del gen *sdrD* y en la
627 capacidad de formación de biopelícula de las cepas evaluadas después de ser
628 enfrentadas a productos que buscaban impactar la producción de biopelícula. Otro
629 estudio, demostró que la proteína SdrD contribuía a la supervivencia de *S. aureus* en

630 sangre debido a que participaba en la evasión de la respuesta inmune (Askarian et al.,
631 2017). Como fue mencionado anteriormente, SdrD también fue evaluada como parte de
632 la vacuna compuesta desarrollada por Stranger-Jones et al. (2006), donde quedó
633 demostrado su potencial antigénico.

634 En cuanto a Bap, esta proteína tiene un tamaño de 2.276 aminoácidos, permite la unión
635 a las superficies, así como, la adhesión intercelular y es codificada por el gen *bap*, el
636 cual hace parte de un transposón insertado en la isla de patogenicidad SaPIbov2
637 (Cucarella et al., 2004). La evidencia sugiere que el gen *bap* se puede transmitir entre
638 cepas mediante transferencia horizontal de genes (Tormo et al., 2005). El gen *bap* se
639 han encontrado en cepas aisladas de bovinos y cerdos, pero su frecuencia entre cepas
640 puede variar por regiones (Cucarella et al., 2004; Feltrin et al., 2016; Torres et al.,
641 2019). Estudios han demostrado que las cepas portadoras de este gen son
642 generalmente fuertes formadoras de biopelículas y generan infecciones más
643 persistentes en bovinos (Cucarella et al., 2004; Torres et al., 2019). Otro estudio
644 demostró que las cepas con este genotipo son menos invasivas, debido a que Bap
645 bloquea la interacción de las FnBPs con su ligando (fibronectina), un proceso
646 fundamental para que la bacteria pueda ingresar a la CEM (Cucarella et al., 2002; Valle
647 et al., 2012).

648 Una vez establecida la infección, las bacterias recubren la cisterna del pezón, así como,
649 la glandular, y luego migran al sistema de conductos donde se multiplican activamente
650 hasta formar agregados bacterianos. En la fase inicial de la infección el daño puede ser
651 mínimo y su eliminación mediante los tratamientos antibióticos puede tener mejores
652 resultados. Durante una infección crónica con *S. aureus*, el daño puede ser variable y la
653 zona afectada será total o parcialmente improductiva, pues las células secretoras se
654 degeneran y junto con los leucocitos obstruyen los conductos galactóforos, lo que
655 conlleva a que se genere tejido cicatricial, y en algunos casos, dependiendo de la
656 extensión del daño, a que se atrofie el alveolo. (Philpot & Nickerson, 2000).

657 **Respuesta inmune contra *S. aureus***

658 **Inmunidad innata**

659 El contacto de *S. aureus* con las células epiteliales del tejido y con las células somáticas
660 durante su ingreso desencadena la respuesta inicial contra el patógeno. La importancia
661 de las células epiteliales mamarias en la respuesta inmune temprana ha sido
662 reconocida en numerosas investigaciones; primero, porque son las células con las que
663 inicialmente entra en contacto la bacteria al ingresar; segundo, por la capacidad de
664 producir mediadores inflamatorios que desencadenan la activación y migración de los
665 leucocitos, principalmente de neutrófilos, la célula somática predominante durante la
666 fase aguda de la respuesta (Bougarn et al., 2010; Yang et al., 2008).

667 Las células epiteliales como las somáticas pueden reconocer a este patógeno mediante
668 los receptores de reconocimiento de patrones (*Pattern Recognition Receptors* – PRR)
669 ubicados en la superficie o a nivel intracelular. Estos receptores se unen a los patrones
670 moleculares asociados a los microorganismos (*Microorganisms-Associated Molecular*
671 *Pattern* – MAMPs), estructuras conservadas y características entre grupos de
672 microorganismos. Es el caso de los lipopolisacáridos (LPS) en las bacterias Gram
673 negativas y los ácidos lipoteicoicos (ALT) en las Gram positivas. Los receptores tipo Toll
674 (*Toll-Like Receptors* – TLR) son una clase de PRRs que reconocen un amplio rango de
675 MAMPs (Abbas et al., 2014; Bougarn et al., 2010). Generalmente los TLRs son
676 específicos y cada uno tiene la capacidad de unirse a un MAMP. En el caso de *S.*
677 *aureus*, bacteria Gram positiva, el TLR2 es el que se ha asociado a su reconocimiento,
678 debido a que pueden unirse a ALT y al peptidoglicano presente en la pared bacteriana;
679 aunque, se ha descrito que este TLR no es tan específico y también puede reconocer
680 LPS de algunas bacterias Gram negativas (Smith et al., 2003). Debido a que *S. aureus*
681 invade eficientemente las células como mecanismo de evasión del sistema inmune,
682 también puede ser reconocido por los receptores tipo NOD, un PRR ubicado en el
683 citosol de la célula hospedera y que interacciona con el peptidoglicano (Jintaek et al.,

684 2014). En un estudio donde se inoculó *S. aureus* en la glándula mamaria de ratas, se
685 evidenció un incremento en la expresión del RNAm para NOD después de la infección,
686 lo que demostró su actividad durante la invasión intracelular del patógeno (Wang et al.,
687 2015).

688 Una vez es reconocida la bacteria, se activan los mecanismos moleculares que
689 promueven la expresión de genes que codifican para las principales citoquinas pro-
690 inflamatorias, el factor de necrosis tumoral alfa (*Tumor Necrosis Factor Alpha* - TNF- α),
691 la Interleuquina 1 β (*Interleukin* 1 β - IL-1 β) y la IL-6. La importancia de estas citoquinas
692 dentro del proceso inflamatorio está dada por la capacidad que tienen de preparar a las
693 células endoteliales para que permitan la migración de los leucocitos al sitio de la
694 agresión (TNF- α y la IL-1 β), promover la fagocitosis en neutrófilos (TNF- α) y estimular
695 la producción de reactantes de fase aguda (IL-1 β e IL-6) (Fu et al., 2013). Los TLR2 en
696 condiciones normales desencadenan la expresión de estos genes por la vía
697 dependiente de la proteína adaptadora MyD88 y del factor nuclear κ B (*Nuclear Factor*
698 *kappa B* - NF- κ B). Se ha observado en diferentes estudios que *S. aureus* tiene la
699 capacidad de bloquear o inhibir la activación del NF- κ B, por consiguiente, alterar la
700 magnitud y tiempo de respuesta de estas citoquinas; contrario a lo que sucede con
701 otros patógenos como *Escherichia coli*, donde se ha descrito una fuerte y rápida
702 respuesta (Lara, 2011; Yang et al., 2008). No obstante, algunos autores, observaron
703 expresión de estas citoquinas en ausencia del factor, sugiriendo la participación de vías
704 independientes, tales como la proteína de activación 1 (*Activating Protein 1* - AP-1) y el
705 elemento de respuesta al AMP cíclico (*Cyclic AMP-Responsive Element* - CRE).
706 Incluso, en otros casos lo que se obtuvo fue transcripción de los genes después del reto
707 pero no hubo traducción, pues no se detectaron las citoquinas (Bougarn et al., 2010;
708 Kim et al., 2011). La variabilidad en los resultados se les ha atribuido a los modelos de
709 ensayo (animal o celular), a las técnicas de medición y al tipo de inmunógeno (bacterias
710 vivas, inactivas o componentes de la pared) empleados.

711 Los neutrófilos son los primeros fagocitos en migrar al sitio de la agresión y pueden
712 reconocer la bacteria directamente mediante los PRRs, o indirectamente, por receptores
713 que se unen a opsoninas (fracción C3a y C5a del complemento o IgG) presentes en la
714 superficie del patógeno. Posteriormente, la célula ingresa la bacteria dentro una vacuola
715 fagocítica (fagosoma) para eliminarla mediante los diferentes mecanismos microbicidas
716 que dispone, entre estos: a) el estallido respiratorio, donde se generan las especies
717 reactivas del oxígeno, moléculas altamente oxidantes; b) la producción de especies
718 reactivas del nitrógeno, especialmente de óxido nítrico; c) la descarga de enzimas
719 proteolíticas dentro del fagosoma. Estos mecanismos en conjunto y bajo condiciones
720 normales lesionan la bacteria hasta su destrucción (Abbas et al., 2014). La rápida y
721 efectiva respuesta de los neutrófilos es clave para la resolución de la infección; sin
722 embargo, en algunos trabajos se ha cuestionado su función fagocítica y bactericida en
723 leche, debido a los efectos inhibitorios que pueden ejercer sobre el proceso la caseína y
724 los glóbulos de grasa cuando son fagocitados. Además, porque *S. aureus* posee varios
725 mecanismos que le permiten escapar de su acción; por ejemplo, cuando invaden las
726 células epiteliales, forman biopelículas o bloquean la migración (Mehrzaad et al., 2005;
727 Thammavongsa et al., 2015). Aunque este proceso puede verse alterado, no es la única
728 función que emplean los neutrófilos para eliminar los microorganismos. Las trampas
729 extracelulares de neutrófilos (NET) es uno de los mecanismos alternos, en el cual la
730 célula libera todo su material nuclear (DNA y proteínas) y el de sus gránulos sobre la
731 bacteria para causarle daño. La presencia en leche de componentes relacionados con
732 la formación de NETs ha sido la evidencia de que los neutrófilos también recurren a
733 este mecanismo para enfrentar al patógeno (Swain et al., 2014).

734 **Inmunidad adaptativa**

735 Los anticuerpos son los principales mediadores de esta respuesta y sus funciones son
736 neutralizar, activar el complemento y opsonizar; pero como el *S. aureus* puede invadir
737 eficientemente las células, así como, formar biopelículas y cápsula, se ha sugerido que

738 este tipo de respuesta no es suficiente ni efectiva (Atalla et al., 2010; Grönlund et al.,
739 2006). Una de las inmunoglobulinas que participa en la respuesta inmune frente a
740 patógenos como *S. aureus* es la IgG, especialmente los subtipos IgG1 e IgG2 (Atalla
741 et al., 2010). En condiciones normales, la IgG1 es la inmunoglobulina predominante en
742 la secreción mamaria, mientras que, la IgG2 se encuentra en bajas concentraciones,
743 pero ambas pueden aumentar significativamente en los procesos inflamatorios. La IgG2
744 se reconoce como una potente opsonina para los *S. aureus* (Atalla et al., 2010). Un
745 estudio donde se vacunó conejos con una cepa de *S. aureus* fuertemente productora de
746 biopelícula PIA dependiente aislada de mastitis bovina, reportó títulos de anticuerpos en
747 sangre más altos en los animales vacunados que en los no vacunados (Raza et al.,
748 2015). Prenafeta et al. (2010) demostró que las vacas a las que se les aplicó una
749 bacterina que tenía alto contenido de biopelícula, generaron títulos de anticuerpos en
750 leche y sangre superiores a los animales vacunados con la bacterina que tenía bajo
751 contenido de biopelícula y los no vacunados. Por otra parte, Cucarella et al. (2004)
752 detectaron anticuerpos IgG contra Bap en sangre de animales infectados con *S. aureus*
753 *bap* positivos.

754 Con respecto a las células que intervienen en esta respuesta, se ha observado, que
755 además de los linfocitos B, también se pueden encontrar linfocitos T (LT) CD4 y CD8.
756 Sin embargo, son los LT CD8 los que tienden a predominar en la fase crónica de la
757 mastitis (Grönlund et al., 2006).

758 **Detección de *S. aureus* en leche de bovinos con infecciones intramamarias**

759 La detección de *S. aureus* se realiza mediante técnicas microbiológicas convencionales
760 como el cultivo o moleculares como la Reacción en Cadena de la Polimerasa
761 (*Polymerase Chain Reaction* – PCR). Su eliminación cíclica en leche, la cual puede
762 estar asociada con la invasión celular y con la formación de biopelícula y de abscesos,
763 dificulta su diagnóstico e impacta la sensibilidad de las técnicas empleadas (Keefe,
764 2012). La sensibilidad reportada del cultivo estándar (siembra de 0,01 ml) para una sola

765 muestra de leche está entre el 75% a 90%, la cual mejora con cultivos seriados. La
766 sensibilidad de la PCR puede ser superior que la del cultivo; sin embargo, su
767 estandarización debido al tipo de muestra (leche) y su nivel de complejidad dificultan su
768 implementación dentro de la rutina diagnóstica (Dohoo et al., 2011; Greg Keefe, 2012;
769 Sears et al., 1990).

770 Otra de las estrategias disponibles para diagnosticar IIM causadas por *S. aureus* es el
771 RCS, la cual presenta ventajas con respecto a las dos mencionadas anteriormente en
772 términos de costos y practicidad (Petzer et al., 2017). Aunque, la sensibilidad reportada
773 para esta técnica es buena, 84,2%, su especificidad es baja, 52,8% (Petzer et al.,
774 2017). Un estudio reciente encontró que el 30,8% de las vacas con IIM generadas por
775 este patógeno pueden no ser detectadas cuando el umbral es de >150.000 células/ml
776 en leche compuesta, dado que se pueden presentar infección con bajos recuentos
777 (Petzer et al., 2017). El problema de las técnicas sensibles, pero no tan específicas, es
778 que también presentan un número importante de falsos positivos. Lo anterior, junto con
779 el hecho de que esta técnica no permita identificar los animales infectados
780 específicamente con *S. aureus*, podría conllevar a prácticas inadecuadas durante su
781 control, debido a que se tratarán infecciones que probablemente no van a responder al
782 tratamiento y facilitarán su propagación al interior del hato.

783 Por otra parte, varios inmunoensayos también han sido descritos como alternativa
784 diagnóstica de IIM causadas por *S. aureus* (Rainard et al., 2018). Sin embargo, este
785 tipo de técnicas aún representan un reto por resolver, debido a que los animales sin IIM,
786 pero colonizados naturalmente, pueden presentar títulos de anticuerpos similares a los
787 infectados (Boerhout et al., 2016). Por lo tanto, el principal reto de este tipo de prueba
788 es encontrar marcadores serológicos que permitan diferenciar entre animales con
789 infecciones activas y sanos. Fabres-Klein et al. (2014) en su revisión, presenta los
790 resultados de algunas de las pruebas realizadas para diagnosticar mastitis empleando

791 muestras de leche. Las sensibilidades y especificidades reportadas variaron entre 75%
792 - 89% y 70% - 90%, respectivamente.

793 **Tratamiento antibiótico contra *S. aureus***

794 El objetivo de cualquier tratamiento antibiótico contra *S. aureus* es reducir el grupo de
795 animales infectados dentro del hato. Sin embargo, las tasas de cura de *S. aureus* son
796 muy bajas comparadas con otras bacterias, lo que dificulta su control y erradicación
797 (Keefe, 2012). Diferentes estudios han demostrado que la probabilidad de curación
798 depende de factores asociados con el animal, el patógeno y el tratamiento (Barkema et
799 al., 2006). Barkema et al. (2006) calcularon que la tasa de curación esperada para
800 animales jóvenes es de aproximadamente del 60%; mientras que, para animales viejos
801 con altos RCS y múltiples cuartos infectados podría ser inferior al 1%. Factores del
802 patógeno como la capacidad de invasión celular, el fenotipo de variantes de colonia
803 pequeña (*Small Colony Variants* – SCV), la resistencia a los antibióticos, la formación
804 de abscesos y de biopelícula dificultan el tratamiento (Barkema et al., 2006). Algunos
805 estudios han demostrado que el uso de terapias extendidas (>5 días) y mezcla de
806 antibióticos generan mejores resultados que los tratamientos de corta duración (2- 3
807 días). La decisión sobre emplearlas o no para tratar las infecciones con *S. aureus*, es
808 un tema de discusión, pues dependerá del análisis costo-beneficio que se le realice a la
809 opción de mantener el animal dentro del hato (Pinzón-Sánchez et al., 2011; Roy &
810 Keefe, 2012; Steeneveld et al., 2011).

811 **Resistencia de *S. aureus* a los beta-lactámicos**

812 Uno de los problemas que han tenido que afrontar los profesionales responsables de la
813 salud en humanos como en animales, es el aumento de cepas resistentes a los
814 antimicrobianos disponibles y la falta de nuevas moléculas con actividad antibiótica
815 (Oldfield & Feng, 2014). Durante los últimos años la Organización Mundial de Sanidad
816 Animal (OIE) junto con la Organización Mundial de la Salud (OMS) vienen desarrollando

817 estrategias y políticas para evitar el uso inadecuado de los antimicrobianos y minimizar
818 los riesgos que lo anterior conlleva sobre la salud pública y el bienestar animal
819 (*AMR_ES: OIE - World Organisation for Animal Health, 2016*). Se ha reportado que,
820 alrededor del 80% de los antibióticos empleados en Estados Unidos en un año, fueron
821 destinados al manejo del ganado (Chang et al., 2015; Hollis & Ahmed, 2013) y que el
822 uso rutinario de antibióticos a nivel agropecuario ha conllevado a la generación de
823 cepas bacterianas resistentes que impactan la salud pública (Chang et al., 2015); un
824 verdadero problema si se tiene en cuenta que aproximadamente el 60% de los
825 patógenos humanos provienen de animales (Organización Mundial de Sanidad Animal,
826 2015).

827 La resistencia a la meticilina desarrollada por *S. aureus* actualmente es reconocida
828 como la resistencia a los antibióticos β -lactámicos. Estos antibióticos tienen la
829 capacidad de unirse a las proteínas de unión a la penicilina (*Penicillin-Binding Protein –*
830 *PBP*), esenciales para la síntesis de la pared celular e inhibir la formación del
831 peptidoglicano (Paterson et al., 2014). La meticilino resistencia es conferida por un
832 elemento genético móvil conocido como cassette cromosómico estafilocócico
833 (*Staphylococcal Cassette Chromosome – SCCmec*), donde se ubica el gen *mecA* o
834 *mecC* (Paterson et al., 2014). Estos genes codifican para unas PBP alteradas
835 (*PBP2a/PBP2'*) que tiene poca afinidad por los antibióticos β -lactámicos, lo cual evita
836 que se afecte la síntesis de la pared celular, por consiguiente, la viabilidad de la
837 bacteria (Paterson et al., 2014). Una de las cepas más reconocidas de *S. aureus*
838 meticilino resistente asociada a animales (cerdos, bovinos, caballos, aves de corral,
839 perros) y con potencial zoonótico es la ST398 (*sequence type 398*); sin embargo, las
840 cepas más comunes entre los bovinos son la ST97, ST126, ST133, ST151, ST479 y
841 ST771 (Holmes & Zadoks, 2011).

842 La correcta y oportuna identificación de cepas de *S. aureus* meticilino resistentes se ha
843 convertido en una necesidad y obligación para todos los profesionales de la salud, pues

844 de esta forma se puede minimizar el uso indiscriminado e irresponsable de antibióticos
845 y evitar la diseminación de estas cepas; dos acciones que al final van a impactar
846 positivamente sobre la salud pública y el bienestar animal.

847 **La meticilino resistencia y el fenotipo de biopelícula**

848 La relación entre la susceptibilidad a los antibióticos β -lactámicos y el fenotipo de la
849 biopelícula fue descrito inicialmente en *Staphylococcus epidermidis*, donde se identificó
850 que diferentes niveles en la producción de PIA fue asociado significativamente con
851 diferentes niveles de susceptibilidad a los β -lactámicos (McCarthy et al., 2015). En *S.*
852 *aureus* se ha encontrado que la producción de PIA fue esencial para la formación de
853 biopelícula en cepas meticilino sensibles, pero no en las meticilino resistentes (O'Neill
854 et al., 2007). Incluso, la delección del locus *ica* en cepas de *S. aureus* meticilino
855 sensibles suprimió la formación de biopelículas (O'Neill et al., 2007). En cuanto al
856 fenotipo formado por las cepas meticilino resistentes, se ha encontrado que el locus *ica*
857 está presente, pero no parece producirse PIA (O'Neill et al., 2007). Además, se observó
858 en un estudio que la expresión del locus *ica* fue reprimida hasta 300 veces en una cepa
859 meticilino resistente, comparado con la meticilino sensible, lo cual conllevó a que se
860 formara una biopelícula de tipo proteico, es decir, independiente de PIA (Pozzi et al.,
861 2012).

862 **Factores de virulencia de *S. aureus* asociados con la evasión de la respuesta** 863 **inmune**

864 Las mastitis por *S. aureus* generalmente evolucionan a infecciones crónicas difíciles de
865 erradicar; hecho que se le ha atribuido a la capacidad que posee el patógeno para
866 evadir y manipular la respuesta inmune a través de los múltiples factores de virulencia
867 descritos. Los mecanismos involucrados en este proceso se pueden dividir en dos
868 categorías; primero, los que le permiten al microorganismo pasar desapercibido ante los

869 elementos de alarma; segundo, aquellos que le ayudan a escapar o manipular la
870 respuesta inmune cuando es reconocido y atacado.

871 En la primera categoría, fundamentales para establecer la infección, se pueden incluir
872 los mecanismos de invasión celular, la formación de cápsula y la producción de una
873 proteína tipo superantígeno de los *Staphylococcus* (*Staphylococcal Superantigen-Like* -
874 SSLs). *S. aureus* siempre se ha considerado un microorganismo extracelular, sin
875 embargo, su habilidad de invadir y sobrevivir dentro de varios tipos de células ha sido
876 evidenciada en numerosos estudios (Finlay & Cossart, 1997; Kim et al., 2011). La
877 importancia de este factor de virulencia es que lo deja fuera del alcance de la
878 fagocitosis y los anticuerpos, dos de los principales mecanismos efectores de la
879 respuesta inmune. Varios elementos se han relacionado con la capacidad de invasión,
880 entre estos, la expresión de receptores e integrinas, el bloqueo o inactivación de NF- κ B,
881 el fenotipo conocido como variantes de colonia pequeña (*Small Colony Variants* - SCV),
882 la presencia de polisacáridos capsulares y la formación de biopelícula. Algunos estudios
883 demostraron que el bloqueo de la integrina $\alpha 5\beta 1$ y de elementos relacionados con la
884 activación de NF- κ B reducen significativamente la invasión intracelular, al igual que la
885 expresión de Bap en la superficie de la bacteria y la presencia de polisacáridos
886 capsulares (Bardiau et al., 2014; Valle et al., 2012). Por el contrario, se ha observado
887 que cuando la bacteria presenta el fenotipo de SCV es más eficiente para ingresar que
888 el fenotipo normal (Atalla et al., 2008). Con respecto a la cápsula, se han descrito
889 alrededor de 11 polisacáridos capsulares, siendo el CP5 y el CP8 los más frecuentes
890 tanto en humanos como en bovinos. Esta estructura le confiere a la célula bacteriana
891 protección frente al reconocimiento y la fagocitosis, debido a que no permite la unión de
892 los PRRs y opsoninas a sus moléculas blanco (Barrio et al., 2003; Camussone et al.,
893 2014). Las SSLs pueden variar entre cepas; sin embargo, la evidencia indica que los
894 genes *ssl1*, *ssl2*, *ssl3*, *ssl11*, *ssl12*, *ssl13*, *ssl14* son frecuentes entre todos los aislados.
895 Una de las más importantes es la SSL3, pues se puede unir a los TLR2 expresados en

896 las células epiteliales e inmunes y bloquear el reconocimiento de la bacteria
897 (Thammavongsa et al., 2015; Yokoyama et al., 2012).

898 En cuanto a los mecanismos que componen la segunda categoría, claves para
899 mantener la infección después de reconocida, se pueden dividir en cinco grupos: a) los
900 factores que intervienen con la quimioatracción y migración de neutrófilos; b) los factores
901 que inhiben el accionar de los neutrófilos y del complemento; c) los factores de
902 destrucción celular; d) los factores con los que se aísla del entorno; e) los factores que
903 alteran la inmunidad adaptativa.

904 *a) Factores que intervienen con la quimioatracción y migración de neutrófilos*

905 *S. aureus* puede afectar estos procesos, fundamentales en el control de la
906 infección, a través de la secreción de algunas SSLs o por proteínas inhibitorias de la
907 quimioatracción (CHIPS). El patógeno puede alterar la generación de las moléculas
908 C3a y C5a del complemento, importantes quimiotácticos de células fagocíticas, al
909 no permitir que se active el sistema. Por ejemplo, la SSL7 tiene la capacidad de
910 secuestrar inmunoglobulinas mediante la unión a la fracción Fc para que no puedan
911 activar el complemento por la vía clásica o puede bloquear las tres vías al inactivar
912 directamente los factores C3 y C5 (Thammavongsa et al., 2015). En caso que se
913 activen las vías del complemento y se produzca el quimioatrayente C5a, la bacteria
914 puede bloquear su función mediante las CHIPS, pues compiten y tienen alta
915 afinidad por los receptores de esta fracción (Postma et al., 2004). Además, la
916 adhesión al endotelio y migración de los neutrófilos puede ser alterada por la SSL5
917 y la SSL11, quienes se adhieren a la glicoproteína PSGL-1, presente en las
918 membranas de los fagocitos y no permiten su unión con la P-selectina, una
919 molécula expresada en el endotelio del huésped, la cual es clave para la adhesión y
920 posterior migración de los leucocitos al sitio de la infección (Bestebroer et al., 2007).

921 *b) Factores que inhiben el accionar de los neutrófilos y del complemento*

922 La sola fagocitosis de *S. aureus* no garantiza su eliminación, pues la bacteria posee
923 varias estrategias con las que puede alterar los mecanismos efectores de este
924 proceso. Frente a las especies reactivas del oxígeno (ROS), como el peróxido de
925 hidrógeno, emplea elementos antioxidantes, tales como el pigmento estafiloxantina
926 y la catalasa, mientras que, contra el superóxido utiliza las superóxido dismutasas
927 (*Superoxide dismutase* - SodA and SodM) (Cosgrove et al., 2007; Karavolos et al.,
928 2003; Liu et al., 2005). Como respuesta al óxido nítrico la bacteria produce
929 flavohemoglobina y Lactato deshidrogenasa. Incluso, puede inhibir la
930 desgranulación al incrementar la concentración extracelular de Adenosina mediante
931 la enzima catalítica de superficie Adenosin sintetasa A (*Adenosine synthase A* -
932 AdsA). La Adenosina producida se une a su receptor en la membrana del fagocito y
933 desencadena una cascada de señalización anti-inflamatoria que bloquea la
934 liberación de los gránulos dentro del fagosoma (Thammavongsa et al., 2009). Otra
935 de las estrategias, es modificar químicamente el peptidoglicano (acetilación) para
936 generar resistencia frente a la lisozima y péptidos antimicrobianos (Bera et al.,
937 2005). Con respecto a las NET, esta bacteria las evade mediante DNasas, enzimas
938 que le permiten degradar este material antes de que le cause daño
939 (Thammavongsa et al., 2013).

940 Además de la SSL7 y el SSL10, descritas anteriormente, *S. aureus* presenta otros
941 mecanismos con los que también puede afectar el sistema del complemento. La
942 Aureolisina (Aur) es una metaloproteasa dependiente de Zinc, secretada por la
943 bacteria para degradar el factor C3, por lo que no se van a generar las fracciones
944 encargadas de la quimioatracción (C3a y C5a), la opsonización (C3b y C5b) y el
945 complejo de ataque a la membrana, objetivo final de este sistema (Laarman et al.,
946 2011). Otra manera es inhibiendo la C3 convertasa por medio del inhibidor del
947 complemento (*Staphylococcal Complement Inhibitor* - SCIN), que en condiciones
948 normales es la responsable de fragmentar C3 en C3a y C3b, dos productos claves

949 en el proceso; pero al igual que con la Aur, se bloquea todo lo que dependa de la
950 activación y correcto funcionamiento de estas moléculas (Rooijackers et al., 2005).

951 *c) Factores que le permiten destruir las células con quien tiene contacto*

952 La destrucción de diferentes tipos de células inmunes esta mediada básicamente
953 por toxinas, especialmente, por las β -toxinas formadoras de poro (β -PFTs). Las más
954 representativas de este grupo son la α -Hemolisina (Hla) y las leucocidinas. Todas
955 las cepas pueden producir al menos tres leucocidinas (Luk): γ -Hemolisina AB
956 (HLgAB), HLgCB y la Leucocidina AB (LukAB), mientras que, la producción de la
957 LukED es cepa dependiente. La Hla forma un anillo heptamérico y las Luk uno
958 octamérico, que contienen un poro central, con el cual debilitan la membrana de la
959 células blanco hasta causarles lisis osmótica (Heuck et al., 2001; Miles et al., 2002).

960 *d) Factores que la aíslan y protegen del entorno*

961 La formación de biopelícula y de abscesos son los principales representantes de
962 este grupo. Las biopelículas son un conglomerado de células inmersas en una
963 matriz que pueden adherirse a una superficie viva o inerte, la cual le confiere
964 protección frente al sistema inmune y antibióticos, pues quedan fuera de su alcance
965 y acción (Gomes et al., 2016). La formación de biopelícula por *S. aureus* será
966 tratada más adelante.

967 Los abscesos son comunidades bacterianas que se protegen dentro de una
968 pseudocápsula formada a base de depósitos de fibrina y de células inmunes
969 muertas. Esta estructura evita la entrada de fagocitos y promueve la supervivencia
970 dentro de la lesión. Su formación esta mediada por la Deoxiadenosina generada
971 durante la degradación de los NET a través de nucleasas secretadas por la
972 bacteria, la cual desencadena la apoptosis de los macrófagos que la rodean y que
973 terminan aislándola de su entorno (Thammavongsa et al., 2013).

974 e) *Factores que alteran la inmunidad adaptativa*

975 *S. aureus* también puede interferir con los mecanismos efectores de la inmunidad
976 adaptativa. En este proceso participan básicamente superantígenos, sobre todo la
977 Proteína A (*Staphylococcal protein A* – SpA), la cual es expresada y secretada por
978 todas las cepas de interés clínico. SpA tiene la capacidad de unirse tanto a la
979 fracción Fc como a la fracción Fab de las inmunoglobulinas. De acuerdo a la
980 evidencia, cuando se une a la fracción Fab de la IgM de superficie de los Linfocitos
981 B desencadena apoptosis; mientras que, cuando sucede en los plasmoblastos, el
982 resultado es la producción de anticuerpos no específicos debido a que altera la
983 hipermutación somática (Goodyear & Silverman, 2004; Thammavongsa et al.,
984 2015). Por otra parte, la respuesta de los Linfocitos T (LT) también se ve afectada
985 por superantígenos, aunque diferentes a la SpA. En este caso, los superantígenos
986 interfieren entre las células presentadoras de antígenos y los LT ayudadores, pues
987 se unen a los receptores involucrados en esta comunicación, el complejo mayor de
988 histocompatibilidad (MHC II) y los receptores de las células T (TCR), lo que
989 desencadena una respuesta no específica para el patógeno (Jardetzky et al., 1994;
990 Thammavongsa et al., 2015).

991 **Formación de biopelícula en glándula mamaria por *S. aureus***

992 La formación de biopelícula es considerada un factor de virulencia que le confiere
993 ventajas a los patógenos causantes de mastitis debido a que les facilita su persistencia
994 en glándula mamaria. De hecho, diferentes autores en los últimos años se han
995 interesado en la formación de biopelícula, pues esta estructura le permite a la bacteria
996 evadir la respuesta inmune e incrementar la tolerancia frente a los diferentes agentes
997 antimicrobianos, por lo que estas infecciones serán más difíciles de eliminar (Gomes
998 et al., 2016). Se ha descrito que alrededor del 40% de las mastitis corresponden a
999 casos que no resolvieron con los tratamientos antibióticos aplicados (Hillerton & Kliem,
1000 2002). Las bacterias cuando forman biopelícula pueden tolerar 10 veces o más la

1001 concentración de antibióticos requerida para eliminarla en condiciones normales y
1002 tampoco son accesibles a la opsonización y fagocitosis, procesos que son
1003 fundamentales para la eliminación de las infecciones mamarias (Donlan & Costerton,
1004 2002; Gomes et al., 2016).

1005 Las biopelículas son ampliamente definidas como un grupo de células inmersas en una
1006 matriz que estas mismas forman. Recientemente Moormeier & Bayles, (2017)
1007 describieron que *S. aureus* forma biopelículas en cinco etapas: 1) adhesión, 2)
1008 multiplicación, 3) éxodo, 4) maduración, y 5) dispersión. La formación de biopelícula
1009 inicia con la adhesión de la bacteria a la superficie viva, que en este caso serían las
1010 CEM, mediante las diferentes proteínas de superficie descritas. Posteriormente, las
1011 bacterias se multiplican y forman varias capas de células. Al tiempo en que éstas se
1012 multiplican, se van generando los componentes que conforman la matriz en la cual
1013 quedarán inmersas las células bacterianas y demás material proveniente del medio
1014 ambiente. Además, durante la formación de la biopelícula se crean en su interior
1015 canales por donde van a fluir elementos indispensables para la supervivencia de las
1016 bacterias, tales como el oxígeno, metabolitos y nutrientes. Pero antes de madurar la
1017 biopelícula, *S. aureus* forma microcolonias y desprende algunas células con el propósito
1018 de reestructurar la biopelícula; este proceso es conocido como éxodo. Una vez madura
1019 la biopelícula, las bacterias allí contenidas generan una ruptura de la estructura
1020 mediante enzimas líticas para liberarse y diseminarse, así como, para renovar la
1021 estructura de la ya establecida. Mediante este mecanismo la bacteria coloniza otras
1022 áreas y se expande la infección (Gomes et al., 2016; McCarthy et al., 2015; Moormeier
1023 & Bayles, 2017).

1024 *S. aureus* es uno de los patógenos más aislado de las infecciones intramamarias a nivel
1025 mundial y una de las bacterias con mayor capacidad de formar biopelícula sobre
1026 superficies vivas e inertes (Gomes et al., 2016; Greg Keefe, 2012). Una particularidad
1027 de las mastitis causadas por *S. aureus* es que tienden a evolucionar a infecciones

1028 crónicas difíciles de eliminar; hecho que se ha asociado en diferentes estudios a su
1029 capacidad de formación de biopelícula (Carme Cucarella et al., 2004; Gomes et al.,
1030 2016).

1031 *S. aureus* puede formar dos tipos de biopelículas, una donde la matriz tiene como base
1032 el polisacárido de adhesión intercelular (*Polysaccharide Intercellular Adhesion* - PIA) y
1033 la otra es a base de proteínas; la primera es conocida como dependiente de PIA y
1034 codificada por el operón *ica*; la segunda es conocida como independiente de PIA y
1035 codificada por gen *bap* y asociada a la meticilino resistencia (McCarthy et al., 2015).
1036 Además, otros genes como el gen regulador accesorio (*accessory gene regulator – agr*)
1037 y el regulador accesorio estafilococcico (*staphylococcal accessory regulator – sar*)
1038 también se han involucrado en el proceso de formación de biopelícula, al igual que
1039 factores como el pH, algunos componentes de la leche, el Cloruro de Sodio (NaCl) y la
1040 glucosa (Gomes et al., 2016; McCarthy et al., 2015).

1041 Entre los mecanismos de formación de biopelícula, el más estudiado ha sido el
1042 dependiente de PIA. En este se produce básicamente el polisacárido poli-N-
1043 acetilglucosamina (PNAG), también conocido como PIA, el cual es codificado por el
1044 operón *ica*. El operón está compuesto por cinco genes; cuatro (A, D, B, C) codifican
1045 para las proteínas involucradas en la biosíntesis y exportación de PIA a la superficie de
1046 la pared bacteriana; el quinto (R) codifica para un regulador transcripcional. Las
1047 proteínas codificadas por los genes *icaA*, *icaD* y el *icaC* corresponden a proteínas
1048 transmembrana. La proteína producto del gen *icaA* tiene actividad glicosiltransferasa y
1049 es la responsable de la síntesis del polisacárido; en este proceso también interviene el
1050 producto del gen *icaD*. Inmediatamente el polisacárido alcanza un tamaño máximo de
1051 20 residuos, el producto derivado del gen *icaC* lo transloca a la superficie celular; sin
1052 embargo, para que el polisacárido formado se desprenda de la bacteria y quede
1053 totalmente sobre su superficie, este debe ser deacetilado por el producto del gen *icaB*
1054 (O’Gara, 2007). El PIA formado queda con una carga neta positiva que promueve la

1055 agregación intercelular y la unión de la bacteria a la superficie inerte (Rohde et al.,
1056 2010). La mayoría de las cepas de importancia clínica son portadoras del operón *ica*
1057 (Cucarella et al., 2004).

1058 Uno de los primeros reportes de formación de biopelícula independiente de PIA en *S.*
1059 *aureus*, fue realizado precisamente en un aislado de mastitis bovina, en el cual se
1060 identificó la proteína asociada a la biopelícula (*Biofilm-Associated Protein – Bap*)
1061 (Cucarella et al., 2001). Bap tiene un tamaño de 2.276 aminoácidos y permite la unión a
1062 las superficies y la adhesión intercelular; es codificada por el gen *bap*, el cual hace
1063 parte de un transposón que se inserta en la isla de patogenicidad SaPIbov2 (Cucarella
1064 et al., 2004). La evidencia sugiere que el gen *bap* se puede transmitir entre cepas
1065 mediante transferencia horizontal de genes (Tormo et al., 2005). Otro de los
1066 mecanismos que se ha relacionado con la formación de biopelícula independiente de
1067 PIA es la meticilino resistencia en *S. aureus* (McCarthy et al., 2015). Algunos estudios
1068 han mostrado que las cepas resistentes a la meticilina expresan el fenotipo proteico;
1069 diferente a lo evidenciado con las cepas sensibles quienes presentan el fenotipo PIA
1070 dependiente (McCarthy et al., 2015). Se ha demostrado que, en cepas de *S. aureus*
1071 meticilino resistentes, el operón *ica* puede estar presente y expresado pero el PIA no se
1072 produce (O'Neill et al., 2007). El operón *ica* en estos casos puede estar reprimido más
1073 de 300 veces comparado con las cepas meticilino sensibles, lo que conlleva a la
1074 formación de una biopelícula a base de proteínas (Pozzi et al., 2012).

1075 **Estudios sobre caracterización de cepas de *S. aureus* formadoras de biopelículas**

1076 La presencia de biopelícula y la capacidad patogénica de las cepas que expresan esta
1077 característica se ha demostrado *In vitro* e *In vivo* mediante diferentes estudios. Desde
1078 principios de los años 90 hay evidencia de esta conformación. Baselga et al. (1993)
1079 evidenció en tejido mamario a través de técnicas histoquímicas la presencia de una
1080 matriz de exopolisacáridos que rodeaba a la cepa de *S. aureus* responsable de la
1081 infección. Otros estudios también han demostrado en forma indirecta la presencia de

1082 biopelícula mediante la detección de anticuerpos contra algunos de sus componentes,
1083 información que ha servido como base para el desarrollo de vacunas contra esta
1084 estructura (Cucarella et al., 2004; Pérez et al., 2009; Prenafeta et al., 2010). Uno de los
1085 estudios más representativos sobre el tema fue el realizado por Cucarella et al. (2004),
1086 pues en este se incluyó cepas de ambos fenotipos y se relacionaron con el RCS, la
1087 tolerancia a antibióticos, la capacidad de formación de biopelícula, persistencia en
1088 glándula mamaria y la producción de anticuerpos contra Bap. Los resultados mostraron
1089 que las cepas formadoras de biopelícula fueron más persistentes, presentaron menos
1090 RCS y mayor tolerancia a los antibióticos *In vitro* que las cepas sin esta característica.
1091 Además, se evidenció que las cepas *bap* positivas fueron mejores formadoras de
1092 biopelículas que las cepas *ica* positivas; lo que llevó a concluir que la sola presencia de
1093 *bap* es suficiente para formar biopelícula; mientras que, las cepas que solo tenían el
1094 operón *ica* probablemente necesitan de otros genes o estímulos para su formación
1095 (Cucarella et al., 2004). Fox et al. (2005) determinó que las cepas de *S. aureus* aisladas
1096 de leche formaron biopelícula con mayor frecuencia que las cepas aisladas de los sitios
1097 extramamarios. En el trabajo realizado por Oliveira et al. (2007) se reportó que el 80,8%
1098 de las cepas de *S. aureus* evaluadas generaron biopelícula a las 72 horas y solo un
1099 34,6% lo había hecho a las 24 horas. Un estudio realizado en Polonia y publicado en el
1100 año 2012, identificó que el 57,6% de los aislados formaron biopelícula (Szweda et al.,
1101 2012). Veh et al. (2015b) publicó que las cepas de *S. aureus* que fueron más
1102 persistentes durante el periodo seco fueron las que mejor formaron biopelícula.

1103 En cuanto a la identificación de proteomas relacionados con la formación de
1104 biopelículas por *S. aureus* aislado de mastitis bovina, no se tiene suficiente información
1105 sobre el tema. Algunos de los estudios donde se han identificado proteomas
1106 relacionados con la infección, se han realizado directamente en leche de animales
1107 infectados con el patógeno y el objetivo no ha sido la formación de biopelícula. Es el
1108 caso del estudio realizado por Kim et al. (2011) donde observaron diferencias en las
1109 proteínas detectadas en leche de animales infectados con tres diferentes cepas SCV de

1110 *S. aureus* (Verma & Ambatipudi, 2016). Huang et al. (2014) también reportó diferencias
1111 en la expresión de al menos 55 proteínas después de analizar los proteomas de la
1112 leche de animales sanos e infectados con *S. aureus*. Uno de los estudios revisados que
1113 tuvo como objetivo identificar proteínas producidas durante la formación de biopelícula,
1114 fue el realizado por den Reijer et al. (2016); sin embargo, en este trabajo solo se
1115 incluyeron cepas aisladas de humanos y las células empleadas en el modelo fueron
1116 extraídas de la epidermis de pacientes; es decir, no tuvo relación con mastitis bovina.
1117 Los resultados mostraron diferencias entre las proteínas producidas durante la
1118 formación de biopelícula en microplaca y en cultivo celular. Las proteínas identificadas
1119 que mostraron diferencias entre los modelos evaluados se relacionaron con la
1120 adhesión, la modulación inmune y toxinas.

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

RESULTADOS POR OBJETIVO

1139 **Resultados del objetivo 1**

1140 **Objetivo 1:** Caracterizar genotípica y fenotípicamente cepas de *S. aureus* y evaluar
1141 diferencias en susceptibilidad a meticilina y capacidad formadora de biopelículas.

1142 Para cumplir con este objetivo se ejecutaron las siete actividades que se describen a
1143 continuación:

- 1144 1. Se confirmó mediante la amplificación del gen *nuc*, especie específico, que las
1145 cepas a emplear en el estudio fueran *S. aureus*.
- 1146 2. Se determinó mediante PCR convencional en las 277 cepas de *S. aureus* la
1147 presencia de los locus *ica* y *bap*, asociados con formación de biopelícula.
- 1148 3. Se evaluó en cada una de las cepas la capacidad de formación de biopelícula
1149 sobre microplacas de poliestireno.
- 1150 4. Se determinó mediante PCR convencional en las 277 cepas de *S. aureus* la
1151 presencia de los locus *mecA* y *mecC*, asociados con metilino resistencia.
- 1152 5. Se tipificaron las 277 cepas mediante la técnica *spa typing*.
- 1153 6. Se secuenció el genoma de una de las cepas fuerte formadora de biopelícula y
1154 se comparó con dos cepas de referencia de *S. aureus* (RF122 y Newbould 305).
- 1155 7. Se evaluó la capacidad de invasión de tres cepas con diferentes genotipos y
1156 fenotipos en términos de formación de biopelículas.

1157

Resultado de la actividad 1 del objetivo 1

1158 El estudio inició con 300 cepas almacenadas como *S. aureus* en el banco de cepas del
1159 laboratorio de microbiología de la Unidad diagnóstica de la facultad de Ciencias
1160 Agrarias de la Universidad de Antioquia. Estas cepas fueron identificadas inicialmente
1161 empleando técnicas microbiológicas convencionales (Coloración de Gram, detección de
1162 Catalasa y prueba de la coagulasa).

1163 La extracción de ADN de cada cepa fue realizada empleando el estuche comercial
1164 DNeasy Blood & Tissue kit (Qiagen, Germany), siguiendo las recomendaciones del
1165 fabricante para bacterias Gram positivas.

1166 En total, 277 cepas de las 300 incluidas fueron confirmadas como *S. aureus* y
1167 continuaron en el estudio, debido a que se obtuvo amplificado del gen *nuc*. De manera
1168 que, las cepas restantes (23/300) fueron descartadas, sugiriendo inconvenientes en la
1169 identificación inicial con las técnicas empleadas.

1170 **Resultados de las actividades 2 y 3 del objetivo 1**

1171 Los resultados de las dos actividades se presentan en el artículo 1 titulado “**Genotypic**
1172 **and phenotypic characterization of biofilm production by *Staphylococcus aureus***
1173 **strains isolated from bovine intramammary infections in Colombian dairy farms**”.

1174 Este artículo se encuentra publicado en la revista “**Heliyon**” 5 (2019) e02535
1175 (<https://doi.org/10.1016/j.heliyon.2019.e02535>).

1176 Sin embargo, es importante anotar que en este artículo se trabajó con 229 cepas,
1177 debido a que 48 de las 277 cepas incluidas presentaron problemas que dificultaron su
1178 evaluación fenotípica en cuanto a capacidad de formación de biopelícula. Las
1179 dificultades evidenciadas fueron: crecimiento inadecuado, probablemente por pérdida
1180 de viabilidad (proceso de congelación y descongelación) y contaminación del cultivo
1181 madre con otras bacterias durante la manipulación en los ensayos previos.

1182 **Resultados de las actividades 4 y 5 del objetivo 1**

1183 Los resultados de estas actividades se relacionan en el artículo 2 titulado “**Molecular**
1184 **epidemiology of bovine mastitis caused by *Staphylococcus aureus* in Colombia**
1185 **reveals high genetic diversity and presence of clones associated with human**
1186 **infections**”.

1187 **Resultados de las actividades 6 y 7 del objetivo 1**

1188 Los resultados de estas actividades se relacionan en el artículo 3 titulado “**Phenotypic**
1189 **characterization and whole genome analysis of a strong biofilm-forming**
1190 ***Staphylococcus aureus* strain associated with subclinical bovine mastitis in**
1191 **Colombia”.**

1192 Este artículo se encuentra publicado en la revista “**Frontiers in Veterinary Science**”
1193 7:530 (2020) (<https://doi:10.3389/fvets.2020.00530>).

1194 .

1195

1196

1197

1198

1199

1200

1201


1202

1203 **Artículo 1**


1204 **Genotypic and phenotypic characterization of biofilm production by**
1205 ***Staphylococcus aureus* strains isolated from bovine intramammary infections in**
1206 **Colombian dairy farms**

1207 El artículo completo se adjunta con el documento final (anexo) o puede ser descargado
1208 en el siguiente link: <https://doi.org/10.1016/j.heliyon.2019.e02535>

1209



Contents lists available at [ScienceDirect](#)




Heliyon

journal homepage: www.heliyon.com

**Genotypic and phenotypic characterization of biofilm production by
Staphylococcus aureus strains isolated from bovine intramammary infections
in Colombian dairy farms**

G. Torres^{a,b,*}, K. Vargas^b, M. Sánchez-Jiménez^a, J. Reyes-Velez^b, M. Olivera-Angel^b

^a Tropical Medicine Colombian Institute, CES University, Cra. 43A No. 52 sur-99 Sabaneta, Antioquia, Colombia
^b Biogenesis Research Group, Faculty of Agricultural Sciences, University of Antioquia, Cra 75 No. 65-87, Medellín, Antioquia, Colombia



ARTICLE INFO

Keywords:
Microbiology
Animal science
Bacteria
Microbial genomics
Microorganism
Biofilms
Genotype
Mastitis
Staphylococcus aureus

ABSTRACT

The ability of *Staphylococcus aureus* to form biofilms is an important virulence factor because this has been associated with persistent bovine intramammary infections. Different mechanisms of biofilm formation have been described in *S. aureus*; however, the process has been found to be mainly driven by the *ica* and *bap* genes. The presence of the *ica* and *bap* genes, as well as the biofilm formation *in vitro* were evaluated in 229 *S. aureus* strains isolated from bovine milk collected from different regions of Department of Antioquia, Colombia. Three different genotypes grouped into three separate clusters were identified from *in vitro* assays. Genotype 1 (*ica* positive and *bap* negative) was the most prevalent (78.17%), followed by genotype 2 (*ica* and *bap* positive) (12.66%) and genotype 0 (*ica* and *bap* negative) (9.17%). Biofilm formation was observed in 81.26% of the strains from which 100% of genotype 2 isolates showed biofilm formation. The biofilms formed by genotype 2 isolates were also found to have the highest optical density (>2.4). These results showed that most of the *S. aureus* strains were capable of biofilm formation, suggesting the virulence potential particularly in *bap*-positive strains.

1210

1211

1212

1213

1214

1215

1216 **Artículo 2**

1217 **Molecular epidemiology of bovine mastitis caused by *Staphylococcus aureus* in**
1218 **Colombia reveals high genetic diversity and presence of clones associated with**
1219 **human infections**

1220

1221 G. Torres^{a,b*}, K. Vargas^a, J. Reyes-Vélez^{a,b}, N. Jiménez^c, M. Olivera-Angel^a

1222

1223 ^a Biogenesis Research Group, Department of Agricultural Sciences, University of
1224 Antioquia, Cra. 75 No. 65-87, Medellín, Antioquia, Colombia.

1225 ^b Colombian Institute of Tropical Medicine – CES University, Cra. 43A No. 52 sur-99
1226 Sabaneta, Antioquia, Colombia.

1227 ^c Basic and Applied Microbiology Research Group, School of Microbiology, University of
1228 Antioquia, Cl. 67 No. 53-108, Medellín, Antioquia, Colombia.

1229

1230 *Corresponding author: giovanny.torresl@udea.edu.co

1231

1232 **Abstract**

1233 *Staphylococcus aureus* is one of the most common pathogens that cause intramammary
1234 infections in cattle. These infections are generally characterized by their poor response
1235 to antibiotics and their persistence in the mammary gland. Genotyping of *S. aureus*
1236 strains isolated from mastitis has become a fundamental tool to understand the complex
1237 epidemiology of this pathogen. Despite of the importance of this pathogen in Colombia,
1238 no information is available on the genotypes that circulate within the herds of Antioquia
1239 (Colombia). A total of 277 strains of *S. aureus* isolated from intramammary infections in
1240 cattle from Antioquia were described and molecular characterization was performed.

1241 Factors such as cattle breed, type and frequency of mastitis, and antibiotic susceptibility
1242 profile were considered for the epidemiological description. Spa typing was also
1243 performed. Of the 38 different spa types found in this investigation (more than 25% of
1244 the genotypes identified per municipality were different), 29 were grouped into 16 clonal
1245 complexes. The most frequent spa types were t267 and t521, both with 41 isolates.
1246 Furthermore, it was determined that 51 (18%) of the genotypes described had been
1247 unreported so far (new) and 26 (68%) had also been previously reported in humans.
1248 Knowledge on the spa types of *S. aureus* strains isolated from cattle with mastitis within
1249 the region increased knowledge on their characteristics and possible behaviors at
1250 clinical, epidemiological, and therapeutic levels. These factors are fundamental for their
1251 control and prevention.

1252

1253 Keywords: Bovine intramammary infection; Clonal complexes; Genotyping; Mastitis;
1254 *Staphylococcus aureus*; Spa type

1255

1256 **Introduction**

1257 It is considered that bovine intramammary infection (IMI) is one of the diseases that
1258 causes the highest economic losses for milk producers throughout the world because it
1259 leads to decreases in milk production, increases in drug costs, and the discarding of
1260 productive cows (Keefe, 2012).

1261 *Staphylococcus aureus* is one of the main pathogens that cause IMI in cattle (Olde
1262 Riekerink et al., 2006). Control of this microorganism in the mammary gland is limited as
1263 it is difficult to identify in most cases, it responds poorly to the antibiotics used for
1264 treatment and tends to give rise to persistent infections (Olde Riekerink et al., 2006;
1265 Zadoks et al., 2011). In a study conducted in Antioquia, two veterinary diagnostic

1266 laboratories reported that *S. aureus* was the second most common microorganism
1267 isolated from milk samples between 2013 and 2015 (Vidal et al., 2016).

1268 Different studies and reported genomes of *S. aureus* have demonstrated much diversity
1269 between strains. Evidence has demonstrated that approximately 20%–30% of its
1270 genome is diverse because of specific lineage genes and mobile genetic elements
1271 (Matuszewska et al., 2020). This variability has been associated with virulence,
1272 response to antibiotic treatment, transmission between hosts, geographic distribution,
1273 and type of mastitis, which makes management and control in herds difficult (Haveri
1274 et al., 2008).

1275 The genotyping of *S. aureus* strains isolated from IMI has become a fundamental tool for
1276 understanding the complex epidemiology of this pathogen (Boss et al., 2016; Smith
1277 et al., 2016; Vanderhaeghen et al., 2014; Zadoks et al., 2011). Pulsed-field gel
1278 electrophoresis (PFGE), multilocus sequence typing (MLST), and *spa* typing are some
1279 of the most widely used methods to typify *S. aureus* strains (Boss et al., 2016). *Spa*
1280 typing is based on the sequencing of the spacer variable region (region X) of the *spa*
1281 gene. It provides comparable resolution but is less expensive and laborious than the
1282 other two methods mentioned above. It is also possible to infer clonal complexes (CCs)
1283 with this methodology, which groups genotypes related to a common ancestor (Feltrin
1284 et al., 2016; Haveri et al., 2008; Olde Riekerink et al., 2006; Sakwinska et al., 2011).
1285 Some of the most important *spa* types reported in bovine IMIs are t521, t267, and t543,
1286 which have been associated with clinical and subclinical mastitis. CC97 is the most
1287 prevalent CC in bovine mastitis worldwide and CC398 is associated with the presence of
1288 methicillin-resistant *S. aureus* clones (MRSA) (Angel-Andrés et al., 2014; Hata et al.,
1289 2010). The genotypes of the circulating strains and their association with sensitivity
1290 profiles to antibiotics *in vitro* were unknown in Antioquia, which is one of the main dairy
1291 regions of Colombia, and where *S. aureus* is one of the main causes of IMI in cattle.
1292 This information is essential for understanding the possible behaviors of these strains at

1293 clinical and epidemiological levels, as well as their response to antibiotic treatments.
1294 Thus, the aim of this study was to identify the genotypes of the *S. aureus* strains isolated
1295 from IMI in Antioquia, Colombia, by means of spa typing.

1296 **Materials and Methods**

1297 *S. aureus* isolates

1298 A total of 277 strains of *S. aureus* stored in the strain bank of the Biogenesis Research
1299 Group of the Department of Agricultural Sciences of the University of Antioquia
1300 (Medellín, Colombia) were characterized. The strains were isolated from bovine milk of
1301 cows suffering from IMI, between July and December 2015, obtained from dairy farms
1302 located in different regions of the department of Antioquia (Table 1). Isolates were
1303 initially classified as *S. aureus* using conventional microbiological techniques, based on
1304 the guidelines of the National Mastitis Council of the United States (National Mastitis
1305 Council, 2004). Isolates were stored at -80°C in Trypticase soy agar (TSA) (Oxoid,
1306 United Kingdom) supplemented with 10% glycerol until use.

1307 **Table 1.** Number of *S. aureus* strains isolated in each region

Region	Municipality	No. of isolates (%)
North	San Pedro de los Milagros, Santa Rosa de Osos, Belmira, Bello, Entrerrios, Don Matías, Carolina del Príncipe, San José de la Montaña	228 (82%)
East	La Unión, Rionegro, Abejorral, La Ceja, Santuario	27 (10%)
Southeast	Urrao	20 (7.2%)

West	San Jerónimo	
		2 (0.7%)
Total		277 (100%)

1308 No: Number

1309 *Clinical and epidemiological characteristics*

1310 Clinical and epidemiological information was obtained from the history and sample entry
1311 records for each animal. The information collected included place of origin, type of
1312 infection (clinical or subclinical), frequency of infection (first time or recurrent), and cattle
1313 breed.

1314 *DNA extraction*

1315 The stored *S. aureus* strains were thawed and cultured in TSA medium (Oxoid, United
1316 Kingdom) and incubated at 37°C for 24 h. DNA was extracted using the DNeasy Blood
1317 & Tissue Kit (Quiagen, Germany) according to the manufacturer's recommendation for
1318 Gram-positive bacteria. A NanoDrop kit (ThermoFisher Scientific, USA) was used to
1319 measure the purity and concentration of the extracted DNA. The DNA was then stored at
1320 -20°C until use.

1321 *Molecular confirmation of S. aureus and mecA gene detection*

1322 The strains used in the study were confirmed as *S. aureus* through polymerase chain
1323 reaction (PCR). The PCR proposed by Graber et al. (2009) allowed the amplification of a
1324 fragment of the *nuc* gene, recognized as being species-specific Sommerhäuser et al.
1325 (2003). The *mecA* gene was detected according to the methodology described by Zehra
1326 et al. (2017). The PCR reactions were conducted in a PTC 200 thermocycler (Perkin-
1327 Elmer Inc., USA).

1328 *Determination of susceptibility to antibiotics*

1329 The antibiotic susceptibility profile of the isolated *S. aureus* strains was determined with
1330 the Kirby–Bauer methodology, following the recommendations of the Clinical and
1331 Laboratory Standards Institute (Clinical and Laboratory Standards Institute, 2020). The
1332 disc-diffusion antibiotic used (Oxoid, United Kingdom) were Penicillin G, Cefoperazone,
1333 Cloxacillin, Ampicillin/Sulbactam, Amoxicillin clavulanic acid, Lincomycin and
1334 Trimethoprim Sulfamethoxazole. *S. aureus* ATCC 25922 strain was used as a control.
1335 The resistance to each of the antibiotics was recorded as a binary attribute for each
1336 isolate. Moreover, two variables were derived from the resistance profiles. The first one
1337 was the number of antibiotics to which the isolate was resistant and the second was the
1338 resistance to at least one of the tested antibiotics.

1339 *Genotyping using spa typing*

1340 The polymorphic region of the gene coding for protein A (*spa* gene), known as region X,
1341 was amplified by PCR for each strain. The primers used in the reaction were those
1342 described by Shopsin et al. (1999), while the thermal profile followed was that reported
1343 by Jiménez et al. (2012), with denaturation at 94°C for 30 s, alignment at 60°C for 1 min,
1344 and 72°C extension for 1 min, for 30 cycles. Expected band size was approximately
1345 1.000 bp, which was later sequenced by Macrogen (USA). Spa types were assigned in
1346 two stages; eGenomics software was used in the first stage (Shopsin et al., 1999) and
1347 the Ridom SpaServer website (<http://www.spaserver.ridom.de/>), developed by Ridom
1348 GmbH, was used in the second. CCs were inferred through analysis of the repetition
1349 pattern of the spa types obtained (Strommenger et al., 2008) or by consulting the Ridom
1350 SpaServer website.

1351 *Statistical analysis*

1352 Descriptive analyses were performed for all the variables of interest. Further bivariate
1353 comparisons using Chi square and Fisher's exact tests were assessed to determine the
1354 relationship between antibiotic resistance, municipalities, and genotypes (CC). A

1355 statistical threshold of $P < 0.05$ was considered. All the analyses were carried out on
1356 Rstudio statistical software program (version 3.6.0) (<https://cran.R-project.org>).

1357 **Results**

1358 *Geographical distribution and epidemiological and clinical characteristics*

1359 The municipality of San Pedro de los Milagros contributed a total of 60 isolates, the
1360 majority in this study, followed by the municipality of Santa Rosa de Osos with 49
1361 isolates. The municipality with the least isolates was San Jerónimo with two (Table 2).

1362 The highest proportion of *S. aureus*-positive samples, 243 (88%), were obtained from
1363 Holstein cattle, followed by the Jersey breed with 30 (11%). The subclinical stage
1364 prevailed (96%) in terms of the presentation of the infection, as did the report of
1365 recurrent infections (69%) (Table 2).

1366 **Table 2.** Distribution and characteristics of the strains under study.

Municipality	Number of isolations	Breeds (n)	Frequency of mastitis (n)	Type of mastitis (n)
San Pedro de los Milagros	60	Holstein (59), Jersey (1)	P (14) R (46)	Subclinical (59) Clinical (1)
Santa Rosa de Osos	49	Holstein (40), Jersey (9)	P (16) R (33)	Subclinical (42) Clinical (7)
Belmira	34	Holstein (30), Jersey (4)	R (34)	Subclinical (34)

Bello	32	Holstein (28), Jersey (4)	P (9) R (23)	Subclinical (32)
Entrerriós	23	Holstein (16), Jersey (7)	P (4) R (19)	Subclinical (23)
Urrao	20	Holstein (15), Bon (3), Jersey (2)	P (18) R (2)	Subclinical (20)
Don Matías	17	Holstein (14), Jersey (3)	P (11) R (6)	Subclinical (16) Clinical (1)
La Unión	9	Holstein (9)	P (5) R (4)	Subclinical (9)
Carolina del Príncipe	8	Holstein (7), Girolando (1)	P (4) R (4)	Subclinical (8)
Rionegro	6	Holstein (6)	R (6)	Subclinical (6)
Abejorral	5	Holstein (5)	P (1) R (4)	Subclinical (5)
San José de la Montaña	5	Holstein (5)	P (2) R (4)	Subclinical (5)
La Ceja	4	Holstein (4)	R (4)	Subclinical (4)
Santuario	3	Holstein (3)	P (2) R (1)	Subclinical (1) Clinical

San Jerónimo	2	Holstein (2)	R (2)	(2) Subclinical (2)
--------------	---	--------------	-------	---------------------------

1367 (n): number of strains; P: first time; R: recurring

1368 *S. aureus strains Typing*

1369 A total of 38 different spa types were identified. Santa Rosa de Osos was the
 1370 municipality with the highest number of different genotypes, 18 in total (38% of
 1371 genotypes found in the municipality). The municipalities that followed were San Pedro
 1372 de los Milagros with 15 (25% of those found in the municipality) and Belmira with 13
 1373 (38% of those found in the municipality). A wide diversity of spa types was generally
 1374 present in all municipalities as more than 25% of the genotypes identified by municipality
 1375 were different (Table 3).

1376 **Table 3.** Spa type and clonal complexes by municipality.

Municipality	Clonal complex identified	Spa type identified*	Different spa type (%)
San Pedro de los Milagros	CC1, CC479, CC97, CC398, CC8	New, t605, t543, t527, t2207, t267, t3626, t521, t571, t2112, t8845, t7753, t398, t345, t064	15 (25%)
Santa Rosa de Osos	CC45, CC97, CC8, CC479, CC1, CC98, CC5, CC522, CC084	New, t521, t543, t267, t2207, t445, t024, t2143, t008, t1106, t1236, t149, t17143, t2112, t2803, t4103, t527, t692	18 (38%)



Belmira	CC479, CC8, CC30, CC1, CC97, CC59, CC98, CC398	New, t543, t267, t2112, t008, t064, t1135, t2207, t4911, t521, t1236, t5051, t571	13 (38%)
Bello	CC97, CC15, CC479, CC 1, CC5, CC98	t267, t521, t605, t1885, t543, t1107, t1236, t2112, t2207, New	10 (31%)
Entrerriós	CC97, CC30, CC 1, CC164, CC97, CC479	t267, t521, t1135, t2207, New, t1429, t2112, t543, t605	10 (44%)
Urrao	CC 1, CC398, CC97, CC037, CC22, CC479	t189, t527, t605, t571, t267, t1190, t515, t521, t543, New	10 (50%)
Don Matías	CC97, CC1, CC4118	t521, t2207, t527, t1106, t426, New	6 (35%)
La Unión	CC97, CC8	New, t521, t2413, t064	4 (44%)
Carolina del Príncipe	CC97, CC479, CC97	t267, t543, t521, New	4 (50%)
Rionegro	CC1, CC97, CC479	New, t2207, t267, t543	4 (67%)
Abejorral	CC97, CC5	New, t267, t458	3 (80%)
San José de la Montaña	CC97, CC1, CC22	t2112, t2207, t521, t515	4 (80%)
La Ceja	CC479, CC4118, CC15	t543, t426, t1885	3 (75%)
Santuario	CC1	New, t2207, t6280	1 (33%)

San Jerónimo CC97 t521 2 (99%)

1377 *The identified spa types are listed from highest to lowest frequency

1378 The most frequent spa types were t267 and t521, both with 41 isolates, which were
 1379 represented in almost all municipalities (12/15 municipalities). We were unable to assign
 1380 a spa type to 51 (18%) of the 277 isolates because no comparable patterns were found,
 1381 and they were classified as new (Table 4). Only 6 of the 277 strains evaluated were
 1382 isolated from clinical mastitis and the t521 (2), t008 (1), t2207 (1), t3626 (1), and t426 (1)
 1383 genotypes were identified. 26 (68%) of the 38 identified spa types had also been
 1384 previously reported in humans (Supplementary table 1).

1385 **Table 4.** Most frequent clonal complexes and spa type.

Clonal complex	Spa type (n)	Total
CC97	t267 (41), t521 (41), t2112 (10), t1236 (7)	99
CC1	t605 (28), t2207 (21), t527 (8), t1190 (2), t345 (1)	60
CC479	t543 (21)	21
CC359	t189 (4)	4
CC8	t064 (3), t008 (2), t024 (2)	7
CC5	t1107 (1), t149 (1), t458 (1)	3
CC30	t1135 (3)	3
CC4118	t426 (3)	3
CC398	t571 (3)	3
CC45	t445 (2), t2143 (1)	3

CC15	t1885 (2)	2
CC22	t515 (2)	2
CC164	t1429 (1)	1
CC522	t17143 (1)	1
CC084	t4103 (1), t692 (1)	2
CC59	t4911 (1)	1
N/A	t1106 (2), t3626 (2), t2413 (1), t2803 (1), t398 (1), t5051 (1), t6280 (1), t7753 (1), t8845 (1)	11
N/A	New (51)	51

1386 N/A (not assigned): it was not possible to assign them a CC.


1387 A total of 16 CCs were inferred from the spa types obtained. The most frequent CC was
1388 CC97. It was represented by spa types t521, t267, t1236, and t2112. CC1 constituted of
1389 more than three different genotypes (t605, t527, t1190, t2207, and t345) (Table 5).

1390 Both the 51 new genotypes and nine other identified genotypes were not possible to be
1391 assigned to a specific clonal complex (Table 4).

1392 *Antibiotic susceptibility and presence of the mecA gene*

1393 The *S. aureus* strains evaluated showed resistance to the antibiotic penicillin and
1394 lincomycin (37%), followed by ampicillin/sulbactam (10%), cefoperazone (7%),
1395 trimethoprim/sulfa (4%), cloxacillin (3%), and amoxicillin/clavulanic acid (2%). Out of the
1396 277 strains evaluated, only 2 were positive for the *mecA* gene. Figure 1 shows the
1397 number of strains per CC and their resistance against to antibiotic tested.


1398



1399

1400 **Figure 1.** Number of strains (frequency) per clonal complex (CC) and number of
 1401 antibiotics to which they were resistant. A.R: Number of antibiotics to which the strains
 1402 evaluated showed resistance. NA: refers to an unassigned CC.

1403 The bivariate analysis performed between resistance to at least one antibiotic and
 1404 municipality was significant ($P=0.01799$) (Figure 2), and between antibiotic resistance to
 1405 at least one antibiotic and genotype (CC) did not show significant association ($P=0.387$).



1406

1407 **Figure 2.** Distribution of the resistance to at least one antibiotic by municipality.

1408 **Discussion**

1409 A total of 38 different spa types were found in this study, of which 29 were grouped into
 1410 16 CCs. More than 25% of the genotypes identified by municipality were different,
 1411 indicating the high diversity of circulating strains in this part of the country. These results
 1412 were consistent with what was reported by Tokajian et al. (2010), who determined a
 1413 diversity of 37%, but differ from those reported by Omar et al. (2014) and Strommenger
 1414 et al. (2008), where diversities of 30% and 18% were found, respectively. The variability
 1415 found in our study could be explained by the management practices that can change
 1416 between areas, geography, and the season of the year, as well as the relationship
 1417 between hosts (Boss et al., 2016; Kosecka-Strojek et al., 2016).

1418 One of the main findings of this investigation was the detection of spa types t064, t024,
 1419 and t008 in cattle, which had previously only been reported in humans in Colombia
 1420 (Jiménez et al., 2012). According to Fenner et al. (2008), t008 has been reported as a

1421 community-associated clone, whereas t024 was associated with the hospital
1422 environment by Bartels et al. (2007). These last two genotypes have been widely
1423 reported as MRSA (Boss et al., 2016); however, in this study they were methicillin
1424 sensitive because the *mecA* gene was not found in them. t024 was first reported as the
1425 cause of human infections associated with the community in the city of Medellín
1426 (Antioquia, Colombia) (Jiménez et al., 2012). Our study is the first to report the presence
1427 of these clones in cattle in Colombia. The above-mentioned spa types are classified as
1428 CC8, which has a clade known as CC8bov. Some studies have associated t024
1429 specifically with the bovine clade, whereas others report their origin in humans,
1430 demonstrating that they have adapted to both species (Boss et al., 2016).

1431 Genotypes t2207, t1135, t2143, t445, t571, t1885, t4911, t3626, and t149, were also
1432 found in this study, and they have been mainly associated with hospital infections in
1433 humans (Israel et al., 2018). Nevertheless, t2207 has also been reported as the cause
1434 of sporadic infections in both cattle and rabbits (Haveri et al., 2008). t571, which has
1435 only been reported in humans, has been strongly associated with the handling of
1436 production animals (cattle). This genotype is classified as CC398, a production livestock-
1437 associated group (Boss et al., 2016) and whose main reservoir is pigs, although clones
1438 adapted to other hosts such as cattle and humans have also been identified (Wang
1439 et al., 2018).

1440 The two most common spa types in our study were t521 and t267, both genotypes
1441 commonly reported as causing subclinical mastitis in cattle (Schmidt et al., 2017). t267
1442 was only found to cause subclinical mastitis in this study, which is consistent with reports
1443 from Brazil, Canada, and Japan (Boss et al., 2016; Hata et al., 2010; Israel et al., 2018;
1444 Olde Riekerink et al., 2006), whereas t521 was found to cause both clinical and
1445 subclinical mastitis. t543, one of the other most frequent genotypes in this study, has
1446 been associated with both clinical and subclinical mastitis. However, t543 was only
1447 found in subclinical infections in this study, agreeing with what was reported in other

1448 investigations worldwide (Israel et al., 2018; Smith et al., 2016; Wang et al., 2016). T521
1449 and t267 are part of CC97, which is recognized as the most reported complex in
1450 genotyping studies of strains obtained from cattle (Wang et al., 2018). These data agree
1451 with the findings of this study as it was the most frequent CC. An investigation
1452 conducted by Budd et al. (2016), where they compared the adhesion capacity of three
1453 CCs, with CC97 among them, found that this formed stronger bonds by means of
1454 fibronectin than CC8 and CC1, suggesting that this behavior could make a difference in
1455 terms of persistence capacity in the bovine mammary gland (Peña & Uffo, 2013).

1456 The CC30 is relatively old and has spread worldwide. Clones belonging to this CC
1457 caused a pandemic after World War II (Cheung et al., 2014) and, over time. CC30
1458 strains have become the main clones associated with hospital settings (Sharma-Kuinkel
1459 et al., 2015). Spa type t1135, a member of this group, was found in this study. CC45 has
1460 been recognized for being successful in colonization processes in humans, mainly in
1461 children, and CC22 has been reported in humans as strains that can be infectious and
1462 colonizing (Rodríguez-Tamayo et al., 2016). CC1 has been reported in strains isolated
1463 from humans and cattle. Evidence suggests that this CC can be transmitted from
1464 animals to humans, an indication that it adapts to the two species (Silva et al., 2013).

1465 This investigation determined that 68% of the identified genotypes have also been
1466 previously implicated in human infections. This situation requires attention from public
1467 health authorities, because in Colombia between 43.6% and 77% of milk harvest
1468 continues to be manual (Ramírez et al., 2014; Reyes et al., 2017), increasing the risk for
1469 milkers to acquire this pathogen and spread it among individuals in their environment.
1470 Furthermore, approximately 41% of raw (unpasteurized) milk is commercialized
1471 informally (Business Bridge, 2015), which may also facilitate its spread among
1472 individuals who are not exposed to livestock. Therefore, this situation turns bovine into
1473 potential sources of the pathogen for humans (Shepherd et al., 2013).

1474 Another relevant finding of this study was that the presence of 51 previously unreported
1475 spa types (18%). These, and another nine genotypes, could not be assigned to any CC.

1476 *S. aureus* strains showed the highest resistance to antibiotics penicillin and lincomycin in
1477 the susceptibility profile obtained. These results are consistent with that reported by
1478 other studies previously carried out in the same region, where these antibiotics showed
1479 the same behavior against the evaluated strains (Ramírez et al., 2018; Ramírez et al.,
1480 2011). The association found between the resistance and the municipality is due to high
1481 frequency of strains resistant at least one antibiotic isolated in several municipalities.

1482 **Conclusions**

1483 Our research is the first in Colombia to perform molecular identification of the circulating
1484 *S. aureus* strains in one of the main dairy regions of the country. These results showed
1485 the wide diversity of circulating strains in cattle. Furthermore, 68% of the genotypes
1486 identified from IMI have been also described as causing infections in humans, making
1487 dairy cattle an important reservoir of the pathogen for people in proximity, such as
1488 milkers, and for individuals who are not from their environment. These findings highlight
1489 the need for active surveillance of circulating *S. aureus* strains in order to identify strains
1490 with zoonotic potential and the occurrence of new clones with high public health risk.

1491 **References**

- 1492 Angel-Andrés, D., Solorio-Rivera, J., Baizabal-Aguirre, V., Bravo-Patiño, A., Cajero-
1493 Juárez, M., Sánchez-Gil, L., Chávez-Moctezuma, M., & Valdez-Alarcón, J.
1494 (2014). Estructura genética de la población de *Staphylococcus aureus* asociada a
1495 mastitis bovina en granjas familiares de Tarímbaro, Michoacán, mediante análisis
1496 de secuencias multilocus (Multilocus sequence typing; MLST). *Biológicas*, 16(1),
1497 1-10.
- 1498 Bartels, M. D., Boye, K., Larsen, A. R., Skov, R., & Westh, H. (2007). Rapid increase of
1499 genetically diverse methicillin-resistant *Staphylococcus aureus*, Copenhagen,
1500 Denmark. *Emerging infectious diseases*, 13(10), 1533-1533.
- 1501 Boss, R., Cosandey, A., Luini, M., Artursson, K., Bardiau, M., Breitenwieser, F.,

- 1502 Hehenberger, E., Lam, T., Mansfeld, M., Michel, A., Mösslacher, G., Naskova, J.,
1503 Nelson, S., Podpečan, O., Raemy, A., Ryan, E., Salat, O., Zangerl, P., Steiner,
1504 A., & Graber, H. U. (2016). Bovine *Staphylococcus aureus*: Subtyping, evolution,
1505 and zoonotic transfer. *Journal of Dairy Science*, 99(1), 515-528.
1506 <https://doi.org/10.3168/jds.2015-9589>
- 1507 Business Bridge. (2015). *Moooli dairy opportunities for Colombian-Dutch collaboration*.
1508 [http://www.cnl.org.co/wp-content/files/Moooli-dairy-opportunities-for-colombian-](http://www.cnl.org.co/wp-content/files/Moooli-dairy-opportunities-for-colombian-dutch-collaboration.pdf)
1509 [dutch-collaboration.pdf](http://www.cnl.org.co/wp-content/files/Moooli-dairy-opportunities-for-colombian-dutch-collaboration.pdf)
- 1510 Cheung, G. Y. C., Kretschmer, D., Duong, A. C., Yeh, A. J., Ho, T. V., Chen, Y., Joo, H.-
1511 S., Kreiswirth, B. N., Peschel, A., & Otto, M. (2014). Production of an attenuated
1512 phenol-soluble modulin variant unique to the MRSA clonal complex 30 increases
1513 severity of bloodstream infection. *PLoS pathogens*, 10(8).
- 1514 Feltrin, F., Alba, P., Kraushaar, B., Ianzano, A., Argudín, M. A., Di Matteo, P., Porrero,
1515 M. C., Aarestrup, F. M., Butaye, P., Franco, A., & Battisti, A. (2016). A Livestock-
1516 Associated, Multidrug-Resistant, Methicillin-Resistant *Staphylococcus aureus*
1517 Clonal Complex 97 Lineage Spreading in Dairy Cattle and Pigs in Italy. *Applied*
1518 *and Environmental Microbiology*, 82(3), 816-821.
1519 <https://doi.org/10.1128/AEM.02854-15>
- 1520 Fenner, L., Widmer, A. F., Dangel, M., & Frei, R. (2008). Distribution of spa types among
1521 methicillin-resistant *Staphylococcus aureus* isolates during a 6 year period at a
1522 low-prevalence university hospital. *Journal of medical microbiology*, 57(5), 612-
1523 616.
- 1524 Graber, H. U., Naskova, J., Studer, E., Kaufmann, T., Kirchhofer, M., Brechbühl, M.,
1525 Schaeren, W., Steiner, A., & Fournier, C. (2009). Mastitis-related subtypes of
1526 bovine *Staphylococcus aureus* are characterized by different clinical properties.
1527 *Journal of dairy science*, 92(4), 1442-1451.
- 1528 Hata, E., Katsuda, K., Kobayashi, H., Uchida, I., Tanaka, K., & Eguchi, M. (2010).
1529 Genetic variation among *Staphylococcus aureus* strains from bovine milk and
1530 their relevance to methicillin-resistant isolates from humans. *Journal of Clinical*
1531 *Microbiology*, 48(6), 2130-2139. <https://doi.org/10.1128/JCM.01940-09>
- 1532 Haveri, M., Hovinen, M., Roslo, A., & Pyo, S. (2008). Molecular Types and Genetic
1533 Profiles of *Staphylococcus aureus* Strains Isolated from Bovine Intramammary
1534 Infections and Extramammary Sites. *Journal of Clinical Microbiology*, 46(11),
1535 3728-3735. <https://doi.org/10.1128/JCM.00769-08>
- 1536 Israel, L. F. S., Rabello, R. F., Domingos, S. C. B., & Medeiros, L. S. (2018). Produção
1537 de biofilme por *Staphylococcus chromogenes* isolados de amostras de leite
1538 provenientes de rebanhos bovinos com mastite. *Arquivo Brasileiro de Medicina*
1539 *Veterinária e Zootecnia*, 70(6), 1943-1949.
- 1540 Jiménez, J. N., Ocampo, A. M., Vanegas, J. M., Rodríguez, E. A., Mediavilla, J. R.,

- 1541 Chen, L., Muskus, C. E., Vélez, L. A., Rojas, C., Restrepo, A. V., Ospina, S.,
1542 Garcés, C., Franco, L., Bifani, P., Kreiswirth, B. N., & Correa, M. M. (2012). CC8
1543 MRSA strains harboring SCCmec type IVc are predominant in Colombian
1544 hospitals. *PLoS ONE*, 7(6), 1-10. <https://doi.org/10.1371/journal.pone.0038576>
- 1545 Keefe, G. (2012). Update on control of *Staphylococcus aureus* and *Streptococcus*
1546 *agalactiae* for management of mastitis. *The Veterinary Clinics of North America.*
1547 *Food Animal Practice*, 28(2), 203-216. <https://doi.org/10.1016/j.cvfa.2012.03.010>
- 1548 Kosecka-Strojek, M., Ilcyszyn, W. M., Buda, A., Polakowska, K., Murzyn, K., Panz, T.,
1549 Bialecka, A., Kasprowicz, A., Jakubczak, A., & Krol, J. (2016). Multiple-locus
1550 variable-number tandem repeat fingerprinting as a method for rapid and cost-
1551 effective typing of animal-associated *Staphylococcus aureus* strains from
1552 lineages other than sequence type 398. *Journal of medical microbiology*, 65(12),
1553 1494-1504.
- 1554 Matuszewska, M., Murray, G., Harrison, E., Holmes, M., & Weinert, L. (2020). The
1555 Evolutionary Genomics of Host Specificity in *Staphylococcus aureus*. *Trends in*
1556 *Microbiology*.
- 1557 National Mastitis Council. (2004). *Microbiological procedures for the diagnosis of bovine*
1558 *udder infection and determination of milk quality* (Fourth edition).
- 1559 Olde Riekerink, R. G. M., Barkema, H. W., Veenstra, S., Poole, D. E., Dingwell, R. T., &
1560 Keefe, G. P. (2006). Prevalence of contagious mastitis pathogens in bulk tank
1561 milk in Prince Edward Island. *The Canadian Veterinary Journal = La Revue*
1562 *Veterinaire Canadienne*, 47(6), 567-572.
- 1563 Omar, N. Y., Ali, H. A. S., Harfoush, R. A. H., & El Khayat, E. H. (2014). Molecular typing
1564 of methicillin resistant *Staphylococcus aureus* clinical isolates on the basis of
1565 protein A and coagulase gene polymorphisms. *International journal of*
1566 *microbiology*, 2014.
- 1567 Peña, J., & Uffo, O. (2013). Producción de biofilme en genotipos de *Staphylococcus*
1568 *aureus* aislados de mastitis bovina en Cuba. *Revista de Salud Animal*, 35, 189-
1569 196.
- 1570 Ramírez, N., Keefe, G., Dohoo, I., Sánchez, J., Arroyave, O., Cerón, J., Jaramillo, M., &
1571 Palacio, L. G. (2014). Herd- and cow-level risk factors associated with subclinical
1572 mastitis in dairy farms from the High Plains of the northern Antioquia, Colombia.
1573 *Journal of Dairy Science*, 97(7), 4141-4150. <https://doi.org/10.3168/jds.2013-6815>
- 1574 Ramírez, N., Fernandez, J., & Palacio, L. G. (2018). Tasa de incidencia de mastitis
1575 clínica y susceptibilidad antibiótica de patógenos productores de mastitis en
1576 ganado lechero del norte de Antioquia. *Revista de Medicina Veterinaria*, 36, 75-
1577 87. <https://doi.org/10.19052/mv.5173>
- 1578 Ramírez Vásquez, N., Arroyave Henao, O., Cerón-Muñoz, M., Jaramillo, M., Cerón, J.,
1579 & Palacio, L. G. (2011). Factores asociados a mastitis en vacas de la

- 1580 microcuenca lechera del altiplano norte de Antioquia, Colombia. *Revista de*
1581 *Medicina Veterinaria*, 22, 31-31. <https://doi.org/10.19052/mv.562>
- 1582 Reyes, J., Sanchez, J., Stryhn, H., Ortiz, T., Olivera, M., & Keefe, G. P. (2017). Influence
1583 of milking method, disinfection and herd management practices on bulk tank milk
1584 somatic cell counts in tropical dairy herds in Colombia. *Veterinary Journal*
1585 (*London, England: 1997*), 220, 34-39. <https://doi.org/10.1016/j.tvjl.2016.12.011>
- 1586 Rodríguez-Tamayo, E. A., Ruiz-Cadavid, A., Sánchez-González, L. M., García-Valencia,
1587 N., & Jiménez-Quiceno, J. N. (2016). Diseminación de cepas *Staphylococcus*
1588 *aureus* sensible a meticilina (SASM) relacionadas genéticamente, pertenecientes
1589 al CC45, entre portadores nasales sanos de hogares infantiles de Medellín,
1590 Colombia. *Enfermedades infecciosas y microbiología clínica*, 34(3), 159-165.
- 1591 Sakwinska, O., Giddey, M., Moreillon, M., Morisset, D., Waldvogel, A., & Moreillon, P.
1592 (2011). *Staphylococcus aureus* Host Range and Human-Bovine Host Shift.
1593 *Applied and Environmental Microbiology*, 77(17), 5908-5915.
1594 <https://doi.org/10.1128/AEM.00238-11>
- 1595 Schmidt, T., Kock, M. M., & Ehlers, M. M. (2017). Molecular Characterization of
1596 *Staphylococcus aureus* Isolated from Bovine Mastitis and Close Human Contacts
1597 in South African Dairy Herds: Genetic Diversity and Inter-Species Host
1598 Transmission. *Frontiers in Microbiology*, 8, 511.
1599 <https://doi.org/10.3389/fmicb.2017.00511>
- 1600 Sharma-Kuinkel, B. K., Mongodin, E. F., Myers, J. R., Vore, K. L., Canfield, G. S.,
1601 Fraser, C. M., Rude, T. H., Fowler, V. G., & Gill, S. R. (2015). Potential influence
1602 of *Staphylococcus aureus* clonal complex 30 genotype and transcriptome on
1603 hematogenous infections. *Open forum infectious diseases*, 2(3).
- 1604 Shephard, M. A., Fleming, V. M., Connor, T. R., Corander, J., Feil, E. J., Fraser, C., &
1605 Hanage, W. P. (2013). Historical Zoonoses and Other Changes in Host Tropism
1606 of *Staphylococcus aureus*, Identified by Phylogenetic Analysis of a Population
1607 Dataset. *PLoS ONE*, 8(5), e62369. <https://doi.org/10.1371/journal.pone.0062369>
- 1608 Shopsin, B., Gomez, M., Montgomery, S. O., Smith, D. H., Waddington, M., Dodge, D.
1609 E., Bost, D. A., Riehman, M., Naidich, S., & Kreiswirth, B. N. (1999). Evaluation of
1610 protein A gene polymorphic region DNA sequencing for typing of *Staphylococcus*
1611 *aureus* strains. *Journal of clinical microbiology*, 37(11), 3556-3563.
- 1612 Silva, N. C. C., Guimarães, F. F., Manzi, M. P., Budri, P. E., Gómez-Sanz, E., Benito, D.,
1613 Langoni, H., Rall, V. L. M., & Torres, C. (2013). Molecular characterization and
1614 clonal diversity of methicillin-susceptible *Staphylococcus aureus* in milk of cows
1615 with mastitis in Brazil. *Journal of Dairy Science*, 96(11), 6856-6862.
1616 <https://doi.org/10.3168/jds.2013-6719>
- 1617 Smith, D. S., Siggins, M. K., Gierula, M., Pichon, B., Turner, C. E., Lynskey, N. N.,
1618 Mosavie, M., Kearns, A. M., Edwards, R. J., & Sriskandan, S. (2016).

- 1619 Identification of commonly expressed exoproteins and proteolytic cleavage events
1620 by proteomic mining of clinically relevant UK isolates of *Staphylococcus aureus*.
1621 *Microbial Genomics*, 2(2), e000049. <https://doi.org/10.1099/mgen.0.000049>
- 1622 Sommerhäuser, J., Kloppert, B., Wolter, W., Zschöck, M., Sobiraj, A., & Failing, K.
1623 (2003). The epidemiology of *Staphylococcus aureus* infections from subclinical
1624 mastitis in dairy cows during a control programme. *Veterinary Microbiology*, 96(1),
1625 91-102. [https://doi.org/10.1016/S0378-1135\(03\)00204-9](https://doi.org/10.1016/S0378-1135(03)00204-9)
- 1626 Strommenger, B., Braulke, C., Heuck, D., Schmidt, C., Pasemann, B., Nübel, U., &
1627 Witte, W. (2008). Spa typing of *Staphylococcus aureus* as a frontline tool in
1628 epidemiological typing. *Journal of clinical microbiology*, 46(2), 574-581.
- 1629 Tokajian, S. T., Khalil, P. A., Jabbour, D., Rizk, M., Farah, M. J., Hashwa, F. A., & Araj,
1630 G. F. (2010). Molecular characterization of *Staphylococcus aureus* in Lebanon.
1631 *Epidemiology & Infection*, 138(5), 707-712.
- 1632 Vanderhaeghen, W., Piepers, S., Leroy, F., Van Coillie, E., Haesebrouck, F., & De
1633 Vlieghe, S. (2014). Invited review: Effect, persistence, and virulence of
1634 coagulase-negative *Staphylococcus* species associated with ruminant udder
1635 health. *Journal of Dairy Science*, 97(9), 5275-5293.
1636 <https://doi.org/10.3168/jds.2013-7775>
- 1637 Vidal, J., Vargas, K., Parra, L., Rivera, A., Macias, D., Torres, G., & Olivera, M. (2016).
1638 Prevalence of mastitis causing bacteria isolated in two diagnostic laboratories in
1639 Antioquia (Colombia), between the years 2013 and 2015. *Journal of Veterinary
1640 Science and Technology*, 7(6), 38. <https://doi.org/10.4172/2157-7579.C1.019>
- 1641 Wang, D., Zhang, L., Zhou, X., He, Y., Yong, C., Shen, M., Szenci, O., & Han, B. (2016).
1642 Antimicrobial susceptibility, virulence genes, and randomly amplified polymorphic
1643 DNA analysis of *Staphylococcus aureus* recovered from bovine mastitis in
1644 Ningxia, China. *Journal of dairy science*, 99(12), 9560-9569.
- 1645 Wang, W., Lin, X., Jiang, T., Peng, Z., Xu, J., Yi, L., Li, F., Fanning, S., & Baloch, Z.
1646 (2018). Prevalence and Characterization of *Staphylococcus aureus* Cultured
1647 From Raw Milk Taken From Dairy Cows With Mastitis in Beijing, China. *Frontiers
1648 in Microbiology*, 9, 1123. <https://doi.org/10.3389/fmicb.2018.01123>
- 1649 Zadoks, R. N., Middleton, J. R., McDougall, S., Katholm, J., & Schukken, Y. H. (2011).
1650 Molecular Epidemiology of Mastitis Pathogens of Dairy Cattle and Comparative
1651 Relevance to Humans. *Journal of Mammary Gland Biology and Neoplasia*, 16(4),
1652 357-372. <https://doi.org/10.1007/s10911-011-9236-y>
- 1653

1654 **Artículo 3**

1655 **Phenotypic characterization and whole genome analysis of a strong biofilm-**
1656 **forming *Staphylococcus aureus* strain associated with subclinical bovine mastitis**
1657 **in Colombia**

1658

1659 El artículo completo se adjunta con el documento final (anexo) o puede ser descargado
1660 en el siguiente link: <https://doi:10.3389/fvets.2020.00530>

1661



Phenotypic Characterization and Whole Genome Analysis of a Strong Biofilm-Forming *Staphylococcus aureus* Strain Associated With Subclinical Bovine Mastitis in Colombia

Giovanny Torres^{1,2*}, Karen Vargas¹, Yesid Cuesta-Astroz², Julián Reyes-Vélez¹ and Martha Olivera-Angel¹

OPEN ACCESS

Edited by:
Rafael Vignoli,
Universidad de la República, Uruguay

Reviewed by:
Paola Scavone,
Instituto de Investigaciones Biológicas
Clemente Estable (IBCE), Uruguay
Mónica Sparo,
National University of Central Buenos
Aires, Argentina

***Correspondence:**
Giovanny Torres
giovanny.torres@udea.edu.co

Specialty section:
This article was submitted to
Veterinary Epidemiology and
Economics,
a section of the journal
Frontiers in Veterinary Science

Received: 21 April 2020

Accepted: 06 July 2020

Published: 04 September 2020

Citation:
Torres G, Vargas K, Cuesta-Astroz Y,
Reyes-Vélez J and Olivera-Angel M
(2020) Phenotypic Characterization
and Whole Genome Analysis of a
Strong Biofilm-Forming
Staphylococcus aureus Strain
Associated With Subclinical Bovine
Mastitis in Colombia.
Front. Vet. Sci. 7:530.
doi: 10.3389/fvets.2020.00530

Staphylococcus aureus represent a serious threat to public health due to food safety, antibiotic resistance, and the potential zoonotic transmission of strains between dairy cattle and humans. Biofilm formation by *S. aureus* results in chronicity of the infections which confers protection against the immune response and antibiotics. Likewise, biofilm allows the exchange of mobile genetic material among different strains through microbial interactions inside the matrix. In Colombia, where *S. aureus* continues to be one of the main pathogens isolated from bovine intramammary infections and where milking by hand is highly frequent, there are knowledge gaps on the zoonotic potential of the strains. Therefore, the aim of this work was to characterize genotypically and phenotypically the *S. aureus* Sa1FB strain with strong biofilm production and to perform genomic and phenotypic comparisons with other relevant *S. aureus* strains (native and references strains). These results show a highly productive strain of biofilm and a low ability of cell invasion compared to the other two native strains. In addition, high genomic similarity between *S. aureus* Sa1FB and the reference strains was observed, despite of the differences reported at the clinical level. However, Sa1FB exhibited special features in terms of mobile genetic elements, highlighting its ability to accept foreign genetic material. Indeed, this could increase mutation, pathogenesis, and adaptability to new hosts, representing a risk for people in contact with the milk obtained from animals infected with these strains. These results present the relevance of surveillance for early detection of emergent clones with zoonotic potential, which reduces the risk of occupational exposure and their spread in the community.

Keywords: biofilm, intramammary infections, mastitis, mobile genetic elements, *Staphylococcus aureus*, virulence factors, whole genome sequencing

1662

1663

1664 **Resultados del objetivo 2**

1665 **Objetivo 2:** Caracterizar y comparar los proteomas generados *In vitro* durante la
1666 formación de biopelícula por cepas de *S. aureus* aisladas de mastitis.

1667 Para cumplir con este objetivo se ejecutaron las cinco actividades que se describen a
1668 continuación:

1669 1. Se seleccionaron tres cepas genotípica y fenotípicamente diferentes de acuerdo
1670 con los resultados obtenidos en el objetivo 1.

1671 2. Se co-cultivaron las tres cepas con células epiteliales mamarias bovinas durante 12
1672 y 24 horas.

1673 3. Se identificaron las proteínas bacterianas extraídas después de cumplido los
1674 tiempos establecidos mediante nano-LC-MS/MS.

1675 4. Se compararon las proteínas obtenidas de las cepas formadoras de biopelículas
1676 con los controles.

1677 5. Se seleccionaron tres proteínas expresadas en las cepas productoras de
1678 biopelículas relacionadas con la formación de esta matriz.

1679 Los resultados de todas las actividades relacionadas se encuentran en el artículo 4
1680 titulado “**Proteomic analysis of the interaction between biofilm-forming**
1681 ***Staphylococcus aureus* strains and bovine mammary epithelial cells**”.

1682

1683

1684

1685

1686 **Artículo 4**

1687 **Proteomic analysis of the interaction between biofilm-forming *Staphylococcus***
1688 ***aureus* strains and bovine mammary epithelial cells**

1689

1690 G. Torres ^{a,b,*}, M. Sánchez ^a, J. Reyes ^{a,b}, M. Olivera-Angel ^b

1691 ^a Colombian Institute of Tropical Medicine, CES University, Cra. 43A No. 52 sur-99
1692 Sabaneta, Antioquia, Colombia.

1693 ^b Biogenesis research group, Faculty of Agricultural sciences, University of Antioquia,
1694 Cra. 75 No. 65-87, Medellín, Antioquia, Colombia.

1695

1696

1697

1698 *Corresponding author: giovanny.torresl@udea.edu.co.

1699

1700

1701 **Abstract**

1702 Several proteomic approaches have been used to study the complex interactions
1703 between the bovine host and *Staphylococcus aureus*. However, most of studies on
1704 biofilms have used bacterial cultures on abiotic surfaces, which probably do not reflect
1705 the behavior of bacteria *in vivo*. Biofilm produced by *S. aureus* on bovine biotic surfaces
1706 has been less studied. The aim of this study was to identify *S. aureus* proteins
1707 associated with the biofilm formation during interaction with bovine mammary epithelial
1708 cells. Three *S. aureus* strains with different genotypic and phenotypic characteristics in
1709 terms of biofilm formation were included. The 1BF strain carried the *ica* and *bap* genes
1710 and exhibited the highest ability to form biofilm. Whereas, 2BF was only *ica* positive and
1711 showed a weaker phenotype. The 3NF strain was used as a control, which it did not
1712 have any of these genes and was classified as non-biofilm former. The strains were co-

1713 cultured with bovine mammary epithelial cells for 12 h and 24 h. Bacterial proteins were
1714 extracted and analyzed with nano-LC-MS/MS. Six proteins were identified associated
1715 with the biofilm formation that were only expressed during the co-culture with mammary
1716 epithelial cells and were not identified in the controls. IsdA and Eap were expressed by
1717 both biofilm-forming strains, enolase, ClfA and SdrD were also produced by 2BF strain,
1718 while TRAP by 1BF. IsdA, ClfA and SdrD were the identified proteins involved with
1719 biofilm production that exhibited the highest predicted antigenicity (> 90%). These
1720 results confirm that IsdA, ClfA and SdrD are potential candidates for vaccines and could
1721 be used as immunogens in immunoassays, since are involved in the early stage of the
1722 infection, in the biofilm formation and have the ability of elicit host immune response.

1723

1724 Keywords: Biofilm; Intramammary infections; Mastitis; Proteins; Proteomic;
1725 *Staphylococcus aureus*; Virulence factors

1726

1727 **Introduction**

1728 *Staphylococcus aureus* is one of the main causing agent of intramammary infections
1729 (IMI) worldwide (Keefe, 2012). The infections caused by this pathogen are characterized
1730 due to their persistence and the poor antibiotic response, which represents an important
1731 economic problem for the dairy industry (Veh et al., 2015).

1732 Different phenotypic characteristics from *S. aureus* have been associated with persistent
1733 IMI, being the ability to form biofilm one of the most important due to confers protection
1734 against antibiotics and the host's immune response (Gomes et al., 2016). This pathogen
1735 can form biofilm through several described mechanisms such as polysaccharide
1736 intercellular adhesion (PIA)-dependent or PIA-independent, and in five stages:
1737 attachment, multiplications, exodus, maturation, and dispersal (McCarthy et al., 2015;
1738 Moormeier & Bayles, 2017). However, proteins involved in this process have not yet
1739 been fully defined.

1740 Proteomics approach and the utilization of bioinformatic tools have been used to study
1741 the complex interactions between host and *S. aureus* (Huang et al., 2014). Studies have
1742 revealed several proteomic profiles in both milk and blood serum of cows with IMI, as
1743 well as in the bacterial cells (Huang et al., 2014; Kim et al., 2011; Smith et al., 2016;
1744 Zhang et al., 2015). Most proteomic studies on biofilms have used bacterial cultures on
1745 abiotic surfaces, which probably have not reflected the actual behavior of bacteria under
1746 *in vivo* conditions (Lei et al., 2017). Evidence has shown that studies that have been
1747 carried out on abiotic surfaces to evaluate the biofilm forming process can show
1748 discrepancies with respect to those that have used cellular or animal models (biotics)
1749 (Brady et al., 2006; den Reijer et al., 2016). Brady et al. (2006) found that only 26 of the
1750 more than 100 proteins identified from biofilm matrix under *in vitro* conditions were
1751 recognized in the biofilms formed *in vivo* (Lei et al., 2017).

1752 The biofilm forming process by *S. aureus* on bovine biotic surfaces (e.g. mammary
1753 epithelial cells) has been less studied. Therefore, increasing knowledge about this
1754 process is essential to understand its performance under *in vivo* conditions. The aim of
1755 this study was to identify *S. aureus* proteins associated with the biofilm formation during
1756 interaction with bovine mammary epithelial cells.

1757 **Materials and methods**

1758 *Staphylococcus aureus* strains

1759 Three *S. aureus* strains were selected from 229 isolates recovered from bovine IMI in
1760 the Department of Antioquia (Colombia), which were previously characterized
1761 genotypically and phenotypically in terms of biofilm formation (Torres et al., 2019). A
1762 strain of each of the three groups of identified genotypes was randomly chosen. Table 1
1763 describes the characteristics of the selected strains. The 3NF strain was used as a non-
1764 biofilm formation control.

1765 **Table 1.** Genotypic and phenotypic characteristics of the selected strains.

Strain	Genotypic characteristic*	Phenotypic characteristic†
1BF	<i>ica(+)-bap(+)</i>	Strong biofilm former
2BF	<i>ica(+)-bap(-)</i>	Weak biofilm former
3NF	<i>ica(-)-bap(-)</i>	Not biofilm former

1766 * Genes amplified associated with biofilm formation. (+) amplified marker; (-) marker not
1767 amplified. †Capacity of biofilm formation on abiotic surfaces (microplates).

1768 *Bovine mammary epithelial cells*

1769 A clonal bovine mammary epithelial cells (MEC) (Yoder et al., 2019) were initially
1770 cultured into a T25 polystyrene culture flask (TrueLine, USA) using DMEM medium
1771 (Sigma-Aldrich, USA) supplemented with 10% fetal bovine serum (Thermo Fisher
1772 Scientific, USA), 5 µg/mL insulin (Sigma-Aldrich, USA), and 1 µg/mL hydrocortisone
1773 (Sigma-Aldrich, USA). The flask with MEC was incubated for five days at 37°C with 5%
1774 CO², until to reach confluency.

1775 After reviewing the purity of culture, the MEC monolayer was washed with sterile PBS
1776 (VWR, USA) and treated with 0.25% trypsin (AMRESCO, USA) until cells detached.
1777 Then, the MEC were resuspended in fresh DMEM medium and seeded (~2X10⁵
1778 cells/well) in 24-well polystyrene tissue culture-treated microtiter plates (TrueLine, USA).
1779 The plates were incubated for 24 h at 37°C with 5% CO².

1780 *Cell infection*

1781 The confluent monolayer of MEC was co-cultured with each *S. aureus* strain at a
1782 multiplicity of infection (MOI) of 10:1 (Valle et al., 2012). Briefly, the bacterial strains
1783 were transferred from stock culture into Trypticase soy agar (TSA) (Oxoid, United
1784 Kingdom) and incubated at 37°C overnight under aerobic conditions. The colonies were
1785 suspended in sterile distilled water until a turbidity comparable to 0.5 MacFarland scale
1786 (~10⁸ CFU/mL) was reached. This suspension was diluted 1:10 in DMEM medium to
1787 reach a bacterial concentration of approximately 10⁷ CFU/mL. Then, 100 µL from the

1788 diluted suspension was aliquoted in each well that contained the MEC monolayer.
1789 Likewise, the same strain was only cultured with DMEM in absence of MEC (control on
1790 abiotic surface – CAS). Two plates were prepared, one for each time of assay (12 and
1791 24 h). The plates were incubated for 12 h and 24 h at 37°C with 5% CO². Experiments
1792 were performed in duplicates and were repeated two times.

1793 *Proteins extraction*

1794 Once the incubation times were completed, the culture medium was removed and
1795 discarded. The proteins were extracted using RNA/Protein Purification Plus Kit (Norgen,
1796 Canada) according to protocol for Gram-positive bacteria with some modifications.
1797 Briefly, the MEC monolayer was detached following the manufacturer recommendations
1798 for cultured animal cells. This material was transferred to a tube and bacteria were
1799 lysate according to protocol. Finally, the genomic DNA was removed, and total proteins
1800 were isolated.

1801 *Protein identification by nano–LC–MS/MS*

1802 Samples were analyzed by Creative Proteomics (USA) using an Ultimate 3000 nano
1803 UHPLC system coupled with Q Exactitive HF mass spectrometer (Thermo Fisher
1804 Scientific, USA) with Nanospray Ion Source.

1805 Samples (5 µL) were loaded onto a nanocolumn: trapping column (PepMap C18, 100Å,
1806 100 µm x 2 cm, 5 µm) and an analytical column (PepMap C18, 100Å, 75 µm x 50 cm, 2
1807 µm) at a flow rate of 250 nL/min. Peptides were separated using a linear gradient from 2
1808 to 8% buffer B (80% ACN, 0.1% formic acid) in 3 min, from 8% to 20% buffer B in 50
1809 min, from 20% to 40% buffer B in 26 min, then from 40% to 90% buffer B in 4 min.

1810 The peptides were subjected to nanospray ionization (2.2 kV) followed by tandem mass
1811 spectrometry (MS/MS). Full scan spectra were measured between m/z 300 – 1.800 at a
1812 resolution of 70.000 at 400 m/z . Peptides were selected for MS/MS using collision-
1813 induced dissociation (CID) with a normalized collision energy of 40%. Data dependent

1814 MS/MS allowed to obtain up to top 15 most intense peptide ions from the preview scan
1815 in the Orbitrap.

1816 The raw file was searched using Maxquant (1.5.6.5) against bovine and *S. aureus*
1817 protein database from Uniprot. Peptides with a probability score < 0.01 were considered
1818 for protein identification.

1819 *Data analysis*

1820 The identified bacterial proteins from each biofilm former strain were contrasted with the
1821 proteins identified from not biofilm former strain (3NF) and with the results obtained from
1822 the same strain cultured without MEC (CAS) in order to determine the proteins that were
1823 only expressed during the interaction with MEC. Those proteins found in the three lists
1824 were removed and only the identified proteins from biofilm producer strains co-cultured
1825 with MEC were selected. These analyses were performed individually for each time
1826 evaluated. Finally, selected proteins by each biofilm-forming strain were compared
1827 between them to find common or unique proteins.

1828 Once the common or unique proteins were recognized between the biofilm-forming
1829 strains, these were submitted to bioinformatic analysis using the websites SCRATCH
1830 Protein Predictor (<http://scratch.proteomics.ics.uci.edu/>) and UniProt
1831 (<https://www.uniprot.org/>) in order to assess their sequence, antigenicity, function, and
1832 subcellular location. Additionally, it was verified by literature review if these proteins
1833 were involved in the biofilm formation process.

1834 *Statistical analysis*

1835 Due to the lack of normality of the outcome variable (number of proteins produced), a
1836 non-parametric analysis was performed using the Kruskal-Wallis test. Comparing the
1837 number of proteins and the given groups formed by genotype and time. A statistical

1838 significance threshold of $P < 0.05$ was used to assess the overall differences between
1839 groups.

1840 **Results**

1841 *Proteins identified in the biofilm-forming strains during contact with MEC*

1842 Proteins that were only identified from the strains co-cultured with MEC but were not
1843 identified from strains cultured without MEC (CAS) are shown in Table S1
1844 (Supplementary table 1).


1845 The results showed that the 2BF isolate was expressed more proteins (33) during the
1846 first 12 h of contact with MEC, followed of the 1BF strain (20). The percentages of
1847 virulence factors expressed by 1BF and 2BF strains were similar at 12 h and 24 h.
1848 Comparable results were observed at 24 h, although in this time, the 1BF strain
1849 presented more proteins (48) than 2BF (Table 2). The Kruskal-Wallis analysis did not
1850 find significant differences among the number of proteins by genotype, times, and
1851 virulence factors ($P > 0.05$).

1852 **Table 2.** Proteins number identified from biofilm-forming strains during contact with
1853 MEC.

Strain	Genotype	Time (h)	No. proteins identified in contact with MEC	No. virulence factors (%)
1BF	<i>ica(+)-bap(+)</i>	12	20	3 (15.0)
2BF	<i>ica(+)-bap(-)</i>	12	33	5 (15.2)
1BF	<i>ica(+)-bap(+)</i>	24	48	8 (16.7)
2BF	<i>ica(+)-bap(-)</i>	24	36	8 (22.2)

1854 (+) amplified marker; (-) marker not amplified; No: number

1855 Of the 53 proteins identified at 12 h between biofilm-forming strains (1BF and 2BF), only
 1856 6 (11.3%) were common between these. Whereas, 14 (26.4%) and 27 (50.9%) of the 53
 1857 proteins were exclusive of 1BF and 2BF strains, respectively. On the other hand, 14
 1858 (16.7%) of the 84 proteins identified at 24 h were common between both strains, 34
 1859 (40.1%) were unique of the 1BF strain and 22 (26.2%) of the 2BF strain (Fig. 1).



1860

1861 **Figure. 1.** Venn diagram. Each oval represents a strain by time evaluated. The numbers
 1862 in intersections indicate common proteins between strains by time evaluated. The
 1863 numbers outside of the intersections are unique proteins identified in each strain by time
 1864 evaluated.

1865 *Virulence factors expressed only by biofilm-forming strains*

1866 Once selected the proteins expressed from two strains producer of biofilm during
 1867 interaction with MEC, these were filtered again. In this phase, only the proteins
 1868 recognized as virulence factors and expressed from biofilm-forming strains, but not
 1869 expressed by the control (3NF strain), were selected (Table 3).

1870 **Table 3.** Proteins only identified from biofilm-forming strains by time evaluated.

Id protein	Protein	Strain		Time	
		1BF	2BF	12h	24h
Q99UX4	Iron-regulated surface determinant protein A	X	X	X	X
Q99SN8	Uncharacterized leukocidin-like protein 1	X	X	X	X
Q99QS1	Protein map/Extracellular adherence protein (Eap)	X	X		X
Q5HEI1	Phospholipase C	X		X	X
Q99W46	Serine-aspartate repeat-containing protein E	X		X	X
Q8NVW1	Signal transduction protein TRAP	X			X
Q6GHV7	Iron-regulated surface determinant protein B	X			X
Q8NVL8	Uncharacterized leukocidin-like protein 2		X	X	X
Q6GE14	Gamma-hemolysin component A		X	X	X
Q6GIL4	Enolase		X	X	X
Q931F4	Immunoglobulin-binding protein sbi		X		X
Q2G015	Clumping factor A		X		X
O86488	Serine-aspartate repeat-containing protein D		X		X

1871 Id: Uniprot identification; X: presence

1872 Two of the three proteins identified in both strains were present from 12 h of contact with

1873 MEC. Similar results were observed with three of the six proteins detected in 2BF strain

1874 and two of the four identified in 1BF strain, which were recognized from 12 h of contact.
1875 The rest of proteins were only detected at 24 h (Table 3).

1876 *Proteins identified associated with the biofilm formation*

1877 According to literature reviewed and the information obtained from the Uniprot website,
1878 six of the 13 (46.2%) proteins selected have been associated with the biofilm formation
1879 (Table 4). Two of the three proteins expressed in both strains, Iron-regulated surface
1880 determinant protein A (IsdA) and Protein map (Map), also referred as Extracellular
1881 adherence protein (Eap), were involved in the biofilm formation process, since these
1882 have the ability to bind to different molecules and to form biofilms under iron-limiting
1883 conditions (in the following part of the article, the Map is only referred to as Eap).

1884 Enolase, Clumping factor A (ClfA), and Serine-aspartate repeat-containing protein D
1885 (SdrD) were identified as proteins related to biofilms. These were only detected in the
1886 2BF strain and play an important role during the process of adhesion and aggregation of
1887 the bacterial cells.

1888 Regarding to the proteins detected only in the 1BF strain associated with biofilm, the
1889 signal transduction protein TRAP acts as an activator of the Agr system, which regulates
1890 the expression of some genes necessary for biofilm formation.

1891 **Table 4.** Main characteristics of the identified proteins involved in the biofilm formation
1892 process.

Protein (Strain)	Gen	Length (Da)	Subcellular location	Key role in biofilm formation process	Predicted antigenicity
IsdA (1BF-	<i>isdA</i>	350 (38,756)	Cell wall	Fibronectin and fibrinogen binding	0.94

2BF)				Biofilm formation under iron-limiting conditions	
Map/Eap (1BF-2BF)	<i>map/eap</i>	476 (53,377)	Secreted Extracellular surface	Fibronectin, fibrinogen, and eDNA binding Biofilm formation under iron-limiting and normal conditions	0.66
TRAP (1BF)	<i>traP</i>	167 (19,563)	Membrane	Regulator of the expression of some genes involved in biofilm formation	0.86
Enolase (2BF)	<i>eno</i>	434 (47,117)	Cytoplasm Secreted Cell surface	Laminin and eDNA binding	0.37
CifA (2BF)	<i>cifA</i>	927 (96,448)	Cell wall	Fibrinogen, AnnexinA2, and fibrin binding	0.94
SdrD (2BF)	<i>sdrD</i>	1,315 (142,776)	Cell wall	Extracellular matrix adhesion	0.98

1894 **Discussion**

1895 Bacterial biofilms have become in an important subject of study in both the medical and
1896 industrial areas, because biofilm gives the bacteria high ability to evade the host
1897 immune system and resist the action of antibiotics and disinfectants. *S. aureus* IMI have
1898 been characterized by their chronicity, which biofilms are one of main virulence factor
1899 associated with this course of infection.

1900 The initial phase in the biofilm formation process is the attachment on an abiotic or biotic
1901 surface (Moormeier & Bayles, 2017). There is not biofilm without adequate and strong
1902 adhesion to surfaces, since non-adhered bacteria could be removed from the host
1903 (Gong et al., 2010). Several studies that blocked or eliminated (mutants) some proteins
1904 involved in the initial adherence of *S. aureus* to the cell matrix, showed a reduction or
1905 avoidance of the biofilm formation, which demonstrated the importance of these
1906 molecules in the development of biofilm matrix (Cheung et al., 2009; Clarke et al., 2004;
1907 Gong et al., 2010). *S. aureus* attaches the surface using different proteins that belong to
1908 a well-characterized group of proteins known as microbial surface components
1909 recognizing adhesive matrix molecules (MSCRAMM), which are part of cell wall-
1910 anchored (CWA) proteins (Foster et al., 2014). Several of these proteins share a
1911 common motif (LPXTG). However, they have different binding target on the host cell
1912 matrix (Moormeier & Bayles, 2017). Some of the main proteins described that have been
1913 involved in the initial adherence to biotic surfaces and the subsequent biofilm formation
1914 are Fibronectin-binding proteins (FnBPA and FnBPB), Clumping factors (ClfA and ClfB),
1915 Serine-aspartate repeat family proteins (SdrC, SdrD, and SdrE), Iron-regulated surface
1916 determinants (IsdA, IsdB, IsdC, and IsdH), and biofilm associated protein (Bap)
1917 (Moormeier & Bayles, 2017).

1918 IsdA and Eap were the two proteins identified in both biofilm-forming strains that have
1919 been associated with the development of biofilm (Lin et al., 2012). Both IsdA and Eap
1920 play an important role in adhesion process and in the biofilm formation in iron limited

1921 environment. Iron is an essential component for bacterial growth and the biofilm
1922 formation, but its availability in the host is generally restricted (Hammer & Skaar, 2011).
1923 Therefore, bacteria can use different mechanisms to iron acquisition from environment,
1924 being the cell invasion (greater than 90% of the iron is located intracellularly) and the
1925 siderophores production some of these (Hammer & Skaar, 2011; Lin et al., 2012). Other
1926 of the way reported that *S. aureus* use to capture iron is the Isd system, which is formed
1927 by a group of proteins encoded by *isd* operon (eight genes). Among these proteins is
1928 IsdA, a surface receptor that participates in the acquisition of iron, especially when its
1929 availability is limited (Maresso & Schneewind, 2006).

1930 The culture media used in this work presented iron-deplete conditions, something similar
1931 to what is found in the cow's milk. Several studies have shown that *S. aureus* expresses
1932 IsdA in the presence of the iron chelating agent or when iron availability is limited. For
1933 example, Clarke, Wiltshire, & Foster (2004) found evidence that related the IsdA
1934 expression under iron-limited conditions. Likewise, Lin et al. (2012) also observed the
1935 increase on the expression of this protein in the presence of the iron chelating agent
1936 1,2,3,4,6-penta-O-galloyl- β -D-glucopyranose (PGG). Although, the results of our study
1937 are in agreement with those observed by these authors, presence of IsdA when iron
1938 availability was limited, these were different because the protein was not identified in the
1939 strains cultured without MEC (abiotic surface with only culture medium). This was only
1940 found in the biofilm producing strains cultured with MEC (biotic surface). The results
1941 could indicate that the main function of this protein under the assay conditions used was
1942 the adhesion to the surface of the MEC.

1943 IsdA protein has also been involved with the adhesion process of *S. aureus* to the host
1944 cells (Moormeier & Bayles, 2017). Fibronectin and fibrinogen are some of the proteins to
1945 which IsdA can bind during the initial stage of the colonization (Clarke et al., 2004). Lei,
1946 Gupta, & Lee (2017) reported the presence of IsdA in the surfactome of the *S. aureus*
1947 strain evaluated during the acute phase of infection of bone implants used in a rat

1948 model. According to the results obtained in our study, this protein was expressed by
1949 biofilm forming strains from 12 h after of MEC inoculation, confirming its participation in
1950 the early stage of the infection. On the other hand, studies that achieved to inactivate
1951 *isdA* gene or block the protein (monoclonal antibodies) observed a decrease in the
1952 ability of *S. aureus* to colonize the host tissue (Bennett et al., 2019; Cheung et al., 2009;
1953 Clarke et al., 2004; Hammer & Skaar, 2011).

1954 Regarding to Eap, other of the proteins identified in the biofilm-forming strains, has also
1955 been reported with a dual function (Yonemoto et al., 2019). Like *IsdA*, Eap is involved in
1956 the process of adhesion and biofilm formation, but differs from this, because Eap belong
1957 to the group of the secretable expanded repertoire adhesive molecules (SERAM) and
1958 not to the group of MSCRAMM (Geraci et al., 2017). This kind of proteins are secreted
1959 and after re-bind to the bacterial cell surface (Geraci et al., 2017; Thompson et al.,
1960 2010). Released Eap can bind to a number of host cell matrix components such as
1961 fibronectin, as well as to plasma proteins (fibrinogen) and extracellular DNA (eDNA)
1962 (Eisenbeis et al., 2018; Thompson et al., 2010).

1963 Reports have suggested that Eap plays an important role in later infection process due
1964 lack of expression in the stationary growth phase (Geraci et al., 2017; Hussain et al.,
1965 2001). We found Eap at 24 h of contact with MEC, suggesting its participation from initial
1966 stage of infection. Our results are similar to those studies that have demonstrated the
1967 importance of this protein in the biofilm development, since this structure could not be
1968 formed without an adequate adhesion process from the early phase. Johnson,
1969 Cockayne, & Morrissey (2008) and Thompson et al. (2010) achieved a reduction of
1970 biofilm formation when inactivated the *eap* gene. Likewise, Yonemoto et al. (2019)
1971 recently reported the role of Eap in the biofilm formation by methicillin-resistant isolates,
1972 founding a large amount of this protein in the bacterial extracellular matrix. Unlike *IsdA*,
1973 Eap can also be found in the biofilm development under iron-replete conditions
1974 (Thompson et al., 2010).

1975 Signal transduction protein TRAP was the protein detected in the 1BF strain, which has
1976 participation in the development of biofilm by *S. aureus*. TRAP is a major regulator of
1977 pathogenesis in *S. aureus*, because its phosphorylation leads to the activation Agr
1978 system, which mediates up-regulation the expression of virulence factor and genes
1979 associated to biofilm formation (Gilot et al., 2002; UniProt Consortium, 2019). Several
1980 studies have concluded that mutations or inhibitions of *traP* locus can limit induction of
1981 *agr*, and consequently reducing the capacity to form biofilm (Tsang et al., 2007).
1982 Moreover, Tsang et al. (2007) reported that the mutations performed on this gene from
1983 *S. aureus* strains did not affect expression of *agr* or the ability to produce biofilm. The
1984 fact of have found this molecule only in the 1BF strain, and not in the 2BF (weak biofilm
1985 former) and 3NF (non-biofilm former) strains, could suggest its importance in the ability
1986 to form a strong biofilm.

1987 Enolase was one of proteins identified in the 2BF strain that has been associated with
1988 biofilm formation. This protein is encoded by the *eno* gene, which functions as a
1989 glycolytic enzyme within the cytoplasm, but can also be released from the cell and
1990 attached at the surface of the bacterial wall (Foulston et al., 2014). Enolase has the
1991 capacity of bind to laminin, mediating the attach to the extracellular matrix during the
1992 early phase of infection (Carneiro et al., 2004; Kot et al., 2018). Several works have
1993 demonstrated the participation of enolase in the development of the matrix biofilm, since
1994 this protein is expressed from the first hours of the colonization. In our study, enolase
1995 was found in the biofilm forming strain from 12 h, but was not identified in the controls
1996 (3NF and CAS), agreeing with the results presented by Kot et al. (2018), who found a
1997 significant increase in the expression level of *eno* gene from biofilm-forming strains
1998 compared to planktonic cells. The gene was expressed from 3 h under biofilm conditions
1999 used, achieving the highest levels at 6 and 8 h. The authors proposed that the
2000 significantly higher transcript level of *eno* gene in the first hour of growth of biofilm
2001 producer strains suggest that this molecule is important for the first stage of biofilm
2002 formation, because bacterial cells interact with host extracellular ligand. Yoshii et al.

2003 (2017) also demonstrated the important role of enolase in the biofilm formation process,
2004 since they achieved to inhibit the staphylococcal biofilm formation using Norgestimate
2005 (acetylated progestin). This product repressed the expression of enolase protein in the
2006 extracellular matrix compared to the control.

2007 The second protein associated with biofilm formation found in the 2BF strain was ClfA.
2008 This protein is an important adhesin, usually covalently anchored to the bacterial cell
2009 wall, belonging to the MSCRAMM group and encoded by the *clfA* gen (Gong et al.,
2010 2010). Although, ClfA protein generally has been associated with the binding to
2011 plasmatic fibrinogen, a study showed that this molecule also has a direct mechanism of
2012 binding to the MEC in the absence of fibrinogen (Ashraf et al., 2017). The authors
2013 confirmed that ClfA interacted with AnnexinA2, a phospholipid-binding protein found on
2014 the surface of MEC. It has described that most of the isolates express ClfA and that this
2015 participates in the initial stage of the infection (Lacey et al., 2017; Zecconi & Scali,
2016 2013). However, in this study, ClfA protein was only present at 24 h and was no
2017 expressed by all strains evaluated, since it was not identified in the 1BF and 3NF strains
2018 under the assay conditions used.

2019 Regarding to the role that ClfA plays in the biofilm formation process, Zapotoczna et al.
2020 (2015) informed about a biofilm phenotype mediated by coagulase and ClfA, since the
2021 latter can bind to fibrin formed by coagulase or fibrinogen available in plasma, leading to
2022 an immediate clumping of bacterial cells (Zapotoczna et al., 2016).

2023 The SdrD protein is another of the molecules that is part of the MSCRAMM group, which
2024 is encoded by the *sdrD* gene located within the *sdr* locus (Josefsson et al., 1998). This
2025 protein plays an important role in the bacterial adhesion to host tissues and the
2026 subsequent biofilm formation (Ma et al., 2012). Both Ma et al. (2012) and Vaishampayan
2027 et al. (2018) observed in their works a down-regulation of *sdrD* gene and a reduction in
2028 the biofilm formation when the strains analyzed were in contact with the evaluated
2029 products. Askarian et al. (2017) carried out another study where demonstrated its

2030 potential pathogenic. They reported that SdrD contributed to *S. aureus* survival and the
2031 ability to escape the innate immune system in human blood. Some studies have shown
2032 that all strains are no carriers of the *sdrD* gene, being found in about 60% of the isolates
2033 tested (Liu et al., 2015; Sohail & Latif, 2018). We only identified this protein in the 2BF,
2034 which is agree with those results. However, since this gene was not tested in the 3NF
2035 isolate, it is not possible assure that this were not carriers of *sdrD*.

2036 The predicted antigenicity of the identified proteins associated with the development of
2037 biofilm ranged between 37% to 98%. SdrD presented the highest antigenicity (98%),
2038 followed by IsdA and ClfA (94%), TRAP (86%), Eap (66%), and enolase (37%).
2039 Stranger-Jones et al. (2006) showed the antigenic potential of SdrD and IsdA, since they
2040 generated significant protective immunity in a murine model against lethal challenge with
2041 human clinical isolates of *S. aureus*. These animals were immunized with a vaccine
2042 composed of four antigens (IsdA, IsdB, SdrD, and SdrE). In addition, Bennett et al.
2043 (2019) evidenced a reduction of bacterial burden in a murine septic model after of the
2044 injection of monoclonal antibodies against IsdA.

2045 Several studies have proposed the ClfA protein as a good vaccine candidate, because it
2046 is an important virulence factor, most of bacterial strains are gene carriers, and show a
2047 high predicted antigenicity, such as was reported in this study (94%). According to
2048 published by Camussone et al. (2014) the vaccine composed of lysed cell of a CP5 *S.*
2049 *aureus* supplemented with different recombinant antigens, among these ClfA, elicited
2050 antibodies that promoted neutrophil phagocytosis and inhibited internalization into MEC.
2051 Similar results were shown by Nour El-Din et al. (2006), who immunized cows with a
2052 DNA vaccine against ClfA and observed a decrease in adherence of *S. aureus* to MEC.
2053 In addition, a recent work also demonstrated that this protein is a potent human T cell
2054 activator, which could be crucial for the generation of vaccines anti-*S. aureus* (Lacey
2055 et al., 2017).

2056 Despite TRAP presented a predicted antigenicity of 86%, we did not find works related
2057 to this characteristic, probably because this is an intracellular protein. Regarding Eap,
2058 which achieved an antigenicity of 66%, Joost et al. (2011) reported significant
2059 differences between antibodies titers against Eap from infected and healthy individuals,
2060 finding the highest titers in infected patients than controls. On the other hand, enolase
2061 was that showed the lowest predicted antigenicity (37%). This result could be explained
2062 because enolase present an identity around 50% with bovine enolase, which are
2063 enzymes essentials for the degradation of carbohydrates.

2064 **Conclusions**

2065 This study identified proteins involved in biofilm production that were only expressed
2066 during interaction with MEC and were not found in the not biofilm formation strain,
2067 demonstrating their importance in the infectious process and, probably, in the
2068 subsequent *in vivo* biofilm formation. Despite of evaluating three genotypically and
2069 phenotypically different strains, not significant differences were found amongst different
2070 attributes (genotype, times, number of proteins and virulence factors).

2071 Furthermore, the results of our study confirmed that SdrD, IsdA and ClfA proteins are
2072 good candidates for vaccines and could be used as immunogens in immunoassays,
2073 since these are involved in the early stage of the infection, in the biofilm formation and
2074 have the ability of elicit an immune response.

2075 **References**

- 2076 Ashraf, S., Cheng, J., & Zhao, X. (2017). Clumping factor A of *Staphylococcus aureus*
2077 interacts with AnnexinA2 on mammary epithelial cells. *Scientific Reports*, 7, 40608.
2078 <https://doi.org/10.1038/srep40608>
- 2079 Askarian, F., Uchiyama, S., Valderrama, J. A., Ajayi, C., Sollid, J. U. E., van Sorge, N.
2080 M., Nizet, V., van Strijp, J. A. G., & Johannessen, M. (2017). Serine-Aspartate
2081 Repeat Protein D Increases *Staphylococcus aureus* Virulence and Survival in
2082 Blood. *Infection and Immunity*, 85(1). <https://doi.org/10.1128/IAI.00559-16>

- 2083 Bennett, M. R., Bombardi, R. G., Kose, N., Parrish, E. H., Nagel, M. B., Petit, R. A.,
2084 Read, T. D., Schey, K. L., Thomsen, I. P., Skaar, E. P., & Crowe, J. E. (2019).
2085 Human mAbs to *Staphylococcus aureus* IsdA Provide Protection Through Both
2086 Heme-Blocking and Fc-Mediated Mechanisms. *The Journal of Infectious Diseases*,
2087 219(8), 1264-1273. <https://doi.org/10.1093/infdis/jiy635>
- 2088 Brady, R. A., Leid, J. G., Camper, A. K., Costerton, J. W., & Shirtliff, M. E. (2006).
2089 Identification of *Staphylococcus aureus* proteins recognized by the antibody-
2090 mediated immune response to a biofilm infection. *Infection and Immunity*, 74(6),
2091 3415-3426. <https://doi.org/10.1128/IAI.00392-06>
- 2092 Camussone, C. M., Veaute, C. M., Pujato, N., Morein, B., Marcipar, I. S., & Calvino, L.
2093 F. (2014). Immune response of heifers against a *Staphylococcus aureus* CP5
2094 whole cell and lysate vaccine formulated with ISCOM Matrix adjuvant. *Research in*
2095 *Veterinary Science*, 96(1), 86-94. <https://doi.org/10.1016/j.rvsc.2013.10.004>
- 2096 Carneiro, C. R. W., Postol, E., Nomizo, R., Reis, L. F. L., & Brentani, R. R. (2004).
2097 Identification of enolase as a laminin-binding protein on the surface of
2098 *Staphylococcus aureus*. *Microbes and Infection*, 6(6), 604-608.
2099 <https://doi.org/10.1016/j.micinf.2004.02.003>
- 2100 Cheung, J., Beasley, F. C., Liu, S., Lajoie, G. A., & Heinrichs, D. E. (2009). Molecular
2101 characterization of staphyloferrin B biosynthesis in *Staphylococcus aureus*.
2102 *Molecular Microbiology*, 74(3), 594-608. <https://doi.org/10.1111/j.1365-2958.2009.06880.x>
- 2104 Clarke, S. R., Wiltshire, M. D., & Foster, S. J. (2004). IsdA of *Staphylococcus aureus* is a
2105 broad spectrum, iron-regulated adhesin. *Molecular Microbiology*, 51(5), 1509-1519.
2106 <https://doi.org/10.1111/j.1365-2958.2003.03938.x>
- 2107 den Reijer, P. M., Haisma, E. M., Lemmens-den Toom, N. A., Willemsse, J., Koning, R. I.,
2108 Koning, R. A., Demmers, J. a. A., Dekkers, D. H. W., Rijkers, E., El Ghalbzouri, A.,
2109 Nibbering, P. H., & van Wamel, W. (2016). Detection of Alpha-Toxin and Other
2110 Virulence Factors in Biofilms of *Staphylococcus aureus* on Polystyrene and a
2111 Human Epidermal Model. *PloS One*, 11(1), e0145722.
2112 <https://doi.org/10.1371/journal.pone.0145722>
- 2113 Eisenbeis, J., Saffarzadeh, M., Peisker, H., Jung, P., Thewes, N., Preissner, K. T.,
2114 Herrmann, M., Molle, V., Geisbrecht, B. V., Jacobs, K., & Bischoff, M. (2018). The
2115 *Staphylococcus aureus* Extracellular Adherence Protein Eap Is a DNA Binding
2116 Protein Capable of Blocking Neutrophil Extracellular Trap Formation. *Frontiers in*
2117 *Cellular and Infection Microbiology*, 8, 235.
2118 <https://doi.org/10.3389/fcimb.2018.00235>
- 2119 Foster, T. J., Geoghegan, J. A., Ganesh, V. K., & Höök, M. (2014). Adhesion, invasion
2120 and evasion: The many functions of the surface proteins of *Staphylococcus*
2121 *aureus*. *Nature Reviews. Microbiology*, 12(1), 49-62.

- 2122 <https://doi.org/10.1038/nrmicro3161>
- 2123 Foulston, L., Elsholz, A. K. W., DeFrancesco, A. S., & Losick, R. (2014). The
2124 extracellular matrix of *Staphylococcus aureus* biofilms comprises cytoplasmic
2125 proteins that associate with the cell surface in response to decreasing pH. *MBio*,
2126 5(5), e01667-01614. <https://doi.org/10.1128/mBio.01667-14>
- 2127 Geraci, J., Neubauer, S., Pöllath, C., Hansen, U., Rizzo, F., Krafft, C., Westermann, M.,
2128 Hussain, M., Peters, G., Pletz, M. W., Löffler, B., Makarewicz, O., & Tuchscher, L.
2129 (2017). The *Staphylococcus aureus* extracellular matrix protein (Emp) has a fibrous
2130 structure and binds to different extracellular matrices. *Scientific Reports*, 7(1),
2131 13665. <https://doi.org/10.1038/s41598-017-14168-4>
- 2132 Gilot, P., Lina, G., Cochard, T., & Poutrel, B. (2002). Analysis of the genetic variability of
2133 genes encoding the RNA III-activating components Agr and TRAP in a population
2134 of *Staphylococcus aureus* strains isolated from cows with mastitis. *Journal of*
2135 *Clinical Microbiology*, 40(11), 4060-4067.
- 2136 Gomes, F., Saavedra, M. J., & Henriques, M. (2016). Bovine mastitis
2137 disease/pathogenicity: Evidence of the potential role of microbial biofilms.
2138 *Pathogens and Disease*, 74(3). <https://doi.org/10.1093/femspd/ftw006>
- 2139 Gong, R., Hu, C., Xu, H., Guo, A., Chen, H., Zhang, G., & Shi, L. (2010). Evaluation of
2140 clumping factor A binding region A in a subunit vaccine against *Staphylococcus*
2141 *aureus*-induced mastitis in mice. *Clinical and Vaccine Immunology: CVI*, 17(11),
2142 1746-1752. <https://doi.org/10.1128/CVI.00162-10>
- 2143 Hammer, N., & Skaar, E. (2011). Molecular mechanisms of *Staphylococcus aureus* iron
2144 acquisition. *Annu Rev Microbiol.*, 65, 1-19. <https://doi.org/doi:10.1146/annurev-micro-090110-102851>
- 2146 Huang, J., Luo, G., Zhang, Z., Wang, X., Ju, Z., Qi, C., Zhang, Y., Wang, C., Li, R., Li,
2147 J., Yin, W., Xu, Y., Moisés, S. J., Loo, J. J., & Zhong, J. (2014). ITRAQ-proteomics
2148 and bioinformatics analyses of mammary tissue from cows with clinical mastitis
2149 due to natural infection with *Staphylococcus aureus*. *BMC Genomics*, 15, 839.
2150 <https://doi.org/10.1186/1471-2164-15-839>
- 2151 Hussain, M., Becker, K., von Eiff, C., Schrenzel, J., Peters, G., & Herrmann, M. (2001).
2152 Identification and characterization of a novel 38.5-kilodalton cell surface protein of
2153 *Staphylococcus aureus* with extended-spectrum binding activity for extracellular
2154 matrix and plasma proteins. *Journal of Bacteriology*, 183(23), 6778-6786.
2155 <https://doi.org/10.1128/JB.183.23.6778-6786.2001>
- 2156 Johnson, M., Cockayne, A., & Morrissey, J. A. (2008). Iron-regulated biofilm formation in
2157 *Staphylococcus aureus* Newman requires ica and the secreted protein Emp.
2158 *Infection and Immunity*, 76(4), 1756-1765. <https://doi.org/10.1128/IAI.01635-07>
- 2159 Joost, I., Jacob, S., Utermöhlen, O., Schubert, U., Patti, J. M., Ong, M.-F., Gross, J.,
2160 Justinger, C., Renno, J. H., Preissner, K. T., Bischoff, M., & Herrmann, M. (2011).

- 2161 Antibody response to the extracellular adherence protein (Eap) of *Staphylococcus*
2162 *aureus* in healthy and infected individuals. *FEMS Immunology and Medical*
2163 *Microbiology*, 62(1), 23-31. <https://doi.org/10.1111/j.1574-695X.2011.00783.x>
- 2164 Josefsson, E., McCrea, K. W., Ní Eidhin, D., O'Connell, D., Cox, J., Höök, M., & Foster,
2165 T. J. (1998). Three new members of the serine-aspartate repeat protein multigene
2166 family of *Staphylococcus aureus*. *Microbiology (Reading, England)*, 144 (Pt 12),
2167 3387-3395. <https://doi.org/10.1099/00221287-144-12-3387>
- 2168 Keefe, G. (2012). Update on control of *Staphylococcus aureus* and *Streptococcus*
2169 *agalactiae* for management of mastitis. *The Veterinary Clinics of North America.*
2170 *Food Animal Practice*, 28(2), 203-216. <https://doi.org/10.1016/j.cvfa.2012.03.010>
- 2171 Kim, Y., Atalla, H., Mallard, B., Robert, C., & Karrow, N. (2011). Changes in Holstein
2172 cow milk and serum proteins during intramammary infection with three different
2173 strains of *Staphylococcus aureus*. *BMC Veterinary Research*, 7, 51.
2174 <https://doi.org/10.1186/1746-6148-7-51>
- 2175 Kot, B., Sytykiewicz, H., & Sprawka, I. (2018). Expression of the Biofilm-Associated
2176 Genes in Methicillin-Resistant *Staphylococcus aureus* in Biofilm and Planktonic
2177 Conditions. *International Journal of Molecular Sciences*, 19(11).
2178 <https://doi.org/10.3390/ijms19113487>
- 2179 Lacey, K. A., Leech, J. M., Lalor, S. J., McCormack, N., Geoghegan, J. A., &
2180 McLoughlin, R. M. (2017). The *Staphylococcus aureus* Cell Wall-Anchored Protein
2181 Clumping Factor A Is an Important T Cell Antigen. *Infection and Immunity*, 85(12).
2182 <https://doi.org/10.1128/IAI.00549-17>
- 2183 Lei, M. G., Gupta, R. K., & Lee, C. Y. (2017). Proteomics of *Staphylococcus aureus*
2184 biofilm matrix in a rat model of orthopedic implant-associated infection. *PloS One*,
2185 12(11), e0187981. <https://doi.org/10.1371/journal.pone.0187981>
- 2186 Lin, M.-H., Shu, J.-C., Huang, H.-Y., & Cheng, Y.-C. (2012). Involvement of iron in
2187 biofilm formation by *Staphylococcus aureus*. *PloS One*, 7(3), e34388.
2188 <https://doi.org/10.1371/journal.pone.0034388>
- 2189 Liu, H., Lv, J., Qi, X., Ding, Y., Li, D., Hu, L., Wang, L., & Yu, F. (2015). The carriage of
2190 the serine-aspartate repeat protein-encoding sdr genes among *Staphylococcus*
2191 *aureus* lineages. *The Brazilian Journal of Infectious Diseases: An Official*
2192 *Publication of the Brazilian Society of Infectious Diseases*, 19(5), 498-502.
2193 <https://doi.org/10.1016/j.bjid.2015.07.003>
- 2194 Ma, Y., Xu, Y., Yestrepky, B. D., Sorenson, R. J., Chen, M., Larsen, S. D., & Sun, H.
2195 (2012). Novel inhibitors of *Staphylococcus aureus* virulence gene expression and
2196 biofilm formation. *PloS One*, 7(10), e47255.
2197 <https://doi.org/10.1371/journal.pone.0047255>
- 2198 Maresso, A. W., & Schneewind, O. (2006). Iron acquisition and transport in
2199 *Staphylococcus aureus*. *Biometals: An International Journal on the Role of Metal*

- 2200 *lons in Biology, Biochemistry, and Medicine*, 19(2), 193-203.
2201 <https://doi.org/10.1007/s10534-005-4863-7>
- 2202 McCarthy, H., Rudkin, J. K., Black, N. S., Gallagher, L., O'Neill, E., & O'Gara, J. P.
2203 (2015). Methicillin resistance and the biofilm phenotype in *Staphylococcus aureus*.
2204 *Frontiers in Cellular and Infection Microbiology*, 5, 1.
2205 <https://doi.org/10.3389/fcimb.2015.00001>
- 2206 Moormeier, D. E., & Bayles, K. W. (2017). *Staphylococcus aureus* biofilm: A complex
2207 developmental organism. *Molecular Microbiology*, 104(3), 365-376.
2208 <https://doi.org/10.1111/mmi.13634>
- 2209 Nour El-Din, A. N. M., Shkreta, L., Talbot, B. G., Diarra, M. S., & Lacasse, P. (2006).
2210 DNA immunization of dairy cows with the clumping factor A of *Staphylococcus*
2211 *aureus*. *Vaccine*, 24(12), 1997-2006. <https://doi.org/10.1016/j.vaccine.2005.11.033>
- 2212 Smith, D. S., Siggins, M. K., Gierula, M., Pichon, B., Turner, C. E., Lynskey, N. N.,
2213 Mosavie, M., Kearns, A. M., Edwards, R. J., & Sriskandan, S. (2016). Identification
2214 of commonly expressed exoproteins and proteolytic cleavage events by proteomic
2215 mining of clinically relevant UK isolates of *Staphylococcus aureus*. *Microbial*
2216 *Genomics*, 2(2), e000049. <https://doi.org/10.1099/mgen.0.000049>
- 2217 Sohail, M., & Latif, Z. (2018). Molecular analysis, biofilm formation, and susceptibility of
2218 methicillin-resistant *Staphylococcus aureus* strains causing community- and health
2219 care-associated infections in central venous catheters. *Revista Da Sociedade*
2220 *Brasileira De Medicina Tropical*, 51(5), 603-609. [https://doi.org/10.1590/0037-](https://doi.org/10.1590/0037-8682-0373-2017)
2221 [8682-0373-2017](https://doi.org/10.1590/0037-8682-0373-2017)
- 2222 Stranger-Jones, Y. K., Bae, T., & Schneewind, O. (2006). Vaccine assembly from
2223 surface proteins of *Staphylococcus aureus*. *Proceedings of the National Academy*
2224 *of Sciences of the United States of America*, 103(45), 16942-16947.
2225 <https://doi.org/10.1073/pnas.0606863103>
- 2226 Thompson, K. M., Abraham, N., & Jefferson, K. K. (2010). *Staphylococcus aureus*
2227 extracellular adherence protein contributes to biofilm formation in the presence of
2228 serum. *FEMS Microbiology Letters*, 305(2), 143-147.
2229 <https://doi.org/10.1111/j.1574-6968.2010.01918.x>
- 2230 Torres, G., Vargas, K., Sánchez-Jiménez, M., Reyes-Velez, J., & Olivera-Angel, M.
2231 (2019). Genotypic and phenotypic characterization of biofilm production by
2232 *Staphylococcus aureus* strains isolated from bovine intramammary infections in
2233 Colombian dairy farms. *Heliyon*, 5(10), e02535.
2234 <https://doi.org/10.1016/j.heliyon.2019.e02535>
- 2235 Tsang, L. H., Daily, S. T., Weiss, E. C., & Smeltzer, M. S. (2007). Mutation of traP in
2236 *Staphylococcus aureus* has no impact on expression of agr or biofilm formation.
2237 *Infection and Immunity*, 75(9), 4528-4533. <https://doi.org/10.1128/IAI.00603-07>
- 2238 UniProt Consortium. (2019). UniProt: A worldwide hub of protein knowledge. *Nucleic*

- 2239 *Acids Research*, 47(D1), D506-D515. <https://doi.org/10.1093/nar/gky1049>
- 2240 Vaishampayan, A., de Jong, A., Wight, D. J., Kok, J., & Grohmann, E. (2018). A Novel
2241 Antimicrobial Coating Represses Biofilm and Virulence-Related Genes in
2242 Methicillin-Resistant *Staphylococcus aureus*. *Frontiers in Microbiology*, 9, 221.
2243 <https://doi.org/10.3389/fmicb.2018.00221>
- 2244 Valle, J., Latasa, C., Gil, C., Toledo-Arana, A., Solano, C., Penadés, J. R., & Lasa, I.
2245 (2012). Bap, a biofilm matrix protein of *Staphylococcus aureus* prevents cellular
2246 internalization through binding to GP96 host receptor. *PLoS Pathogens*, 8(8),
2247 e1002843. <https://doi.org/10.1371/journal.ppat.1002843>
- 2248 Veh, K. A., Klein, R. C., Ster, C., Keefe, G., Lacasse, P., Scholl, D., Roy, J.-P., Haine,
2249 D., Dufour, S., Talbot, B. G., Ribon, A. O. B., & Malouin, F. (2015). Genotypic and
2250 phenotypic characterization of *Staphylococcus aureus* causing persistent and
2251 nonpersistent subclinical bovine intramammary infections during lactation or the
2252 dry period. *Journal of Dairy Science*, 98(1), 155-168.
2253 <https://doi.org/10.3168/jds.2014-8044>
- 2254 Yoder, P. S., Ruiz-Cortes, T., Castro, J. J., & Hanigan, M. D. (2019). Effects of varying
2255 extracellular amino acid profile on intracellular free amino acid concentrations and
2256 cell signaling in primary mammary epithelial cells. *Journal of Dairy Science*,
2257 102(10), 8977-8985. <https://doi.org/10.3168/jds.2018-16122>
- 2258 Yonemoto, K., Chiba, A., Sugimoto, S., Sato, C., Saito, M., Kinjo, Y., Marumo, K., &
2259 Mizunoe, Y. (2019). Redundant and Distinct Roles of Secreted Protein Eap and
2260 Cell Wall-Anchored Protein SasG in Biofilm Formation and Pathogenicity of
2261 *Staphylococcus aureus*. *Infection and Immunity*, 87(4).
2262 <https://doi.org/10.1128/IAI.00894-18>
- 2263 Yoshii, Y., Okuda, K.-I., Yamada, S., Nagakura, M., Sugimoto, S., Nagano, T., Okabe,
2264 T., Kojima, H., Iwamoto, T., Kuwano, K., & Mizunoe, Y. (2017). Norgestimate
2265 inhibits staphylococcal biofilm formation and resensitizes methicillin-resistant
2266 *Staphylococcus aureus* to β -lactam antibiotics. *NPJ Biofilms and Microbiomes*, 3,
2267 18. <https://doi.org/10.1038/s41522-017-0026-1>
- 2268 Zapotoczna, M., McCarthy, H., Rudkin, J. K., O’Gara, J. P., & O’Neill, E. (2015). An
2269 Essential Role for Coagulase in *Staphylococcus aureus* Biofilm Development
2270 Reveals New Therapeutic Possibilities for Device-Related Infections. *The Journal*
2271 *of Infectious Diseases*, 212(12), 1883-1893. <https://doi.org/10.1093/infdis/jiv319>
- 2272 Zapotoczna, M., O’Neill, E., & O’Gara, J. P. (2016). Untangling the Diverse and
2273 Redundant Mechanisms of *Staphylococcus aureus* Biofilm Formation. *PLoS*
2274 *Pathogens*, 12(7), e1005671. <https://doi.org/10.1371/journal.ppat.1005671>
- 2275 Zecconi, A., & Scali, F. (2013). *Staphylococcus aureus* virulence factors in evasion from
2276 innate immune defenses in human and animal diseases. *Immunology Letters*,
2277 150(1-2), 12-22. <https://doi.org/10.1016/j.imlet.2013.01.004>

2278 Zhang, L., Boeren, S., van Hooijdonk, A. C. M., Vervoort, J. M., & Hettinga, K. A. (2015).
2279 A proteomic perspective on the changes in milk proteins due to high somatic cell
2280 count. *Journal of Dairy Science*, 98(8), 5339-5351.
2281 <https://doi.org/10.3168/jds.2014-9279>

2282

2283

2284

2285

2286

2287

2288

2289

2290

2291

2292

2293

2294

2295

2296

2297 **Resultados del objetivo 3**

2298 **Objetivo 3:** Determinar anticuerpos en muestras de leche y sangre frente a las
2299 proteínas recombinantes de interés.

2300 Para cumplir con este objetivo se ejecutaron las tres actividades que se describen a
2301 continuación:

2302 1. Se sintetizaron de forma recombinante las tres proteínas seleccionadas según los
2303 resultados del objetivo 2.

2304 2. Se tomaron muestras de leche y sangre de animales positivos y negativos a *S.*
2305 *aureus*.

2306 3. Se evaluaron todas las muestras frente a las proteínas recombinantes mediante una
2307 prueba de ELISA.

2308 Los resultados de todas las actividades relacionadas se encuentran en el artículo 5
2309 titulado “**Utility of an indirect ELISA test based in recombinants proteins lsdA, ClfA
2310 and SdrD of *Staphylococcus aureus* to detect bovine intramammary infections**”.

2311

2312

2313

2314

2315

2316

2317 **Artículo 5**

2318 **Utility of an indirect ELISA test based in recombinants proteins IsdA, ClfA and**
2319 **SdrD of *Staphylococcus aureus* to detect bovine intramammary infections**

2320

2321 G. Torres ^{a,b,*}, K. Vargas ^b, M. Sánchez ^a, J. Reyes-Vélez ^{a,b}, M. Olivera-Angel ^b

2322 ^a Colombian Institute of Tropical Medicine, CES University, Cra. 43A No. 52 sur-99
2323 Sabaneta, Antioquia, Colombia.

2324 ^b Biogenesis research group, Faculty of Agricultural sciences, University of Antioquia,
2325 Cra. 75 No. 65-87, Medellín, Antioquia, Colombia.

2326

2327

2328 *Corresponding author: giovanny.torresl@udea.edu.co

2329

2330 **Abstract**

2331 Fast and accurate diagnosis is one of the key strategies in the successful control of
2332 intramammary infections caused by *Staphylococcus aureus*. Among the diagnostic tools
2333 that have been proposed for the detection of *S. aureus* infection are the immunoassays,
2334 because these offer advantage in terms of costs, fast, and ease compared to other
2335 diagnostic tools. However, the main challenge of this type of test is to identify
2336 immunogens that allow to accurately discriminate between infected and uninfected cows
2337 with *S. aureus*, since this bacterium can colonize naturally different sites of animal body.
2338 Therefore, the aim was to detect antibodies in bovine samples against three *S. aureus*
2339 proteins (IsdA, ClfA, SdrD) involved in biofilm formation. Ninety-eight cows in lactation
2340 and not vaccinated were included. Forty-eight of these cows were infected with *S.*
2341 *aureus*, while the rest (48 cows) were uninfected. Blood and milk samples were taken
2342 from each animal to collect serum. IgG titers against the three proteins and a mixture of
2343 them were measured in each sample using an ELISA test. The result showed significant

2344 differences in the IgG response against proteins evaluated, highlighting the antigenic
2345 potential of IsdA and demonstrating that some antigens can be better indicators of
2346 infection than others. According to ROC curves analysis, the protein mixture was the
2347 one that showed the greatest capacity (sensitivity of 79% and specificity of 77%) to
2348 differentiate between infected and uninfected cows when the blood samples were used.
2349 In addition, this mixture also showed the highest specificity (94%) using milk samples,
2350 suggesting its possible use as a diagnostic complement to somatic cell counts. Our
2351 finding will contribute to the knowledge about the identification of potential antigens and
2352 their possible usefulness as indicator of infections in diagnostic test or as vaccine
2353 targets.

2354

2355 Keywords: Biofilm; ELISA; IgG; Immunoassays; Mastitis; Proteins; *Staphylococcus*
2356 *aureus*.

2357

2358 **Introduction**

2359 Bovine mastitis caused by *Staphylococcus aureus* is a common disease, and is
2360 characterized by the onset of chronic and subclinical intramammary infections (IMI)
2361 (Keefe, 2012). These infections can impact animal welfare and also lead to economic
2362 losses for farmers (Halasa et al., 2007; Hernández-Castellano et al., 2017).

2363 The ability of *S. aureus* to form biofilms is one of the key mechanisms of pathogenesis,
2364 conferring protection against antibiotics and the host's immune response (Gomes et al.,
2365 2016). Therefore, this structure will allow bacteria to persist in the mammary gland and a
2366 potential pathogen reservoir (Cucarella et al., 2004). Several studies have shown that
2367 the biofilm formation process is a diverse and complex process, which involves different
2368 proteins belonging to a group known as microbial surface components recognizing

2369 adhesive matrix molecules (MSCRAMM) (McCarthy et al., 2015; Zapotoczna et al.,
2370 2016). Some of the proteins in this group that have been involved in the initial
2371 adherence and the subsequent biofilm formation are Fibronectin-binding proteins
2372 (FnBPA and FnBPB), Clumping factors (ClfA and ClfB), Serine-aspartate repeat family
2373 proteins (SdrC, SdrD, and SdrE), Iron-regulated surface determinants (IsdA, IsdB, IsdC,
2374 and IsdH), and biofilm associated protein (Bap) (Moormeier & Bayles, 2017). In addition,
2375 several studies have also shown the immunogenic potential (vaccines) of different
2376 MSCRAMM and their usefulness as targets for screening tests (Bennett et al., 2019;
2377 Stranger-Jones et al., 2006).

2378 Early detection of *S. aureus* is crucial to optimize treatments, segregate infected
2379 animals, and therefore, interrupt the pathogen transmission's cycle (Hernández-
2380 Castellano et al., 2017). Mastitis diagnosis is regularly performed using somatic cell
2381 counts (SCC) and bacteriological culture (Rainard et al., 2018). However, a recent study
2382 showed that a number significative (30.8%) of cows could remain undetected due to the
2383 low SCC values that can have the infected animals with this pathogen (Petzer et al.,
2384 2017). On the other hand, culture methods could be complex, time consuming, and with
2385 variable sensitivity (Rainard et al., 2018). Hence, the interest in finding efficient
2386 diagnostic tools that allow to improve the pathogen detection process or even
2387 complement the conventional methods.

2388 The immunogenic potential of some of the proteins expressed during biofilm production
2389 could be used for diagnostic purposes, since evidence has shown that infected patients
2390 can generate higher antibody titers against these proteins than healthy individuals (den
2391 Reijer et al., 2017; Joost et al., 2011). Therefore, the objective of this study was to
2392 evaluate three *S. aureus* proteins (IsdA, ClfA, SdrD) involved in biofilm formation as
2393 indicators of intramammary infections.

2394 **Materials and methods**

2395 *Animals*

2396 Ninety-eight cows in lactation and not vaccinated against *S. aureus* from dairy herds
 2397 located in eight municipalities of the Department of Antioquia (Colombia) were included
 2398 in this study. Forty-eight of these cows were infected with *S. aureus*, while the rest (48
 2399 cows) were non-infected with this bacterium (non-*S. aureus* control). Regarding
 2400 uninfected, 16 were infected with other pathogens and 32 did not present IMI (Table 1).
 2401 A cow was considered infected if a sample had ≥ 10 CFU/10 μ l. On the other hand,
 2402 animals without IMI were those that had three negative results of bacteriological culture
 2403 from independent samples taken weekly. Bacteriological culture was performed based
 2404 on standard protocols recommended by National Mastitis Council (National Mastitis
 2405 Council, 2004).

2406 **Table 1.** Cows included in the study infected with a pathogen different to *S. aureus*.

No. of cows included infected with a pathogen different to <i>S. aureus</i>	Pathogen isolated
6	Non-aureus <i>Staphylococcus</i> spp.
3	<i>Streptococcus agalactiae</i>
4	<i>Streptococcus uberis</i>
3	<i>Escherichia coli</i>

2407 No: number

2408 *Sampling and serum collection*

2409 Blood (coccygeal vein) and milk samples (morning milking) were aseptically collected
 2410 from cows using standard procedures. Both blood and milk were centrifuged for 10 min
 2411 at 3,000 g to collect serum. All samples were stored at -20 until use.

2412 The procedures used in this study were approved by the Ethics Committee for Animal
 2413 Experimentation at the University of Antioquia (Medellín, Colombia).

2414 *Staphylococcus aureus* molecular typing

2415 The isolates recovered from sampled cows, which initially were identified as *S. aureus*
2416 through conventional bacteriological methods, were confirmed by amplification of *nuc*
2417 gene using the Polymerase chain reaction (PCR) protocol described by Fournier et al.
2418 (2008).

2419 Once confirmed the isolates as *S. aureus*, two different PCRs were carried out to detect
2420 the *ica* and *bap* genes, following the conditions published by Cucarella et al. (2004) and
2421 Torres et al. (2019). These genes have been described as being involved in the biofilm
2422 formation process (Cucarella et al., 2004). *S. aureus* strain V329 was used as positive
2423 control, since this strain harbors both markers.

2424 *Recombinant proteins of S. aureus*

2425 Proteins included were selected based on the results obtained in the objective number
2426 two from doctoral thesis. The criteria taken into account to select the proteins were:
2427 expression by *S. aureus* strains evaluated; involvement with biofilm formation process;
2428 display on the cell wall; and exhibit a predicted antigenicity higher than 90% calculated
2429 in the websites SCRATCH Protein Predictor (<http://scratch.proteomics.ics.uci.edu/>).
2430 Using these criteria, IsdA, ClfA, and SdrD proteins were chosen.

2431 The three recombinant proteins were generated by CUSABIO (www.cusabio.com) under
2432 the protocols of expression and purification established for them. The expression system
2433 used to IsdA and SdrD were *Escherichia coli*; whereas in ClfA was a yeast. Both ClfA
2434 (AA 229–559) and SdrD (AA 36–330) were generated partially in comparison with
2435 mature proteins. Instead, IsdA was produced complete (full length). Purity obtained for
2436 these proteins were greater than 85% and the predicted antigenicity were higher than
2437 89%.

2438 *Immunoassay*

2439 Bovine IgG levels against the three recombinant proteins (RP) were measured in the
2440 serum samples through the indirect Enzyme-linked immunoSorbent assay (ELISA).
2441 Initially, the ELISA was standardized using different concentrations of each RP and
2442 sample dilutions to determine the best assay conditions. The RP concentrations tested
2443 per well were 0.1 and 0.5 μg ; whereas serum dilutions were 1:100, 1:200, and 1:500.
2444 The RP concentrations and sample dilution that showed the best results were 0.1 μg for
2445 IldA and 0.5 μg for the other two proteins, ClfA and SdrD. Regarding sample dilutions,
2446 this was 1:100.

2447 Once the assay conditions were defined, each RP was diluted using coating buffer (4.42
2448 g of Na_2CO_3 and 5.04 g of NaHCO_3 in a liter of distilled water, pH 9.6) until to reach the
2449 concentration established. Then, 100 μl from each diluted protein was dispensed into
2450 96-well plates (Greiner Bio-One, USA) and incubated at 4 $^\circ\text{C}$ overnight. At the same
2451 time, a protein mixture was prepared based on the defined concentrations. We prepared
2452 two plate for each protein and mixture tested, one per each sample type (blood and milk
2453 serum). The next day, the wells were washed four times with Tris-buffered saline (50
2454 mM Tris-Cl, 150 mM NaCl in a liter of distilled water, pH 7.6) with Tween 20 at 0.05%
2455 (TBS-T). After washing, the plates were blocked using 200 μl of blocking buffer (TBS
2456 with 5% non-fat milk) and incubated at 37 $^\circ\text{C}$ for 1 h. Plates were washed again as
2457 mentioned previously. Next, 50 μl of each serum samples, diluted 1:100 in blocking
2458 buffer, were dispensed to each well and incubated at 37 $^\circ\text{C}$ for 1 h. Completion of
2459 incubation, plates were washed four times with TBS-T to remove of excess antibodies.
2460 After 50 μl the anti-bovine IgG (Sigma-Aldrich, USA) was added at wells, which was
2461 previously diluted 1:5000 in blocking buffer. Plates were incubated again at 37 $^\circ\text{C}$ for 1
2462 h. Finally, a fourth wash was performed and subsequently 100 μl from a substrate
2463 solution (1-StepTM Turbo TMB-ELISA; ThermoFisher Scientific, USA) was dispensed
2464 according to protocol suggested by manufacturer. The reaction was stopped by the
2465 addition of 100 μl of 1 M sulfuric acid, and absorbance was read at 450 nm in a plate

2466 reader for ELISA (Bio-Rad, USA). Antibody levels were expressed as optical density
2467 (OD). Experiments were performed in duplicate and repeated two times.

2468 *Statistical analysis*

2469 Descriptive analysis was performed for all the variables of interest. Normality
2470 assessment of the outcome variable was performed. Due to the lack of normality of the
2471 outcome variable (optical densities) obtained from infected and uninfected animals, a
2472 non-parametric analysis was performed using the Kruskal-Wallis test and non
2473 parametric multiple comparisons (Wilcoxon test). A statistical significance threshold of P
2474 < 0.05 was used to assess the overall differences between groups.

2475 The diagnostic accuracy (sensitivity and specificity) was evaluated using receiver
2476 operating characteristic (ROC) curves. These curves were plotted, and area under curve
2477 (AUC) was used to determine the capacity of test to discriminate between animals
2478 infected and uninfected with *S. aureus*. ROC curves were performed using R package
2479 “pROC” (version 1.15.3).

2480 **Results**

2481 *Genotypes of S. aureus strains isolated from infected cows*

2482 The strains evaluated were confirmed as *S. aureus*, since the *nuc* gene was amplified in
2483 all of these.

2484 The PCR analysis for the two markers associated with the biofilm formation evaluated,
2485 showed the *ica* locus amplification in 42 (87.5%) strains, and 10 (20.8%) of these also
2486 carried the *bap* gene. On the other hands, in six (12.5%) isolates none of the markers
2487 were amplified. According to these results, we classified the strains into three genotypes
2488 as follows: genotype 1 those strains that only harbored *ica* locus, genotype 2 harboring

2489 both loci, and genotype 0 for strains where the none of the markers were amplified
2490 (Table 2).

2491 **Table 2.** Genotypes identified in *S. aureus* isolates.

Genotype	Markers	No. Of strains (%)
1	<i>ica(+)-bap(-)</i>	32 (66.7)
2	<i>ica(+)-bap(+)</i>	10 (20.8)
0	<i>ica(-)-bap(-)</i>	6 (12.5)
Total		48 (100)

2492 (+) amplified marker; (-) marker not amplified

2493 *Characterization of protein-specific IgG levels in blood and milk serum samples*

2494 The IgG concentration showed a wide variation of values (OD) according to the protein
2495 evaluated (IsdA, ClfA, and SdrD), cows status (infected and uninfected), and sample
2496 type (blood and milk serum). The values of OD \leq 0.06 (Blank) were interpreted as the
2497 absence of specific antibodies. The levels of total IgG are summarized in Table 3.

2498 **Table 3.** IgG levels against the proteins evaluated by sample type and cows status.

Protein	Sample	Cows status	Min. OD value	Mean OD value	Median OD value	Max. OD value
IsdA	Blood	Infected	0.3110	0.5826	0.6125	0.7150
	serum	Uninfected	0.1690	0.4885	0.5170	0.7010
	Milk	Infected	0.0511	0.0887	0.0730	0.2370
	serum	Uninfected	0.0520	0.0633	0.0590	0.1000
ClfA	Blood	Infected	0.0155	0.2705	0.2445	0.6100

	serum	Uninfected	0.0019	0.1869	0.1310	0.6920
	Milk	Infected	0.0520	0.0678	0.0628	0.1575
	serum	Uninfected	0.0565	0.0716	0.0710	0.1240
	Blood	Infected	0.0570	0.2051	0.1760	0.4895
SdrD	serum	Uninfected	0.0035	0.1898	0.1625	0.4495
	Milk	Infected	0.0445	0.0557	0.0548	0.0780
	serum	Uninfected	0.0535	0.0677	0.0678	0.1025
	Blood	Infected	0.1270	0.4590	0.4855	0.6240
Mix	serum	Uninfected	0.0960	0.2745	0.2665	0.5390
	Milk	Infected	0.0510	0.0768	0.0665	0.2100
	serum	Uninfected	0.0510	0.0568	0.0560	0.0700

2499 Min: minimum; Max: maximum; Mix: assay performed with a mixture of the three
2500 proteins; OD: optical density. The bold number highlight the best results obtained.

2501 According to these results, the levels of IgG in blood serum against IsdA were higher
2502 compared to other proteins and mixture of them, especially those found in the infected
2503 animals. Whereas, the milk serum concentrations were similar among assays
2504 performed.


2505 *Differences in the IgG response according to protein evaluated, sample type and cows*
2506 *status*

2507 *IgG levels in blood serum samples*

2508 Among the infected animals a higher response against IsdA protein compared to the
2509 other proteins and mixture of them was observed. The Wilcoxon test analysis showed
2510 significant differences among the proteins tested, except between ClfA and SdrD
2511 proteins (Figure 1A). Amongst the uninfected animals, the results showed differences in
2512 the response for all proteins (Figure 1B).


2513 When were compared the results between infected and uninfected animals for each
2514 assay, these presented differences for IsdA, ClfA, and the mixture, but not for SdrD. The
2515 highest differences between the two groups of animals were observed in the mixture
2516 and IsdA ($P < 0.0001$) (Figure 2).

2517 **A**




2518

2519 **B**



2520

2521 **Figure 1. A.** Total IgG response against the proteins identified in blood serum samples
 2522 from infected animals (n = 48). **B.** Total IgG response against the proteins identified in
 2523 blood serum samples from uninfected animals (n = 48). The blue points represent the
 2524 optical densities (OD) obtained in each sample for ClfA protein, yellow points for IsdA,
 2525 grey points for SdrD, and red points for the mixture of proteins. Asterisks indicate
 2526 statistically significant differences among proteins (ns: $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; ***
 2527 $P < 0.001$; **** $P < 0.0001$). Horizontal red line corresponds to the blank measurement
 2528 (OD = 0.06).



2529

2530 **Figure 2.** Total IgG response against the proteins evaluated (n = 48 infected and 48
 2531 uninfected). Pos-B correspond to the optical densities (OD) obtained in the blood
 2532 samples collected from infected animals; Neg-B correspond to the OD obtained in the
 2533 blood samples collected from uninfected animals; Pos-M correspond to the OD obtained
 2534 in the milk samples collected from infected animals; Neg-M correspond to the OD
 2535 obtained in the milk samples collected from uninfected animals. Asterisks indicate
 2536 statistically significant differences among proteins (ns: $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; ***
 2537 $P < 0.001$; **** $P < 0.0001$). Horizontal red line corresponds to the blank measurement
 2538 (OD = 0.06).


2539 *IgG levels in milk serum samples*

2540 The concentrations of IgG in milk were lowest with respect to those found in blood, but
 2541 were significantly different among most of these in both infected and uninfected animals
 2542 (Figure 3). The Kruskal-Wallis analysis did not show differences between the IgG titers

2543 generated by infected cows for ClfA and the mixture of proteins (Figure 3A). Whereas in
 2544 the uninfected, no differences were observed between IsdA and SdrD (Figure 3B).


2545 The comparison of the response among infected and uninfected cows identified
 2546 differences between these groups for all proteins and the mixture evaluated. As was
 2547 observed in blood samples, the protein mixture was the one that showed the highest
 2548 differences between infected and uninfected animals ($P < 0.0001$). Although statistically
 2549 significant differences of $P < 0.0001$ also were observed in SdrD. The lowest IgG titers
 2550 against SdrD in milk were observed in the cows infected (Figure 2).

2551 **A**



2552

2553 **B**




2554

2555 **Figure 3. A.** Total IgG response against the proteins identified in milk serum samples
 2556 from infected animals (n = 48). **B.** Total IgG response against the proteins identified in
 2557 milk serum samples from uninfected animals (n = 48). The blue points represent the
 2558 optical densities (OD) obtained in each sample for ClfA protein, yellow points for IsdA,
 2559 grey points for SdrD, and red points for the mix of proteins. Asterisks indicate statistically
 2560 significant differences among proteins (ns: $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$;
 2561 **** $P < 0.0001$). Horizontal red line corresponds to the blank measurement (OD = 0.06).

2562 *Total IgG titers versus genotype*

2563 According to the analysis carried out to determine the association between the IgG
 2564 concentrations obtained and the identified genotypes, no statistically significant
 2565 differences were found among the comparison performed for both the blood and milk
 2566 serum samples (Figure 4).

2567 **A**




2568

2569

2570

B



2571

2572 **Figure 4. A.** Total IgG titers in blood serum versus genotype isolated. **B.** Total IgG titers
 2573 in milk serum versus genotype isolated. The data are presented as optical densities
 2574 (OD). The red box represents the genotype 1 (n = 32), green box to genotype 2 (n = 10),
 2575 and blue box to genotype 0 (n = 6). The statistical analysis is interpreted as follow (ns: P
 2576 >0.05 ; * $P <0.05$; ** $P <0.01$; *** $P <0.001$; **** $P <0.0001$).

2577 *Sensitivity and specificity analysis*

2578 The diagnostic use potential of each protein and their mixture were determined by
 2579 sensitivity and specificity analysis using ROC curves estimation. The calculated
 2580 thresholds, sensitivity and specificity for each protein are shown in the Table 4.


2581 **Table 4.** Results obtained in the sensitivity and specificity analysis for each protein and
 2582 sample type.

Protein	Sample	AUC	CI (95%)	Threshold	Sensitivity	Specificity
				(OD)		
IsdA	Blood serum	0.74	0.63 – 0.83	0.61	54%	90%
	Milk serum	0.75	0.65 – 0.85	0.061	83%	60%
CIfA	Blood serum	0.61	0.50 – 0.73	0.2	58%	71%
	Milk serum	0.67	0.55 – 0.77	0.068	71%	60%
SdrD	Blood serum	0.54	0.42 – 0.65	0.056	100%	17%
	Milk serum	0.79	0.72 – 0.86	0.063	92%	60%
Mix	Blood	0.82	0.72 – 0.88	0.385	79%	77%

serum					
Milk	0.84	0.76 – 0.91	0.065	60%	94%
serum					

2583 AUC; area under the curve; CI: confidence interval; Mix: assay performed with a mixture
 2584 of the three proteins; OD: optical densities. The bold number highlight the best results
 2585 obtained.

2586 Overall, the protein mixture evaluated with the blood samples presented the best results,
 2587 since the AUC calculated based on a threshold of 0.385 allowed to achieve a sensitivity
 2588 and specificity with which was possible to obtain the higher true positive rate with the
 2589 lower false positive rate (Figure 5).



2590

2591 **Figure 5.** ROC curve derived from analysis performed between the protein mixture and
2592 the blood serum samples. The AUC, as well as the best sensitivity and specificity
2593 calculated were 0.82, 79%, and 77%, respectively.

2594 **Discussion**

2595 Early detection of IMI caused by *S. aureus* is essential to interrupt the chain of
2596 transmission, to optimize antibiotic treatment and to adjust management measures
2597 within herds. On a regular basis, IMI diagnosis uses SCC detection in milk. However,
2598 according to a study performed in 95,228 quarters milk samples and 386,031 composite
2599 milk samples, 20.5% of quarters and 30.8% of cows infected with *S. aureus* could
2600 remain undetected when using the thresholds of 200.000 cell/ml in quarters samples
2601 and 150.000 cell/ml in composite samples, since these infections can occur with low
2602 SCC (Petzer et al., 2017). Regarding to bacteriological culture, other ways that can be
2603 used to detect *S. aureus* from cows with IMI, this has some limitations for its routine use,
2604 because it time consuming, has a highest cost than SCC, and the sensitivity can be
2605 variable due to an intermittent or low number of bacteria in the samples (Britten, 2012;
2606 Fabres-Klein et al., 2014; Rainard et al., 2018). Misdiagnosis of IMI caused by *S. aureus*
2607 will allowed its fast spreading and persistence in dairy herds (Costa et al., 2018;
2608 Cucarella et al., 2004). Hence, the importance and need to find alternative diagnostic
2609 tools to improve the diagnosis of this pathogen or complement those that exist.

2610 The detection of specific antibodies against antigens of several pathogens have also
2611 been implemented as effective diagnostic tools (Fabres-Klein et al., 2014). However, this
2612 type of diagnosis in *S. aureus* infections still represents a challenge to solve, especially
2613 those immunoassays that can be developed for identification of IMI caused by this
2614 pathogen (Rainard et al., 2018). Several proteins with immunogenic potential that are
2615 expressed during early stage of biofilm-forming process have been evaluated as vaccine
2616 targets and serological markers (Bennett et al., 2019; Stranger-Jones et al., 2006). In
2617 this study, we tested three proteins involved in the biofilm production by *S. aureus*. IsdA

2618 protein play an important role in the adhesion process and in the biofilm formation under
2619 iron limited conditions (Clarke et al., 2004; Moormeier & Bayles, 2017). Studies that
2620 blocked this protein or inactivate the gene achieved decreases the capacity of *S. aureus*
2621 to colonize the host tissue, and therefore, the ability to form biofilm (Bennett et al., 2019;
2622 Hammer & Skaar, 2011). ClfA has generally been associated to the binding of plasmatic
2623 fibrinogen; nevertheless, it was also reported that this protein can attach directly to MEC
2624 in the absence of fibrinogen (Ashraf et al., 2017). Zapotoczna et al. (2015) described a
2625 biofilm phenotype mediated by coagulase and ClfA, since that their interaction with
2626 formed fibrin or fibrinogen lead to a clumping of bacterial cells. As with IsdA and ClfA,
2627 some of the roles described of the SdrD protein are the adhesion to extracellular matrix
2628 of host cells and subsequent biofilm formation (Ma et al., 2012). Several authors
2629 observed that the down-regulation of *sdrD* gene caused a reduction in the biofilm
2630 formation (Ma et al., 2012; Vaishampayan et al., 2018).

2631 We observed that the specific IgG levels varied according to the protein tested, sample
2632 type and cows status (infected or uninfected). These results agree with Nishitani et al.
2633 (2015) study, who also found a response broad and variable between the patients
2634 groups (Infected and control) and antigens repertoire evaluated. Main IgG function is the
2635 opsonization of microorganisms and therefore promote their phagocytosis by
2636 macrophages and neutrophils (Schukken et al., 2011). Studies have reported the
2637 increase of the IgG₁ and IgG₂ subclass in the gland after challenging it with different
2638 immunogens (Schukken et al., 2011). However, the IgG₁ is the predominant subclass in
2639 milk of health bovines, whereas in animals with IMI is IgG₂, becoming it in the main
2640 opsonin for the phagocytosis process mediated by neutrophils in the infected mammary
2641 gland (Boerhout et al., 2016; Pastoret, 1998; Schukken et al., 2011). In this study, we
2642 did not discriminate by subclass, on the contrary, we measured the total IgG against
2643 each protein in the samples evaluated, since the objective was to obtain the highest
2644 antibodies concentration per antigen tested.

2645 Comparisons of IgG levels in blood from infected cows for each protein showed
2646 significant differences in the response among almost all, except between ClfA and SdrD.
2647 Highest IgG titers evidenced were against lsdA, even above of the protein mixture. This
2648 result is in accordance with what was found in a study conducted in patients with
2649 osteomyelitis. Authors reported that lsdA was one of the 14 proteins evaluated that
2650 presented the highest IgG levels, demonstrating its immunogenic potential (Nishitani
2651 et al., 2015). Other of the studies that highlighted the potential of this protein, was the
2652 performed by den Reijer et al. (2017), who also tested the IgG response against 50
2653 proteins in humans with osteomyelitis. They detected that lsdA was one of the 10
2654 antigens that had highest titers. On the other hand, Stranger-Jones et al. (2006)
2655 generated significant protective immunity in a murine model challenged with pathogens
2656 *S. aureus* strains and previously immunized with a vaccine composed of four antigens,
2657 among these lsdA, confirming also the antigenic capacity of this protein.

2658 Regarding to IgG detected in blood from uninfected animals, we observed the same
2659 differences among proteins. However, when we compared the results between the two
2660 groups of animals, differences were identified for lsdA, Mix and ClfA, but not for SdrD.
2661 Similar results were observed in some immunoassays performed with human samples,
2662 since these also showed differences in IgG levels against several antigens between
2663 patients and controls (den Reijer et al., 2017; Nishitani et al., 2015). Likewise, the result
2664 obtained with SdrD (no differences between groups) has also been reported, which
2665 suggest that there are better markers (immunodominant) than others (Nishitani et al.,
2666 2015). The IgG titers detection in uninfected animals could be explained by natural
2667 colonization with *S. aureus*. This pathogen could be naturally found in the teat skin and
2668 external orifices from healthy cows, where it triggers an immune response (Boerhout
2669 et al., 2016). Indeed, this has been one of the main limitations in the development of
2670 diagnostic techniques based on the detection of specific antibodies.

2671 IgG levels reported in milk samples were significantly lowest than in blood in both
2672 infected and uninfected, which are in accordance with what have been previously
2673 reported. Increased blood antibodies do not necessarily lead to an increase of these in
2674 milk (Boerhout et al., 2016). In addition, evidence has shown that the increase of IgG in
2675 milk is probably pathogen-dependent, since its transfer has been related to disrupt of the
2676 blood-mammary barrier caused by the inflammatory process. Because *S. aureus*
2677 commonly causes subclinical IMI, this barrier could be not affected, and therefore the
2678 exudation of IgG from plasma to milk would be limited (Hernández-Castellano et al.,
2679 2017; Rainard et al., 2018; Renna et al., 2019).

2680 Different IgG responses against *S. aureus* have been reported in milk. For example,
2681 Doymaz et al. (1988) did not find statistically significant differences in the IgG
2682 concentration in milk from infected and uninfected quarters. Instead, Renna et al. (2019)
2683 identified differences in milk obtained from cows during early involution of the mammary
2684 gland. Although, they observed IgG titers higher in uninfected than in infected cows.
2685 This data differs from most of our results, because we found that the highest mean IgG
2686 titers in infected animals in three (IsdA, Mix, ClfA) of the four assays performed. Some
2687 causes that could explain these discrepancies are the stage of lactation (dry period vs
2688 milking), the infection progress (acute or chronic; new or re-infection) or the specific IgG
2689 measured (Rainard et al., 2018; Renna et al., 2019). In this study, we did not take into
2690 account the stage of the infection of the animals, our inclusion criteria were cows
2691 infected with *S. aureus* and not vaccinated against this pathogen, since the objective
2692 was to determine if the immunoassay had the ability to discriminate between infected
2693 and uninfected animals independently of the infection stage. This could be other
2694 limitation in our work due to a study reported that the increasing of antibodies in milk
2695 could take two weeks (Fox & Adams, 2000). Therefore, the cows with early infections
2696 could not be detected.

2697 Regarding to the diagnostic usefulness of the immunoassay based on ROC curves
2698 analysis, the best AUC obtained was 0.82 corresponding to the evaluation performed
2699 between the protein mixture and the blood samples. The calculated sensitivity (79%)
2700 and specificity (77%) calculated allowed us to achieve the higher true positive rate with
2701 the lowest false positive rate. An immunoassay (Multiplex Luminex assay) carried out
2702 with 14 proteins *S. aureus*, which were tested with samples from human with
2703 osteomyelitis, achieved an AUC of almost 0.90, as well as a sensitivity and specificity of
2704 80% and 92.5%, respectively. Authors combined the IgG titers obtained with 14 proteins
2705 (Nishitani et al., 2015). The results obtained with blood samples are not totally
2706 comparable with those reported by Fabres-Klein et al. (2014) in their review on
2707 immunodiagnosis of staphylococcal IMI, because the data included by them correspond
2708 to milk evaluation. The sensitivity of the immunoassays tested was between 75% - 89%
2709 and the specificity between 70% - 90%. In our work, the sensitivity and specificity with
2710 an AUC above 0.80 obtained in milk were of 60% and 94% for Mix, respectively.

2711 Taking into account the *S. aureus* infections are difficult to treat and in most of cases
2712 animals are culled because of the lack of response to antibiotics, it is necessary to
2713 identify the highest number of positive animals within the herd in order to timely interrupt
2714 the transmission chain. In this case, it is recommended to use a highly sensitive
2715 screening test, such as is the SCC, because animals with the disease rarely are lost
2716 (Maxim et al., 2014). According to Petzer et al. (2017), the sensitivity and specificity of
2717 the SCC to detect this pathogen when a threshold of >150 000 cell/ml was used in
2718 composite milk was 84.2% and 52.8%, respectively. However, a highly sensitive test but
2719 not so specific can also include a high number of false positives, which should be
2720 discharged using a highly specific test such as bacteriological culture. Nevertheless, the
2721 use of bacteriological culture in the routine is limited due to the reasons mentioned
2722 above. Therefore, our highly specific test (94%) could be used in milk as a complement
2723 to SCC, since it would allow to confirm, quickly and inexpensively, the true negatives
2724 (uninfected) and those infections caused by other pathogens. A highly specific test

2725 would help optimize treatments (adequate use of antibiotics), since it is widely known
2726 that animals infected with *S. aureus* generally do not respond to antibiotic therapy.

2727 Recently a research reported that the host cell immune response varied according to *S.*
2728 *aureus* lineage. They found that strains belonging to clonal complex 97 (CC97), the
2729 major bovine *S. aureus* complex, were highly immunogenic compared to other lineages
2730 evaluated (Murphy et al., 2019; Spoor et al., 2013). In contrast to these results, we did
2731 not observe an influence of the identified genotypes on the IgG titers in both in blood
2732 and milk.

2733 **Conclusions**

2734 We found significant differences in the IgG response against proteins involved in the
2735 biofilm formation by *S. aureus*, highlighting the antigenic potential of IsdA compared to
2736 the other proteins and demonstrating that some antigens can be better indicators of
2737 infection than others.

2738 Although, the highest IgG titers in both blood and milk were obtained against IsdA, the
2739 protein mixture showed the greatest capacity to differentiate between infected and
2740 uninfected cows when blood samples were used. Furthermore, this mixture also showed
2741 the highest specificity using milk samples, suggesting its possible use as a diagnostic
2742 complement to SCC.

2743 These results will contribute to the knowledge about the identification of potential
2744 antigens, as well as their behavior *in vivo* and possible utilization as indicators of
2745 infection in diagnostic test or as vaccine targets, both essential tools for the successful
2746 control of any pathogen.

2747 **References**

2748 Ashraf, S., Cheng, J., & Zhao, X. (2017). Clumping factor A of *Staphylococcus aureus*

- 2749 interacts with AnnexinA2 on mammary epithelial cells. *Scientific Reports*, 7,
2750 40608. <https://doi.org/10.1038/srep40608>
- 2751 Bennett, M. R., Bombardi, R. G., Kose, N., Parrish, E. H., Nagel, M. B., Petit, R. A.,
2752 Read, T. D., Schey, K. L., Thomsen, I. P., Skaar, E. P., & Crowe, J. E. (2019).
2753 Human mAbs to *Staphylococcus aureus* IsdA Provide Protection Through Both
2754 Heme-Blocking and Fc-Mediated Mechanisms. *The Journal of Infectious*
2755 *Diseases*, 219(8), 1264-1273. <https://doi.org/10.1093/infdis/jiy635>
- 2756 Boerhout, E. M., Koets, A. P., Vernooij, J. C. M., Mols-Vorstermans, T. G. T., Nuijten, P.
2757 J. M., Rutten, V. P. M. G., Bijlsma, J. J. E., & Eisenberg, S. W. F. (2016).
2758 Reisolation of *Staphylococcus aureus* from bovine milk following experimental
2759 inoculation is influenced by fat percentage and specific immunoglobulin G1 titer in
2760 milk. *Journal of Dairy Science*, 99(6), 4259-4269.
2761 <https://doi.org/10.3168/jds.2015-10648>
- 2762 Britten, A. M. (2012). The role of diagnostic microbiology in mastitis control programs.
2763 *The Veterinary Clinics of North America. Food Animal Practice*, 28(2), 187-202.
2764 <https://doi.org/10.1016/j.cvfa.2012.03.006>
- 2765 Clarke, S. R., Wiltshire, M. D., & Foster, S. J. (2004). IsdA of *Staphylococcus aureus* is a
2766 broad spectrum, iron-regulated adhesin. *Molecular Microbiology*, 51(5), 1509-
2767 1519. <https://doi.org/10.1111/j.1365-2958.2003.03938.x>
- 2768 Costa, F. N., Belo, N. O., Costa, E. A., Andrade, G. I., Pereira, L. S., Carvalho, I. A., &
2769 Santos, R. L. (2018). Frequency of enterotoxins, toxic shock syndrome toxin-1,
2770 and biofilm formation genes in *Staphylococcus aureus* isolates from cows with
2771 mastitis in the Northeast of Brazil. *Tropical Animal Health and Production*, 50(5),
2772 1089-1097. <https://doi.org/10.1007/s11250-018-1534-6>
- 2773 Cucarella, C., Tormo, M. A., Ubeda, C., Trotonda, M. P., Monzón, M., Peris, C.,
2774 Amorena, B., Lasa, I., & Penadés, J. R. (2004). Role of biofilm-associated protein
2775 bap in the pathogenesis of bovine *Staphylococcus aureus*. *Infection and*
2776 *Immunity*, 72(4), 2177-2185.
- 2777 den Reijer, P. M., Sandker, M., Snijders, S. V., Tavakol, M., Hendrickx, A. P. A., & van
2778 Wamel, W. J. B. (2017). Combining in vitro protein detection and in vivo antibody
2779 detection identifies potential vaccine targets against *Staphylococcus aureus*
2780 during osteomyelitis. *Medical Microbiology and Immunology*, 206(1), 11-22.
2781 <https://doi.org/10.1007/s00430-016-0476-8>
- 2782 Doymaz, M. Z., Sordillo, L. M., Oliver, S. P., & Guidry, A. J. (1988). Effects of
2783 *Staphylococcus aureus* mastitis on bovine mammary gland plasma cell
2784 populations and immunoglobulin concentrations in milk. *Veterinary Immunology*
2785 *and Immunopathology*, 20(1), 87-93. [https://doi.org/10.1016/0165-2427\(88\)90028-1](https://doi.org/10.1016/0165-2427(88)90028-1)
- 2787 Fabres-Klein, M. H., Aguilar, A. P., Silva, M. P., Silva, D. M., & Ribon, A. O. B. (2014).

- 2788 Moving towards the immunodiagnosis of staphylococcal intramammary infections.
2789 *European Journal of Clinical Microbiology & Infectious Diseases: Official*
2790 *Publication of the European Society of Clinical Microbiology*, 33(12), 2095-2104.
2791 <https://doi.org/10.1007/s10096-014-2181-0>
- 2792 Fournier, C., Kuhnert, P., Frey, J., Miserez, R., Kirchhofer, M., Kaufmann, T., Steiner, A.,
2793 & Graber, H. U. (2008). Bovine *Staphylococcus aureus*: Association of virulence
2794 genes, genotypes and clinical outcome. *Research in Veterinary Science*, 85(3),
2795 439-448. <https://doi.org/10.1016/j.rvsc.2008.01.010>
- 2796 Fox, L. K., & Adams, D. S. (2000). The ability of the enzyme-linked immunosorbent
2797 assay to detect antibody against *Staphylococcus aureus* in milk following
2798 experimental intramammary infection. *Journal of Veterinary Medicine. B,*
2799 *Infectious Diseases and Veterinary Public Health*, 47(7), 517-526.
2800 <https://doi.org/10.1046/j.1439-0450.2000.00379.x>
- 2801 Gomes, F., Saavedra, M. J., & Henriques, M. (2016). Bovine mastitis
2802 disease/pathogenicity: Evidence of the potential role of microbial biofilms.
2803 *Pathogens and Disease*, 74(3). <https://doi.org/10.1093/femspd/ftw006>
- 2804 Halasa, T., Huijps, K., Østerås, O., & Hogeveen, H. (2007). Economic effects of bovine
2805 mastitis and mastitis management: A review. *The Veterinary Quarterly*, 29(1), 18-
2806 31. <https://doi.org/10.1080/01652176.2007.9695224>
- 2807 Hammer, N., & Skaar, E. (2011). Molecular mechanisms of *Staphylococcus aureus* iron
2808 acquisition. *Annu Rev Microbiol.*, 65, 1-19. [https://doi.org/doi:10.1146/annurev-](https://doi.org/doi:10.1146/annurev-micro-090110-102851)
2809 [micro-090110-102851](https://doi.org/doi:10.1146/annurev-micro-090110-102851)
- 2810 Hernández-Castellano, L., Wall, S. K., Stephan, R., Corti, S., & Bruckmaier, R. (2017).
2811 Milk somatic cell count, lactate dehydrogenase activity, and immunoglobulin G
2812 concentration associated with mastitis caused by different pathogens: A field
2813 study. *Schweizer Archiv Fur Tierheilkunde*, 159(5), 283-290.
2814 <https://doi.org/10.17236/sat00115>
- 2815 Joost, I., Jacob, S., Utermöhlen, O., Schubert, U., Patti, J. M., Ong, M.-F., Gross, J.,
2816 Justinger, C., Renno, J. H., Preissner, K. T., Bischoff, M., & Herrmann, M. (2011).
2817 Antibody response to the extracellular adherence protein (Eap) of *Staphylococcus*
2818 *aureus* in healthy and infected individuals. *FEMS Immunology and Medical*
2819 *Microbiology*, 62(1), 23-31. <https://doi.org/10.1111/j.1574-695X.2011.00783.x>
- 2820 Keefe, G. (2012). Update on control of *Staphylococcus aureus* and *Streptococcus*
2821 *agalactiae* for management of mastitis. *The Veterinary Clinics of North America.*
2822 *Food Animal Practice*, 28(2), 203-216. <https://doi.org/10.1016/j.cvfa.2012.03.010>
- 2823 Ma, Y., Xu, Y., Yestrepky, B. D., Sorenson, R. J., Chen, M., Larsen, S. D., & Sun, H.
2824 (2012). Novel inhibitors of *Staphylococcus aureus* virulence gene expression and
2825 biofilm formation. *PloS One*, 7(10), e47255.
2826 <https://doi.org/10.1371/journal.pone.0047255>

- 2827 Maxim, L., Niebo, R., & Utell, M. (2014). Screening tests: A review with examples.
2828 *Inhalation Toxicology*, 26(13), 811-828.
2829 <https://doi.org/10.3109/08958378.2014.955932>
- 2830 McCarthy, H., Rudkin, J. K., Black, N. S., Gallagher, L., O'Neill, E., & O'Gara, J. P.
2831 (2015). Methicillin resistance and the biofilm phenotype in *Staphylococcus*
2832 *aureus*. *Frontiers in Cellular and Infection Microbiology*, 5, 1.
2833 <https://doi.org/10.3389/fcimb.2015.00001>
- 2834 Moormeier, D. E., & Bayles, K. W. (2017). *Staphylococcus aureus* biofilm: A complex
2835 developmental organism. *Molecular Microbiology*, 104(3), 365-376.
2836 <https://doi.org/10.1111/mmi.13634>
- 2837 Murphy, M. P., Niedziela, D. A., Leonard, F. C., & Keane, O. M. (2019). The in vitro host
2838 cell immune response to bovine-adapted *Staphylococcus aureus* varies according
2839 to bacterial lineage. *Scientific Reports*, 9(1), 6134.
2840 <https://doi.org/10.1038/s41598-019-42424-2>
- 2841 National Mastitis Council. (2004). *Microbiological procedures for the diagnosis of bovine*
2842 *udder infection and determination of milk quality* (Fourth edition).
- 2843 Nishitani, K., Beck, C. A., Rosenberg, A. F., Kates, S. L., Schwarz, E. M., & Daiss, J. L.
2844 (2015). A Diagnostic Serum Antibody Test for Patients With *Staphylococcus*
2845 *aureus* Osteomyelitis. *Clinical Orthopaedics and Related Research*, 473(9), 2735-
2846 2749. <https://doi.org/10.1007/s11999-015-4354-2>
- 2847 Pastoret, P. (1998). *Handbook invertebrate immunology*. Academic Press.
- 2848 Petzer, I.-M., Karzis, J., Donkin, E. F., Webb, E. C., & Etter, E. M. C. (2017). Validity of
2849 somatic cell count as indicator of pathogen-specific intramammary infections.
2850 *Journal of the South African Veterinary Association*, 88(0), e1-e10.
2851 <https://doi.org/10.4102/jsava.v88i0.1465>
- 2852 Rainard, P., Foucras, G., Fitzgerald, J. R., Watts, J. L., Koop, G., & Middleton, J. R.
2853 (2018). Knowledge gaps and research priorities in *Staphylococcus aureus*
2854 mastitis control. *Transboundary and Emerging Diseases*, 65 Suppl 1, 149-165.
2855 <https://doi.org/10.1111/tbed.12698>
- 2856 Renna, M. S., Silvestrini, P., Beccaria, C., Velázquez, N. S., Baravalle, C., Engler, C.,
2857 Pereyra, E. A. L., Calvinho, L. F., & Dallard, B. E. (2019). Effects of chronic
2858 *Staphylococcus aureus* infection on immunological parameters and functionality
2859 of macrophages isolated from bovine mammary secretions. *Microbial*
2860 *Pathogenesis*, 137, 103743. <https://doi.org/10.1016/j.micpath.2019.103743>
- 2861 Schukken, Y., Günther, J., Fitzpatrick, J., Fontaine, M. C., Goetze, L., Holst, O., Leigh,
2862 J., Petzl, W., Schuberth, H.-J., Sipka, A., Smith, D. G. E., Quesnell, R., Watts, J.,
2863 Yancey, R., Zerbe, H., Gurjar, A., Zadoks, R. N., & Seyfert, H.-M. (2011). Host-
2864 response patterns of intramammary infections in dairy cows. *Veterinary*
2865 *Immunology and Immunopathology*, 144(3-4), 270-289.

- 2866 <https://doi.org/10.1016/j.vetimm.2011.08.022>
- 2867 Spoor, L. E., McAdam, P. R., Weinert, L. A., Rambaut, A., Hasman, H., Aarestrup, F. M.,
2868 Kearns, A. M., Larsen, A. R., Skov, R. L., & Fitzgerald, J. R. (2013). Livestock
2869 origin for a human pandemic clone of community-associated methicillin-resistant
2870 *Staphylococcus aureus*. *MBio*, 4(4). <https://doi.org/10.1128/mBio.00356-13>
- 2871 Stranger-Jones, Y. K., Bae, T., & Schneewind, O. (2006). Vaccine assembly from
2872 surface proteins of *Staphylococcus aureus*. *Proceedings of the National Academy*
2873 *of Sciences of the United States of America*, 103(45), 16942-16947.
2874 <https://doi.org/10.1073/pnas.0606863103>
- 2875 Torres, G., Vargas, K., Sánchez-Jiménez, M., Reyes-Velez, J., & Olivera-Angel, M.
2876 (2019). Genotypic and phenotypic characterization of biofilm production by
2877 *Staphylococcus aureus* strains isolated from bovine intramammary infections in
2878 Colombian dairy farms. *Heliyon*, 5(10), e02535.
2879 <https://doi.org/10.1016/j.heliyon.2019.e02535>
- 2880 Vaishampayan, A., de Jong, A., Wight, D. J., Kok, J., & Grohmann, E. (2018). A Novel
2881 Antimicrobial Coating Represses Biofilm and Virulence-Related Genes in
2882 Methicillin-Resistant *Staphylococcus aureus*. *Frontiers in Microbiology*, 9, 221.
2883 <https://doi.org/10.3389/fmicb.2018.00221>
- 2884 Zapotoczna, M., McCarthy, H., Rudkin, J. K., O’Gara, J. P., & O’Neill, E. (2015). An
2885 Essential Role for Coagulase in *Staphylococcus aureus* Biofilm Development
2886 Reveals New Therapeutic Possibilities for Device-Related Infections. *The Journal*
2887 *of Infectious Diseases*, 212(12), 1883-1893. <https://doi.org/10.1093/infdis/jiv319>
- 2888 Zapotoczna, M., O’Neill, E., & O’Gara, J. P. (2016). Untangling the Diverse and
2889 Redundant Mechanisms of *Staphylococcus aureus* Biofilm Formation. *PLoS*
2890 *Pathogens*, 12(7), e1005671. <https://doi.org/10.1371/journal.ppat.1005671>
- 2891
- 2892
- 2893
- 2894
- 2895
- 2896

2897

Conclusiones generales

- 2898 • La mayoría (81,3%) de las cepas de *S. aureus* aisladas de bovinos con infecciones
2899 intramamarias en la región presentaron capacidad para formar biopelículas.
- 2900 • Las cepas de *S. aureus* portadoras el gen *bap* (genotipo 2) fueron las que
2901 presentaron mayor capacidad para formar biopelículas comparadas con los
2902 genotipos 0 y 1, sugiriendo su virulencia y potencial para generar infecciones
2903 persistentes difíciles de eliminar.
- 2904 • La tipificación de las cepas de *S. aureus* mediante la técnica “*spa typing*” mostró
2905 una amplia diversidad (38 *spa* tipos) de genotipos circulantes en la región.
- 2906 • El 68% de los genotipos identificados también han sido previamente reportados
2907 como causantes de infecciones en humanos, demostrando la influencia de los
2908 ordeñadores en la transmisión y convirtiendo a los bovinos en reservorios
2909 importantes del patógeno. Además, la cercanía de estos genotipos con cepas
2910 propias de los bovinos incrementa el riesgo de recombinación genética entre estas,
2911 por consiguiente, la posible aparición de clones con potencial zoonótico.
- 2912 • El 18,4% de los aislados de *S. aureus* presentaron genotipos nuevos, previamente
2913 no reportados, sugiriendo la posibilidad de que sean cepas propias de la región y
2914 mostrando el potencial de variación de este patógeno.
- 2915 • El 37% de las cepas de *S. aureus* fueron resistentes a los antibióticos Penicilina y
2916 Lincomicina, tal como había sido reportado en trabajos previos, en los cuales se
2917 demostró que estos son los antibióticos a los que la mayoría de cepas presentan
2918 resistencia en la región.
- 2919 • No se encontró asociación entre los genotipos de *S. aureus* identificados y la
2920 resistencia a los antibióticos.
- 2921 • El genoma de la cepa de *S. aureus* Sa1FB, la cual fue reconocida como fuerte
2922 formadora de biopelícula y causante de mastitis subclínica, mostró alta identidad
2923 con los genomas de las cepas de referencia RF122 y Newbould 305, ambas cepas
2924 causantes de mastitis clínicas en bovinos.

- 2925 • La presencia de material genético móvil (profagos, transposasas, isla de
2926 patogenicidad) en el genoma de la cepa Sa1FB secuenciada, resalta su capacidad
2927 para aceptar material genético externo, el cual podría modificar su genoma, por lo
2928 tanto, incrementar su patogenicidad y capacidad de adaptación a nuevos
2929 huéspedes.
- 2930 • En este estudio, a medida que incrementó la capacidad de formación de biopelícula
2931 disminuyó la capacidad de invasión celular.
- 2932 • Se comprobó mediante microscopía electrónica que las cepas portadoras del gen
2933 *bap* muestran un fenotipo de biopelícula independiente de PIA (a base de
2934 proteínas), a pesar de la presencia del locus *ica*, sugiriendo que en presencia de
2935 *bap* este es el que conduce la formación de biopelícula. Mientras que, las cepas
2936 portadoras solo del operón *ica*, generaron una biopelícula donde, probablemente,
2937 predominó PIA, debido a que se observó una matriz en la cual estaban embebidas
2938 las células bacterianas.
- 2939 • La identificación de proteínas implicadas en el proceso de formación de biopelícula
2940 que solo fueron expresadas por las cepas formadoras durante la interacción con las
2941 CEM, pero ausentes en los controles, demuestran su importancia en las primeras
2942 horas del proceso infeccioso y, probablemente, en la posterior formación de
2943 biopelícula *in vivo*.
- 2944 • Los resultados confirmaron que las proteínas IsdA, ClfA y SdrD de *S. aureus* son
2945 potenciales candidatos para vacunas contra infecciones intramamarias y podrían
2946 ser usadas en inmunoensayos como marcadores de infección, debido a que están
2947 implicadas en la fase temprana de la infección, en la formación de biopelículas y
2948 tienen la capacidad (antigenicidad) de desencadenar la respuesta inmune.
- 2949 • Los títulos de IgG encontrados contra las proteínas evaluadas en el inmunoensayo
2950 demostraron que algunos antígenos son mejores marcadores de infección que
2951 otros, resaltando el potencial antigénico de IsdA, dado que fue la proteína que
2952 presentó los mayores títulos de anticuerpos con respecto a las otras.

- 2953 • A pesar de que fue IsdA la proteína que tuvo los títulos más altos de IgG específica,
2954 fue la mezcla de las tres proteínas la que exhibió, según el análisis de curvas ROC,
2955 la más alta sensibilidad (79%) y especificidad (77%) en conjunto cuando se
2956 emplean muestras de sangre, o la mayor especificidad (94%) al usar muestras de
2957 leche.
- 2958 • Los resultados obtenidos en el inmunoensayo ampliará el conocimiento sobre
2959 potenciales antígenos, su comportamiento *in vivo* y posible utilidad como
2960 marcadores de infección en pruebas diagnósticas.

2961

2962

2963

2964

2965

2966

2967

2968

2969

2970

2971

2972

Anexos

2973

1. Artículo 1

2974

Se anexa el artículo publicado en la revista Heliyon (Q1)

2975

<https://doi.org/10.1016/j.heliyon.2019.e02535>)

2976

2. Artículo 3

2977

Se anexa el artículo publicado en la revista Frontiers in Veterinary Science (Q1)

2978

<https://doi:10.3389/fvets.2020.00530>)

2979

3. Archivo con material suplementario de los artículos

2980

2981

2982

2983

2984

2985

2986

2987

2988

2989

Referencias

- 2990 Abbas, A., Lichtman, A., & Pillai, S. (2014). *Cellular and Molecular Immunology* (Eighth).
2991 Elsevier.
- 2992 AMR_ES: OIE - World Organisation for Animal Health. (2016). OIE.
2993 <http://www.oie.int/es/para-los-periodistas/amr-es/>
- 2994 Ashraf, S., Cheng, J., & Zhao, X. (2017). Clumping factor A of *Staphylococcus aureus*
2995 interacts with AnnexinA2 on mammary epithelial cells. *Scientific Reports*, 7,
2996 40608. <https://doi.org/10.1038/srep40608>
- 2997 Askarian, F., Uchiyama, S., Valderrama, J. A., Ajayi, C., Sollid, J. U. E., van Sorge, N.
2998 M., Nizet, V., van Strijp, J. A. G., & Johannessen, M. (2017). Serine-Aspartate
2999 Repeat Protein D Increases *Staphylococcus aureus* Virulence and Survival in
3000 Blood. *Infection and Immunity*, 85(1). <https://doi.org/10.1128/IAI.00559-16>
- 3001 Atalla, H., Gyles, C., Jacob, C. L., Moisan, H., Malouin, F., & Mallard, B. (2008).
3002 Characterization of a *Staphylococcus aureus* small colony variant (SCV)
3003 associated with persistent bovine mastitis. *Foodborne Pathogens and Disease*,
3004 5(6), 785-799. <https://doi.org/10.1089/fpd.2008.0110>
- 3005 Atalla, H., Wilkie, B., Gyles, C., Leslie, K., Mutharia, L., & Mallard, B. (2010). Antibody
3006 and cell-mediated immune responses to *Staphylococcus aureus* small colony
3007 variants and their parental strains associated with bovine mastitis. *Developmental*
3008 *and Comparative Immunology*, 34(12), 1283-1290.
3009 <https://doi.org/10.1016/j.dci.2010.07.005>
- 3010 Bardiau, M., Detilleux, J., Farnir, F., Mainil, J. G., & Ote, I. (2014). Associations between
3011 properties linked with persistence in a collection of *Staphylococcus aureus*
3012 isolates from bovine mastitis. *Veterinary Microbiology*, 169(1-2), 74-79.
3013 <https://doi.org/10.1016/j.vetmic.2013.12.010>
- 3014 Barkema, H. W., Schukken, Y. H., & Zadoks, R. N. (2006). Invited Review: The role of
3015 cow, pathogen, and treatment regimen in the therapeutic success of bovine
3016 *Staphylococcus aureus* mastitis. *Journal of Dairy Science*, 89(6), 1877-1895.
3017 [https://doi.org/10.3168/jds.S0022-0302\(06\)72256-1](https://doi.org/10.3168/jds.S0022-0302(06)72256-1)
- 3018 Barrio, M. B., Rainard, P., & Poutrel, B. (2003). Milk complement and the
3019 opsonophagocytosis and killing of *Staphylococcus aureus* mastitis isolates by
3020 bovine neutrophils. *Microbial Pathogenesis*, 34(1), 1-9.
3021 [https://doi.org/10.1016/S0882-4010\(02\)00186-9](https://doi.org/10.1016/S0882-4010(02)00186-9)
- 3022 Baselga, R., Albizu, I., De La Cruz, M., Del Cacho, E., Barberan, M., & Amorena, B.
3023 (1993). Phase variation of slime production in *Staphylococcus aureus*:
3024 Implications in colonization and virulence. *Infection and Immunity*, 61(11), 4857-
3025 4862.

- 3026 Bedoya, C., & Ponce de León, M. (2008). Pérdidas económicas ocasionadas por las
3027 mastitis bovina en la industria lechera. *Revista electrónica de Veterinaria*, IX.
3028 www.veterinaria.org/revistas/redvet
- 3029 Bennett, M. R., Bombardi, R. G., Kose, N., Parrish, E. H., Nagel, M. B., Petit, R. A.,
3030 Read, T. D., Schey, K. L., Thomsen, I. P., Skaar, E. P., & Crowe, J. E. (2019).
3031 Human mAbs to *Staphylococcus aureus* IsdA Provide Protection Through Both
3032 Heme-Blocking and Fc-Mediated Mechanisms. *The Journal of Infectious*
3033 *Diseases*, 219(8), 1264-1273. <https://doi.org/10.1093/infdis/jiy635>
- 3034 Bera, A., Herbert, S., Jakob, A., Vollmer, W., & Götz, F. (2005). Why are pathogenic
3035 staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase
3036 OatA is the major determinant for lysozyme resistance of *Staphylococcus aureus*.
3037 *Molecular Microbiology*, 55(3), 778-787. <https://doi.org/10.1111/j.1365-2958.2004.04446.x>
- 3039 Bestebroer, J., Poppelier, M. J. J. G., Ulfman, L. H., Lenting, P. J., Denis, C. V., van
3040 Kessel, K. P. M., van Strijp, J. A. G., & de Haas, C. J. C. (2007). Staphylococcal
3041 superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil
3042 rolling. *Blood*, 109(7), 2936-2943. <https://doi.org/10.1182/blood-2006-06-015461>
- 3043 Boerhout, E. M., Koets, A. P., Vernooij, J. C. M., Mols-Vorstermans, T. G. T., Nuijten, P.
3044 J. M., Rutten, V. P. M. G., Bijlsma, J. J. E., & Eisenberg, S. W. F. (2016).
3045 Reisolation of *Staphylococcus aureus* from bovine milk following experimental
3046 inoculation is influenced by fat percentage and specific immunoglobulin G1 titer in
3047 milk. *Journal of Dairy Science*, 99(6), 4259-4269.
3048 <https://doi.org/10.3168/jds.2015-10648>
- 3049 Bougarn, S., Cunha, P., Harmache, A., Fromageau, A., Gilbert, F. B., & Rainard, P.
3050 (2010). Muramyl dipeptide synergizes with *Staphylococcus aureus* lipoteichoic
3051 acid to recruit neutrophils in the mammary gland and to stimulate mammary
3052 epithelial cells. *Clinical and Vaccine Immunology: CVI*, 17(11), 1797-1809.
3053 <https://doi.org/10.1128/CVI.00268-10>
- 3054 Brady, R. A., Leid, J. G., Camper, A. K., Costerton, J. W., & Shirtliff, M. E. (2006).
3055 Identification of *Staphylococcus aureus* proteins recognized by the antibody-
3056 mediated immune response to a biofilm infection. *Infection and Immunity*, 74(6),
3057 3415-3426. <https://doi.org/10.1128/IAI.00392-06>
- 3058 Brouillette, E., Grondin, G., Shkreta, L., Lacasse, P., & Talbot, B. G. (2003). In vivo and
3059 in vitro demonstration that *Staphylococcus aureus* is an intracellular pathogen in
3060 the presence or absence of fibronectin-binding proteins. *Microbial Pathogenesis*,
3061 35(4), 159-168.
- 3062 Budd, K. E., Mitchell, J., & Keane, O. M. (2016). Lineage associated expression of
3063 virulence traits in bovine-adapted *Staphylococcus aureus*. *Veterinary*
3064 *Microbiology*, 189, 24-31. <https://doi.org/10.1016/j.vetmic.2016.04.013>

- 3065 Camussone, C. M., Veaute, C. M., Pujato, N., Morein, B., Marcipar, I. S., & Calvino, L.
3066 F. (2014). Immune response of heifers against a *Staphylococcus aureus* CP5
3067 whole cell and lysate vaccine formulated with ISCOM Matrix adjuvant. *Research*
3068 *in Veterinary Science*, 96(1), 86-94. <https://doi.org/10.1016/j.rvsc.2013.10.004>
- 3069 Chang, Q., Wang, W., Regev-Yochay, G., Lipsitch, M., & Hanage, W. P. (2015).
3070 Antibiotics in agriculture and the risk to human health: How worried should we
3071 be? *Evolutionary Applications*, 8(3), 240-247. <https://doi.org/10.1111/eva.12185>
- 3072 Cheung, J., Beasley, F. C., Liu, S., Lajoie, G. A., & Heinrichs, D. E. (2009). Molecular
3073 characterization of staphyloferrin B biosynthesis in *Staphylococcus aureus*.
3074 *Molecular Microbiology*, 74(3), 594-608. [https://doi.org/10.1111/j.1365-](https://doi.org/10.1111/j.1365-2958.2009.06880.x)
3075 [2958.2009.06880.x](https://doi.org/10.1111/j.1365-2958.2009.06880.x)
- 3076 Clarke, S. R., Wiltshire, M. D., & Foster, S. J. (2004). IsdA of *Staphylococcus aureus* is a
3077 broad spectrum, iron-regulated adhesin. *Molecular Microbiology*, 51(5), 1509-
3078 1519. <https://doi.org/10.1111/j.1365-2958.2003.03938.x>
- 3079 Cosgrove, K., Coutts, G., Jonsson, I.-M., Tarkowski, A., Kokai-Kun, J. F., Mond, J. J., &
3080 Foster, S. J. (2007). Catalase (KatA) and alkyl hydroperoxide reductase (AhpC)
3081 have compensatory roles in peroxide stress resistance and are required for
3082 survival, persistence, and nasal colonization in *Staphylococcus aureus*. *Journal of*
3083 *Bacteriology*, 189(3), 1025-1035. <https://doi.org/10.1128/JB.01524-06>
- 3084 Cucarella, C., Solano, C., Valle, J., Amorena, B., Lasa, I., & Penadés, J. R. (2001). Bap,
3085 a *Staphylococcus aureus* surface protein involved in biofilm formation. *Journal of*
3086 *Bacteriology*, 183(9), 2888-2896. [https://doi.org/10.1128/JB.183.9.2888-](https://doi.org/10.1128/JB.183.9.2888-2896.2001)
3087 [2896.2001](https://doi.org/10.1128/JB.183.9.2888-2896.2001)
- 3088 Cucarella, Carme, Tormo, M. A., Knecht, E., Amorena, B., Lasa, I., Foster, T. J., &
3089 Penadés, J. R. (2002). Expression of the biofilm-associated protein interferes with
3090 host protein receptors of *Staphylococcus aureus* and alters the infective process.
3091 *Infection and Immunity*, 70(6), 3180-3186.
- 3092 Cucarella, Carme, Tormo, M. A., Ubeda, C., Trotonda, M. P., Monzón, M., Peris, C.,
3093 Amorena, B., Lasa, I., & Penadés, J. R. (2004). Role of biofilm-associated protein
3094 bap in the pathogenesis of bovine *Staphylococcus aureus*. *Infection and*
3095 *Immunity*, 72(4), 2177-2185.
- 3096 den Reijer, P. M., Haisma, E. M., Lemmens-den Toom, N. A., Willemsse, J., Koning, R. I.,
3097 Koning, R. A., Demmers, J. a. A., Dekkers, D. H. W., Rijkers, E., El Ghalbzouri,
3098 A., Nibbering, P. H., & van Wamel, W. (2016). Detection of Alpha-Toxin and
3099 Other Virulence Factors in Biofilms of *Staphylococcus aureus* on Polystyrene and
3100 a Human Epidermal Model. *PloS One*, 11(1), e0145722.
3101 <https://doi.org/10.1371/journal.pone.0145722>
- 3102 den Reijer, P. Martijn, Sandker, M., Snijders, S. V., Tavakol, M., Hendrickx, A. P. A., &
3103 van Wamel, W. J. B. (2017). Combining in vitro protein detection and in vivo

- 3104 antibody detection identifies potential vaccine targets against *Staphylococcus*
3105 *aureus* during osteomyelitis. *Medical Microbiology and Immunology*, 206(1), 11-
3106 22. <https://doi.org/10.1007/s00430-016-0476-8>
- 3107 Dohoo, I. R., Smith, J., Andersen, S., Kelton, D. F., Godden, S., & Mastitis Research
3108 Workers' Conference. (2011). Diagnosing intramammary infections: Evaluation of
3109 definitions based on a single milk sample. *Journal of Dairy Science*, 94(1), 250-
3110 261. <https://doi.org/10.3168/jds.2010-3559>
- 3111 Donlan, R. M., & Costerton, J. W. (2002). Biofilms: Survival mechanisms of clinically
3112 relevant microorganisms. *Clinical Microbiology Reviews*, 15(2), 167-193.
- 3113 Fabres-Klein, M. H., Aguilar, A. P., Silva, M. P., Silva, D. M., & Ribon, A. O. B. (2014).
3114 Moving towards the immunodiagnosis of staphylococcal intramammary infections.
3115 *European Journal of Clinical Microbiology & Infectious Diseases: Official*
3116 *Publication of the European Society of Clinical Microbiology*, 33(12), 2095-2104.
3117 <https://doi.org/10.1007/s10096-014-2181-0>
- 3118 Feltrin, F., Alba, P., Kraushaar, B., Ianzano, A., Argudín, M. A., Di Matteo, P., Porrero,
3119 M. C., Aarestrup, F. M., Butaye, P., Franco, A., & Battisti, A. (2016). A Livestock-
3120 Associated, Multidrug-Resistant, Methicillin-Resistant *Staphylococcus aureus*
3121 Clonal Complex 97 Lineage Spreading in Dairy Cattle and Pigs in Italy. *Applied*
3122 *and Environmental Microbiology*, 82(3), 816-821.
3123 <https://doi.org/10.1128/AEM.02854-15>
- 3124 Finlay, B. B., & Cossart, P. (1997). Exploitation of mammalian host cell functions by
3125 bacterial pathogens. *Science (New York, N.Y.)*, 276(5313), 718-725.
- 3126 Foster, T. J., Geoghegan, J. A., Ganesh, V. K., & Höök, M. (2014). Adhesion, invasion
3127 and evasion: The many functions of the surface proteins of *Staphylococcus*
3128 *aureus*. *Nature Reviews. Microbiology*, 12(1), 49-62.
3129 <https://doi.org/10.1038/nrmicro3161>
- 3130 Fowler, T., Wann, E. R., Joh, D., Johansson, S., Foster, T. J., & Höök, M. (2000).
3131 Cellular invasion by *Staphylococcus aureus* involves a fibronectin bridge between
3132 the bacterial fibronectin-binding MSCRAMMs and host cell β 1 integrins.
3133 *European Journal of Cell Biology*, 79(10), 672-679. <https://doi.org/10.1078/0171-9335-00104>
- 3135 Fox, L. K., Zadoks, R. N., & Gaskins, C. T. (2005). Biofilm production by *Staphylococcus*
3136 *aureus* associated with intramammary infection. *Veterinary Microbiology*, 107(3-
3137 4), 295-299. <https://doi.org/10.1016/j.vetmic.2005.02.005>
- 3138 Fu, Y., Zhou, E., Liu, Z., Li, F., Liang, D., Liu, B., Song, X., Zhao, F., Fen, X., Li, D., Cao,
3139 Y., Zhang, X., Zhang, N., & Yang, Z. (2013). *Staphylococcus aureus* and
3140 *Escherichia coli* elicit different innate immune responses from bovine mammary
3141 epithelial cells. *Veterinary Immunology and Immunopathology*, 155(4), 245-252.
3142 <https://doi.org/10.1016/j.vetimm.2013.08.003>

- 3143 Gomes, F., Saavedra, M. J., & Henriques, M. (2016). Bovine mastitis
3144 disease/pathogenicity: Evidence of the potential role of microbial biofilms.
3145 *Pathogens and Disease*, 74(3). <https://doi.org/10.1093/femspd/ftw006>
- 3146 Gong, R., Hu, C., Xu, H., Guo, A., Chen, H., Zhang, G., & Shi, L. (2010). Evaluation of
3147 clumping factor A binding region A in a subunit vaccine against *Staphylococcus*
3148 *aureus*-induced mastitis in mice. *Clinical and Vaccine Immunology: CVI*, 17(11),
3149 1746-1752. <https://doi.org/10.1128/CVI.00162-10>
- 3150 Goodyear, C. S., & Silverman, G. J. (2004). Staphylococcal toxin induced preferential
3151 and prolonged in vivo deletion of innate-like B lymphocytes. *Proceedings of the*
3152 *National Academy of Sciences of the United States of America*, 101(31), 11392-
3153 11397. <https://doi.org/10.1073/pnas.0404382101>
- 3154 Grönlund, U., Johannisson, A., & Persson Waller, K. (2006). Changes in blood and milk
3155 lymphocyte sub-populations during acute and chronic phases of *Staphylococcus*
3156 *aureus* induced bovine mastitis. *Research in Veterinary Science*, 80(2), 147-154.
3157 <https://doi.org/10.1016/j.rvsc.2005.05.002>
- 3158 Halasa, T., Huijps, K., Østerås, O., & Hogeveen, H. (2007). Economic effects of bovine
3159 mastitis and mastitis management: A review. *The Veterinary Quarterly*, 29(1), 18-
3160 31. <https://doi.org/10.1080/01652176.2007.9695224>
- 3161 Hammer, N., & Skaar, E. (2011). Molecular mechanisms of *Staphylococcus aureus* iron
3162 acquisition. *Annu Rev Microbiol.*, 65, 1-19. <https://doi.org/doi:10.1146/annurev-micro-090110-102851>
- 3164 Hernández-Castellano, L., Wall, S. K., Stephan, R., Corti, S., & Bruckmaier, R. (2017a).
3165 Milk somatic cell count, lactate dehydrogenase activity, and immunoglobulin G
3166 concentration associated with mastitis caused by different pathogens: A field
3167 study. *Schweizer Archiv Fur Tierheilkunde*, 159(5), 283-290.
3168 <https://doi.org/10.17236/sat00115>
- 3169 Hernández-Castellano, L., Wall, S. K., Stephan, R., Corti, S., & Bruckmaier, R. (2017b).
3170 Milk somatic cell count, lactate dehydrogenase activity, and immunoglobulin G
3171 concentration associated with mastitis caused by different pathogens: A field
3172 study. *Schweizer Archiv Fur Tierheilkunde*, 159(5), 283-290.
3173 <https://doi.org/10.17236/sat00115>
- 3174 Heuck, A. P., Tweten, R. K., & Johnson, A. E. (2001). Beta-barrel pore-forming toxins:
3175 Intriguing dimorphic proteins. *Biochemistry*, 40(31), 9065-9073.
- 3176 Hillerton, J. E., & Kliem, K. E. (2002). Effective treatment of *Streptococcus uberis* clinical
3177 mastitis to minimize the use of antibiotics. *Journal of Dairy Science*, 85(4), 1009-
3178 1014. [https://doi.org/10.3168/jds.S0022-0302\(02\)74161-1](https://doi.org/10.3168/jds.S0022-0302(02)74161-1)
- 3179 Hollis, A., & Ahmed, Z. (2013). Preserving antibiotics, rationally. *The New England*
3180 *Journal of Medicine*, 369(26), 2474-2476. <https://doi.org/10.1056/NEJMp1311479>

- 3181 Holmes, M. A., & Zadoks, R. N. (2011). Methicillin resistant *S. aureus* in human and
3182 bovine mastitis. *Journal of Mammary Gland Biology and Neoplasia*, 16(4), 373-
3183 382. <https://doi.org/10.1007/s10911-011-9237-x>
- 3184 Huang, J., Luo, G., Zhang, Z., Wang, X., Ju, Z., Qi, C., Zhang, Y., Wang, C., Li, R., Li,
3185 J., Yin, W., Xu, Y., Moisés, S. J., Llor, J. J., & Zhong, J. (2014). ITRAQ-
3186 proteomics and bioinformatics analyses of mammary tissue from cows with
3187 clinical mastitis due to natural infection with *Staphylococcus aureus*. *BMC*
3188 *Genomics*, 15, 839. <https://doi.org/10.1186/1471-2164-15-839>
- 3189 Jardetzky, T. S., Brown, J. H., Gorga, J. C., Stern, L. J., Urban, R. G., Chi, Y. I.,
3190 Stauffacher, C., Strominger, J. L., & Wiley, D. C. (1994). Three-dimensional
3191 structure of a human class II histocompatibility molecule complexed with
3192 superantigen. *Nature*, 368(6473), 711-718. <https://doi.org/10.1038/368711a0>
- 3193 Jintaek, Im, Jung, H., Kang, S.-S., Yun, C.-H., Kim, H., & Han, S. H. (2014). Gene
3194 expression profiling of bovine mammary gland epithelial cells stimulated with
3195 lipoteichoic acid plus peptidoglycan from *Staphylococcus aureus*. *International*
3196 *Immunopharmacology*, 21(1), 231-240.
3197 <https://doi.org/10.1016/j.intimp.2014.05.002>
- 3198 Joost, I., Jacob, S., Utermöhlen, O., Schubert, U., Patti, J. M., Ong, M.-F., Gross, J.,
3199 Justinger, C., Renno, J. H., Preissner, K. T., Bischoff, M., & Herrmann, M. (2011).
3200 Antibody response to the extracellular adherence protein (Eap) of
3201 *Staphylococcus aureus* in healthy and infected individuals. *FEMS Immunology*
3202 *and Medical Microbiology*, 62(1), 23-31. <https://doi.org/10.1111/j.1574-695X.2011.00783.x>
- 3204 Josefsson, E., McCrea, K. W., Ní Eidhin, D., O'Connell, D., Cox, J., Höök, M., & Foster,
3205 T. J. (1998). Three new members of the serine-aspartate repeat protein multigene
3206 family of *Staphylococcus aureus*. *Microbiology (Reading, England)*, 144 (Pt 12),
3207 3387-3395. <https://doi.org/10.1099/00221287-144-12-3387>
- 3208 Karavolos, M. H., Horsburgh, M. J., Ingham, E., & Foster, S. J. (2003). Role and
3209 regulation of the superoxide dismutases of *Staphylococcus aureus*. *Microbiology*
3210 *(Reading, England)*, 149(Pt 10), 2749-2758. <https://doi.org/10.1099/mic.0.26353-0>
- 3212 Keefe, G. (2010). Control de la mastitis en hatos lecheros. *Actas del VI Seminario*
3213 *internacional en competitividad en carne y leche*, 43-52.
- 3214 Keefe, Greg. (2012). Update on control of *Staphylococcus aureus* and *Streptococcus*
3215 *agalactiae* for management of mastitis. *The Veterinary Clinics of North America.*
3216 *Food Animal Practice*, 28(2), 203-216. <https://doi.org/10.1016/j.cvfa.2012.03.010>
- 3217 Kim, K. W., Im, J., Jeon, J. H., Lee, H.-G., Yun, C.-H., & Han, S. H. (2011).
3218 *Staphylococcus aureus* induces IL-1 β expression through the activation of MAP
3219 kinases and AP-1, CRE and NF- κ B transcription factors in the bovine mammary

- 3220 gland epithelial cells. *Comparative Immunology, Microbiology and Infectious*
3221 *Diseases*, 34(4), 347-354. <https://doi.org/10.1016/j.cimid.2011.04.004>
- 3222 Laarman, A. J., Ruyken, M., Malone, C. L., van Strijp, J. A. G., Horswill, A. R., &
3223 Rooijackers, S. H. M. (2011). *Staphylococcus aureus* metalloprotease aureolysin
3224 cleaves complement C3 to mediate immune evasion. *Journal of Immunology*
3225 (*Baltimore, Md.: 1950*), 186(11), 6445-6453.
3226 <https://doi.org/10.4049/jimmunol.1002948>
- 3227 Lara, Á. R. (2011). Producción de proteínas recombinantes en *Escherichia coli*. *Revista*
3228 *mexicana de ingeniería química*, 10(2), 209-223.
- 3229 Lei, M. G., Gupta, R. K., & Lee, C. Y. (2017). Proteomics of *Staphylococcus aureus*
3230 biofilm matrix in a rat model of orthopedic implant-associated infection. *PloS One*,
3231 12(11), e0187981. <https://doi.org/10.1371/journal.pone.0187981>
- 3232 Lin, M.-H., Shu, J.-C., Huang, H.-Y., & Cheng, Y.-C. (2012). Involvement of iron in
3233 biofilm formation by *Staphylococcus aureus*. *PloS One*, 7(3), e34388.
3234 <https://doi.org/10.1371/journal.pone.0034388>
- 3235 Liu, G. Y., Essex, A., Buchanan, J. T., Datta, V., Hoffman, H. M., Bastian, J. F., Fierer,
3236 J., & Nizet, V. (2005). *Staphylococcus aureus* golden pigment impairs neutrophil
3237 killing and promotes virulence through its antioxidant activity. *The Journal of*
3238 *Experimental Medicine*, 202(2), 209-215. <https://doi.org/10.1084/jem.20050846>
- 3239 Ma, Y., Xu, Y., Yestrepky, B. D., Sorenson, R. J., Chen, M., Larsen, S. D., & Sun, H.
3240 (2012). Novel inhibitors of *Staphylococcus aureus* virulence gene expression and
3241 biofilm formation. *PloS One*, 7(10), e47255.
3242 <https://doi.org/10.1371/journal.pone.0047255>
- 3243 McCarthy, H., Rudkin, J. K., Black, N. S., Gallagher, L., O'Neill, E., & O'Gara, J. P.
3244 (2015). Methicillin resistance and the biofilm phenotype in *Staphylococcus*
3245 *aureus*. *Frontiers in Cellular and Infection Microbiology*, 5, 1.
3246 <https://doi.org/10.3389/fcimb.2015.00001>
- 3247 Mehrzad, J., Duchateau, L., & Burvenich, C. (2005). High milk neutrophil
3248 chemiluminescence limits the severity of bovine coliform mastitis. *Veterinary*
3249 *Research*, 36(1), 101-116. <https://doi.org/10.1051/vetres:2004055>
- 3250 Miles, G., Movileanu, L., & Bayley, H. (2002). Subunit composition of a bicomponent
3251 toxin: Staphylococcal leukocidin forms an octameric transmembrane pore. *Protein*
3252 *Science: A Publication of the Protein Society*, 11(4), 894-902.
3253 <https://doi.org/10.1110/ps.4360102>
- 3254 Moormeier, D. E., & Bayles, K. W. (2017). *Staphylococcus aureus* biofilm: A complex
3255 developmental organism. *Molecular Microbiology*, 104(3), 365-376.
3256 <https://doi.org/10.1111/mmi.13634>

- 3257 Nour El-Din, A. N. M., Shkreta, L., Talbot, B. G., Diarra, M. S., & Lacasse, P. (2006).
3258 DNA immunization of dairy cows with the clumping factor A of *Staphylococcus*
3259 *aureus*. *Vaccine*, 24(12), 1997-2006.
3260 <https://doi.org/10.1016/j.vaccine.2005.11.033>
- 3261 O'Gara, J. P. (2007). *ica* and beyond: Biofilm mechanisms and regulation in
3262 *Staphylococcus epidermidis* and *Staphylococcus aureus*. *FEMS Microbiology*
3263 *Letters*, 270(2), 179-188. <https://doi.org/10.1111/j.1574-6968.2007.00688.x>
- 3264 Oldfield, E., & Feng, X. (2014). Resistance-resistant antibiotics. *Trends in*
3265 *Pharmacological Sciences*, 35(12), 664-674.
3266 <https://doi.org/10.1016/j.tips.2014.10.007>
- 3267 Oliveira, M., Nunes, S. F., Carneiro, C., Bexiga, R., Bernardo, F., & Vilela, C. L. (2007).
3268 Time course of biofilm formation by *Staphylococcus aureus* and *Staphylococcus*
3269 *epidermidis* mastitis isolates. *Veterinary Microbiology*, 124(1-2), 187-191.
3270 <https://doi.org/10.1016/j.vetmic.2007.04.016>
- 3271 O'Neill, E., Pozzi, C., Houston, P., Smyth, D., Humphreys, H., Robinson, D. A., &
3272 O'Gara, J. P. (2007). Association between methicillin susceptibility and biofilm
3273 regulation in *Staphylococcus aureus* isolates from device-related infections.
3274 *Journal of Clinical Microbiology*, 45(5), 1379-1388.
3275 <https://doi.org/10.1128/JCM.02280-06>
- 3276 Organización Mundial de Sanidad Animal. (2015). *Resistencia a los antimicrobianos* (p.
3277 2) [Hojas informativas]. www.oie.int
- 3278 Paterson, G. K., Harrison, E. M., & Holmes, M. A. (2014). The emergence of *mecC*
3279 methicillin-resistant *Staphylococcus aureus*. *Trends in Microbiology*, 22(1), 42-47.
3280 <https://doi.org/10.1016/j.tim.2013.11.003>
- 3281 Pérez, M. M., Prenafeta, A., Valle, J., Penadés, J., Rota, C., Solano, C., Marco, J.,
3282 Grilló, M. J., Lasa, I., Irache, J. M., Maira-Litran, T., Jiménez-Barbero, J., Costa,
3283 L., Pier, G. B., de Andrés, D., & Amorena, B. (2009). Protection from
3284 *Staphylococcus aureus* mastitis associated with poly-N-acetyl beta-1,6
3285 glucosamine specific antibody production using biofilm-embedded bacteria.
3286 *Vaccine*, 27(17), 2379-2386. <https://doi.org/10.1016/j.vaccine.2009.02.005>
- 3287 Petzer, I.-M., Karzis, J., Donkin, E. F., Webb, E. C., & Etter, E. M. C. (2017). Validity of
3288 somatic cell count as indicator of pathogen-specific intramammary infections.
3289 *Journal of the South African Veterinary Association*, 88(0), e1-e10.
3290 <https://doi.org/10.4102/jsava.v88i0.1465>
- 3291 Philpot, N., & Nickerson, S. (2000). *Ganando la lucha contra la mastitis* (Vol. 1).
3292 Westfalia.
- 3293 Pinzón-Sánchez, C., Cabrera, V. E., & Ruegg, P. L. (2011). Decision tree analysis of
3294 treatment strategies for mild and moderate cases of clinical mastitis occurring in

- 3295 early lactation. *Journal of Dairy Science*, 94(4), 1873-1892.
3296 <https://doi.org/10.3168/jds.2010-3930>
- 3297 Postma, B., Poppelier, M. J., van Galen, J. C., Prossnitz, E. R., van Strijp, J. A. G., de
3298 Haas, C. J. C., & van Kessel, K. P. M. (2004). Chemotaxis inhibitory protein of
3299 *Staphylococcus aureus* binds specifically to the C5a and formylated peptide
3300 receptor. *Journal of Immunology (Baltimore, Md.: 1950)*, 172(11), 6994-7001.
- 3301 Pozzi, C., Waters, E. M., Rudkin, J. K., Schaeffer, C. R., Lohan, A. J., Tong, P., Loftus,
3302 B. J., Pier, G. B., Fey, P. D., Massey, R. C., & O'Gara, J. P. (2012). Methicillin
3303 resistance alters the biofilm phenotype and attenuates virulence in
3304 *Staphylococcus aureus* device-associated infections. *PLoS Pathogens*, 8(4),
3305 e1002626. <https://doi.org/10.1371/journal.ppat.1002626>
- 3306 Prenafeta, A., March, R., Foix, A., Casals, I., & Costa, L. (2010). Study of the humoral
3307 immunological response after vaccination with a *Staphylococcus aureus* biofilm-
3308 embedded bacterin in dairy cows: Possible role of the exopolysaccharide specific
3309 antibody production in the protection from *Staphylococcus aureus* induced
3310 mastitis. *Veterinary Immunology and Immunopathology*, 134(3-4), 208-217.
3311 <https://doi.org/10.1016/j.vetimm.2009.09.020>
- 3312 Rainard, P., Foucras, G., Fitzgerald, J. R., Watts, J. L., Koop, G., & Middleton, J. R.
3313 (2018). Knowledge gaps and research priorities in *Staphylococcus aureus*
3314 mastitis control. *Transboundary and Emerging Diseases*, 65 Suppl 1, 149-165.
3315 <https://doi.org/10.1111/tbed.12698>
- 3316 Ramírez, N. F., Keefe, G., Dohoo, I., Sánchez, J., Arroyave, O., Cerón, J., Jaramillo, M.,
3317 & Palacio, L. G. (2014). Herd- and cow-level risk factors associated with
3318 subclinical mastitis in dairy farms from the High Plains of the northern Antioquia,
3319 Colombia. *Journal of Dairy Science*, 97(7), 4141-4150.
3320 <https://doi.org/10.3168/jds.2013-6815>
- 3321 Raza, A., G, M., S U, R., I, R., K, H., A, A., & S, S. (2015). Evaluation of humoral
3322 immunity and protective efficacy of biofilm producing *Staphylococcus aureus*
3323 bacterin-toxoid prepared from a bovine mastitis isolate in rabbit. *Iranian Journal of*
3324 *Veterinary Research*, 16(1), 69-74.
- 3325 Rohde, H., Frankenberger, S., Zähringer, U., & Mack, D. (2010). Structure, function and
3326 contribution of polysaccharide intercellular adhesin (PIA) to *Staphylococcus*
3327 *epidermidis* biofilm formation and pathogenesis of biomaterial-associated
3328 infections. *European Journal of Cell Biology*, 89(1), 103-111.
3329 <https://doi.org/10.1016/j.ejcb.2009.10.005>
- 3330 Rooijackers, S. H. M., Ruyken, M., Roos, A., Daha, M. R., Presanis, J. S., Sim, R. B.,
3331 van Wamel, W. J. B., van Kessel, K. P. M., & van Strijp, J. A. G. (2005). Immune
3332 evasion by a staphylococcal complement inhibitor that acts on C3 convertases.
3333 *Nature Immunology*, 6(9), 920-927. <https://doi.org/10.1038/ni1235>

- 3334 Roy, J.-P., & Keefe, G. (2012). Systematic review: What is the best antibiotic treatment
3335 for *Staphylococcus aureus* intramammary infection of lactating cows in North
3336 America? *The Veterinary Clinics of North America. Food Animal Practice*, 28(1),
3337 39-50, viii. <https://doi.org/10.1016/j.cvfa.2011.12.004>
- 3338 Schukken, Y., Günther, J., Fitzpatrick, J., Fontaine, M. C., Goetze, L., Holst, O., Leigh,
3339 J., Petzl, W., Schuberth, H.-J., Sipka, A., Smith, D. G. E., Quesnell, R., Watts, J.,
3340 Yancey, R., Zerbe, H., Gurjar, A., Zadoks, R. N., & Seyfert, H.-M. (2011). Host-
3341 response patterns of intramammary infections in dairy cows. *Veterinary*
3342 *Immunology and Immunopathology*, 144(3-4), 270-289.
3343 <https://doi.org/10.1016/j.vetimm.2011.08.022>
- 3344 Schwarz-Linek, U., Werner, J. M., Pickford, A. R., Gurusiddappa, S., Kim, J. H., Pilka, E.
3345 S., Briggs, J. A. G., Gough, T. S., Höök, M., Campbell, I. D., & Potts, J. R. (2003).
3346 Pathogenic bacteria attach to human fibronectin through a tandem beta-zipper.
3347 *Nature*, 423(6936), 177-181. <https://doi.org/10.1038/nature01589>
- 3348 Sears, P. M., Smith, B. S., English, P. B., Herer, P. S., & Gonzalez, R. N. (1990).
3349 Shedding pattern of *Staphylococcus aureus* from bovine intramammary
3350 infections. *Journal of Dairy Science*, 73(10), 2785-2789.
3351 [https://doi.org/10.3168/jds.S0022-0302\(90\)78964-3](https://doi.org/10.3168/jds.S0022-0302(90)78964-3)
- 3352 Shim, E. H., Shanks, R. D., & Morin, D. E. (2004). Milk loss and treatment costs
3353 associated with two treatment protocols for clinical mastitis in dairy cows. *Journal*
3354 *of Dairy Science*, 87(8), 2702-2708. [https://doi.org/10.3168/jds.S0022-0302\(04\)73397-4](https://doi.org/10.3168/jds.S0022-0302(04)73397-4)
- 3356 Smith, M. F., Mitchell, A., Li, G., Ding, S., Fitzmaurice, A. M., Ryan, K., Crowe, S., &
3357 Goldberg, J. B. (2003). Toll-like Receptor (TLR) 2 and TLR5, but Not TLR4, Are
3358 Required for *Helicobacter pylori*-induced NF- κ B Activation and Chemokine
3359 Expression by Epithelial Cells. *Journal of Biological Chemistry*, 278(35), 32552-
3360 32560. <https://doi.org/10.1074/jbc.M305536200>
- 3361 Steeneveld, W., van Werven, T., Barkema, H. W., & Hogeveen, H. (2011). Cow-specific
3362 treatment of clinical mastitis: An economic approach. *Journal of Dairy Science*,
3363 94(1), 174-188. <https://doi.org/10.3168/jds.2010-3367>
- 3364 Stranger-Jones, Y. K., Bae, T., & Schneewind, O. (2006). Vaccine assembly from
3365 surface proteins of *Staphylococcus aureus*. *Proceedings of the National Academy*
3366 *of Sciences of the United States of America*, 103(45), 16942-16947.
3367 <https://doi.org/10.1073/pnas.0606863103>
- 3368 Swain, D. K., Kushwah, M. S., Kaur, M., Patbandha, T. K., Mohanty, A. K., & Dang, A. K.
3369 (2014). Formation of NET, phagocytic activity, surface architecture, apoptosis and
3370 expression of toll like receptors 2 and 4 (TLR2 and TLR4) in neutrophils of
3371 mastitic cows. *Veterinary Research Communications*, 38(3), 209-219.
3372 <https://doi.org/10.1007/s11259-014-9606-1>

- 3373 Szweda, P., Schielmann, M., Milewski, S., Frankowska, A., & Jakubczak, A. (2012).
3374 Biofilm production and presence of ica and bap genes in *Staphylococcus aureus*
3375 strains isolated from cows with mastitis in the eastern Poland. *Polish Journal of*
3376 *Microbiology*, 61(1), 65-69.
- 3377 Thammavongsa, V., Kern, J. W., Missiakas, D. M., & Schneewind, O. (2009).
3378 *Staphylococcus aureus* synthesizes adenosine to escape host immune
3379 responses. *The Journal of Experimental Medicine*, 206(11), 2417-2427.
3380 <https://doi.org/10.1084/jem.20090097>
- 3381 Thammavongsa, V., Kim, H. K., Missiakas, D., & Schneewind, O. (2015).
3382 Staphylococcal manipulation of host immune responses. *Nature Reviews.*
3383 *Microbiology*, 13(9), 529-543. <https://doi.org/10.1038/nrmicro3521>
- 3384 Thammavongsa, V., Missiakas, D. M., & Schneewind, O. (2013). *Staphylococcus aureus*
3385 degrades neutrophil extracellular traps to promote immune cell death. *Science*
3386 (*New York, N.Y.*), 342(6160), 863-866. <https://doi.org/10.1126/science.1242255>
- 3387 Tormo, M. A., Knecht, E., Götz, F., Lasa, I., & Penadés, J. R. (2005). Bap-dependent
3388 biofilm formation by pathogenic species of *Staphylococcus*: Evidence of
3389 horizontal gene transfer? *Microbiology (Reading, England)*, 151(Pt 7), 2465-2475.
3390 <https://doi.org/10.1099/mic.0.27865-0>
- 3391 Torres, G., Vargas, K., Sánchez-Jiménez, M., Reyes-Velez, J., & Olivera-Angel, M.
3392 (2019). Genotypic and phenotypic characterization of biofilm production by
3393 *Staphylococcus aureus* strains isolated from bovine intramammary infections in
3394 Colombian dairy farms. *Heliyon*, 5(10), e02535.
3395 <https://doi.org/10.1016/j.heliyon.2019.e02535>
- 3396 Vaishampayan, A., de Jong, A., Wight, D. J., Kok, J., & Grohmann, E. (2018). A Novel
3397 Antimicrobial Coating Represses Biofilm and Virulence-Related Genes in
3398 Methicillin-Resistant *Staphylococcus aureus*. *Frontiers in Microbiology*, 9, 221.
3399 <https://doi.org/10.3389/fmicb.2018.00221>
- 3400 Valle, J., Latasa, C., Gil, C., Toledo-Arana, A., Solano, C., Penadés, J. R., & Lasa, I.
3401 (2012). Bap, a biofilm matrix protein of *Staphylococcus aureus* prevents cellular
3402 internalization through binding to GP96 host receptor. *PLoS Pathogens*, 8(8),
3403 e1002843. <https://doi.org/10.1371/journal.ppat.1002843>
- 3404 Veh, K. A., Klein, R. C., Ster, C., Keefe, G., Lacasse, P., Scholl, D., Roy, J.-P., Haine,
3405 D., Dufour, S., Talbot, B. G., Ribon, A. O. B., & Malouin, F. (2015a). Genotypic
3406 and phenotypic characterization of *Staphylococcus aureus* causing persistent and
3407 nonpersistent subclinical bovine intramammary infections during lactation or the
3408 dry period. *Journal of Dairy Science*, 98(1), 155-168.
3409 <https://doi.org/10.3168/jds.2014-8044>
- 3410 Veh, K. A., Klein, R. C., Ster, C., Keefe, G., Lacasse, P., Scholl, D., Roy, J.-P., Haine,
3411 D., Dufour, S., Talbot, B. G., Ribon, A. O. B., & Malouin, F. (2015b). Genotypic

- 3412 and phenotypic characterization of *Staphylococcus aureus* causing persistent and
3413 nonpersistent subclinical bovine intramammary infections during lactation or the
3414 dry period. *Journal of Dairy Science*, 98(1), 155-168.
3415 <https://doi.org/10.3168/jds.2014-8044>
- 3416 Verma, A., & Ambatipudi, K. (2016). Challenges and opportunities of bovine milk
3417 analysis by mass spectrometry. *Clinical Proteomics*, 13, 8.
3418 <https://doi.org/10.1186/s12014-016-9110-4>
- 3419 Vidal, J., Vargas, K., Parra, L., Rivera, A., Macias, D., Torres, G., & Olivera, M. (2016).
3420 Prevalence of mastitis causing bacteria isolated in two diagnostic laboratories in
3421 Antioquia (Colombia), between the years 2013 and 2015. *Journal of Veterinary
3422 Science and Technology*, 7(6), 38. <https://doi.org/10.4172/2157-7579.C1.019>
- 3423 Viguier, C., Arora, S., Gilmartin, N., Welbeck, K., & O'Kennedy, R. (2009). Mastitis
3424 detection: Current trends and future perspectives. *Trends in Biotechnology*, 27(8),
3425 486-493. <https://doi.org/10.1016/j.tibtech.2009.05.004>
- 3426 Wang, H., Yu, G., Yu, H., Gu, M., Zhang, J., Meng, X., Liu, Z., Qiu, C., & Li, J. (2015).
3427 Characterization of TLR2, NOD2, and related cytokines in mammary glands
3428 infected by *Staphylococcus aureus* in a rat model. *Acta Veterinaria Scandinavica*,
3429 57, 25. <https://doi.org/10.1186/s13028-015-0116-0>
- 3430 Wellnitz, O., & Bruckmaier, R. M. (2012). The innate immune response of the bovine
3431 mammary gland to bacterial infection. *Veterinary Journal (London, England:
3432 1997)*, 192(2), 148-152. <https://doi.org/10.1016/j.tvjl.2011.09.013>
- 3433 Yang, W., Zerbe, H., Petzl, W., Brunner, R. M., Günther, J., Draing, C., von Aulock, S.,
3434 Schuberth, H.-J., & Seyfert, H.-M. (2008). Bovine TLR2 and TLR4 properly
3435 transduce signals from *Staphylococcus aureus* and *E. coli*, but *S. aureus* fails to
3436 both activate NF-kappaB in mammary epithelial cells and to quickly induce
3437 TNFalpha and interleukin-8 (CXCL8) expression in the udder. *Molecular
3438 Immunology*, 45(5), 1385-1397. <https://doi.org/10.1016/j.molimm.2007.09.004>
- 3439 Yokoyama, R., Itoh, S., Kamoshida, G., Takii, T., Fujii, S., Tsuji, T., & Onozaki, K.
3440 (2012). Staphylococcal superantigen-like protein 3 binds to the Toll-like receptor 2
3441 extracellular domain and inhibits cytokine production induced by *Staphylococcus
3442 aureus*, cell wall component, or lipopeptides in murine macrophages. *Infection
3443 and Immunity*, 80(8), 2816-2825. <https://doi.org/10.1128/IAI.00399-12>
- 3444 Zapotoczna, M., McCarthy, H., Rudkin, J. K., O'Gara, J. P., & O'Neill, E. (2015). An
3445 Essential Role for Coagulase in *Staphylococcus aureus* Biofilm Development
3446 Reveals New Therapeutic Possibilities for Device-Related Infections. *The Journal
3447 of Infectious Diseases*, 212(12), 1883-1893. <https://doi.org/10.1093/infdis/jiv319>
- 3448 Zapotoczna, M., O'Neill, E., & O'Gara, J. P. (2016). Untangling the Diverse and
3449 Redundant Mechanisms of *Staphylococcus aureus* Biofilm Formation. *PLoS
3450 Pathogens*, 12(7), e1005671. <https://doi.org/10.1371/journal.ppat.1005671>

3451 Zecconi, A., & Scali, F. (2013). *Staphylococcus aureus* virulence factors in evasion from
3452 innate immune defenses in human and animal diseases. *Immunology Letters*,
3453 150(1-2), 12-22. <https://doi.org/10.1016/j.imlet.2013.01.004>
3454
3455